


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T13:51:58Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406974" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406974</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell</journal-id><journal-id journal-id-type="iso-abbrev">Cell</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Cell</journal-title></journal-title-group><issn pub-type="ppub">0092-8674</issn><issn pub-type="epub">1097-4172</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406974</article-id><article-id pub-id-type="pmcid-ver">PMC12406974.1</article-id><article-id pub-id-type="pmcaid">12406974</article-id><article-id pub-id-type="pmcaiid">12406974</article-id><article-id pub-id-type="manuscript-id">NIHMS2100174</article-id><article-id pub-id-type="pmid">40818455</article-id><article-id pub-id-type="doi">10.1016/j.cell.2025.07.034</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2100174</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2100174</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>RNA Pol II inhibition activates cell death independently from the loss of transcription</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Harper</surname><given-names initials="NW">Nicholas W.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Birdsall</surname><given-names initials="GA">Gavin A.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Honeywell</surname><given-names initials="ME">Megan E.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ward</surname><given-names initials="KM">Kelly M.</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pai</surname><given-names initials="AA">Athma A.</given-names></name><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="MJ">Michael J.</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A4" ref-type="aff">4</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Systems Biology, UMass Chan Medical School, Worcester, MA 01605, USA</aff><aff id="A2"><label>2</label>Program in Molecular Medicine and Department of Molecular, Cell and Cancer Biology, UMass Chan Medical School, Worcester, MA 01605, USA</aff><aff id="A3"><label>3</label>RNA Therapeutics Institute, UMass Chan Medical School, Worcester, MA 01605, USA</aff><aff id="A4"><label>4</label>Lead contact</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">AUTHOR CONTRIBUTIONS</p><p id="P2">N.W.H. and M.J.L. conceptualized this project, including selection of methodology, analytical strategies, data visualization, and interpretation. N.W.H. performed all experiments and analyses. G.A.B. assisted with the evaluation of death subtypes activated by each drug. M.E.H. generated materials used in chemogenetic profiling and assisted with the design and analysis of chemogenetic profiling data. K.M.W. assisted with image quantification and evaluating death regulation by rapidly lost genes. A.A.P. designed experiments and analytical strategies used for quantifying RNA localization/splicing. The original draft was written by N.W.H. and M.J.L. All authors participated in manuscript review/editing.</p></fn><corresp id="CR1"><label>*</label>Correspondence: <email>michael.lee@umassmed.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>14</day><month>8</month><year>2025</year></pub-date><issue-id pub-id-type="pmc-issue-id">496082</issue-id><elocation-id>S0092-8674(25)00856-6</elocation-id><pub-history><event event-type="nihms-submitted"><date><day>27</day><month>08</month><year>2025</year></date></event><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="nihms-2100174.pdf"/><related-article related-article-type="preprint" xml:lang="en" xlink:title="research-article" journal-id="bioRxiv" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC11661175"><article-title>Pol II degradation activates cell death independently from the loss of transcription</article-title><date><day>14</day><month>1</month><year>2025</year></date><elocation-id>2024.12.09.627542</elocation-id><source>bioRxiv</source><pub-id pub-id-type="pmcid">PMC11661175</pub-id><pub-id pub-id-type="pmid">39713309</pub-id></related-article><abstract id="ABS1"><title>SUMMARY</title><p id="P3">RNA Pol II-mediated transcription is essential for eukaryotic life. Although loss of transcription is thought to be universally lethal, the associated mechanisms promoting cell death are not yet known. Here, we show that death following the loss of RNA Pol II activity does not result from dysregulated gene expression. Instead, it occurs in response to loss of the hypophosphorylated form of Rbp1 (also called RNA Pol IIA). Loss of RNA Pol IIA exclusively activates apoptosis, and expression of a transcriptionally inactive version of Rpb1 rescues cell viability. Using functional genomics, we identify the mechanisms driving lethality following the loss of RNA Pol IIA, which we call the Pol II degradation-dependent apoptotic response (PDAR). Using the genetic dependencies of PDAR, we identify clinically used drugs that owe their lethality to a PDAR-dependent mechanism. Our findings unveil an apoptotic signaling response that contributes to the efficacy of a wide array of anti-cancer therapies.</p></abstract><abstract id="ABS2" abstract-type="graphical"><title>Graphical Abstract</title><p id="P4">
<graphic position="anchor" orientation="portrait" xlink:href="nihms-2100174-f0001.jpg"/>
</p></abstract><abstract id="ABS3" abstract-type="summary"><title>In brief</title><p id="P5">When RNA polymerase II (RNA Pol II) is inhibited, the inhibition is sensed and signaled to mitochondria, leading to programmed cell death independently of the loss of RNA Pol II transcription activity.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="S1"><title>INTRODUCTION</title><p id="P6">Accurate control of gene expression is critical for all cellular processes. For nuclear protein-coding genes, expression depends on transcriptional activity of RNA polymerase II (hereafter, RNA Pol II). RNA Pol II activity is considered a life-essential function, and prolonged inhibition of RNA Pol II is expected to be universally lethal.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> In recent years, drugs targeting the transcriptional machinery have been investigated as cancer therapies.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> However, despite the importance of RNA Pol II and clinical interest in drugs targeting transcription, the mechanisms of lethality following transcriptional inhibition remain unclear.</p><p id="P7">Lethality following RNA Pol II inhibition remains mechanistically uncharacterized largely due to the presumption that death in this context is not regulated. Regulated cell death refers to death induced by active signaling through specific effector enzymes or defined pathways.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> By contrast, transcriptional inhibition is generally assumed to cause death using passive mechanisms, and this begins with mRNA decay and the subsequent loss of protein, leading to some unavoidable catastrophic event. Cell death of this type is sometimes referred to as &#8220;accidental cell death,&#8221; highlighting the use of passive mechanisms, such as decay.<sup><xref rid="R4" ref-type="bibr">4</xref></sup></p><p id="P8">In contrast with the notion that transcriptional inhibition causes accidental death, recent studies highlight that cells are remarkably capable of buffering against perturbations to the mRNA pool.<sup><xref rid="R5" ref-type="bibr">5</xref>&#8211;<xref rid="R9" ref-type="bibr">9</xref></sup> For instance, in normal conditions, mRNA concentration scales with cell size, and variations in cell size are buffered by tuning RNA Pol II activity or mRNA decay to maintain stable mRNA concentrations.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup> Likewise, following perturbations that reduce mRNA production, the effects are blunted by reduced mRNA degradation rates.<sup><xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref></sup> Thus, if cells have the capacity to buffer against downstream effects of transcriptional inhibition, why do they instead die? To address this question, we aimed to formally characterize the mechanism(s) of lethality following RNA Pol II inhibition in different contexts.</p><p id="P9">Here, we make the discovery that cell death following RNA Pol II inhibition is not caused by general decay of mRNA and protein. Instead, death is activated by loss of RNA Pol II itself, specifically loss of the hypophosphorylated and non-transcribing forms of RNA Pol II, collectively referred to as RNA Pol IIA. We determine that lethality following loss of RNA Pol IIA is initiated by an apoptotic signaling response, and using chemogenetic profiling, we identify the mechanism by which levels of RNA Pol IIA are sensed and transmitted from the nucleus to the mitochondria to initiate apoptosis. Finally, we profile a panel of compounds, including clinically useful drugs, identifying several unrelated compounds that kill cells using an RNA Pol II degradation-dependent mechanism. Collectively, our results reveal the existence of an apoptotic pathway that senses RNA Pol IIA levels, not RNA Pol II transcription, triggering death when RNA Pol IIA levels become too low.</p></sec><sec id="S2"><title>RESULTS</title><sec id="S3"><title>Transcriptional inhibition exclusively activates apoptosis</title><p id="P10">To investigate transcriptional inhibition-induced cell death, we focused on triptolide and &#9082;-amanitin, two well-validated transcriptional inhibitors that degrade RNA Pol II.<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref></sup> We first measured levels of Rpb1, the largest essential subunit of RNA Pol II. As expected, U2OS cells exposed to triptolide rapidly and completely degraded Rpb1, and Rpb1 degradation kinetics could be titrated in a drug-dose-dependent manner (<xref rid="F1" ref-type="fig">Figures 1A</xref>, <xref rid="F1" ref-type="fig">1B</xref>, and <xref rid="SD8" ref-type="supplementary-material">S1A</xref>). To validate that Rpb1 protein levels could be used to interpret the transcriptional state in the context of triptolide, we also measured incorporation of 5-ethynyl uridine (EU) into nascent RNAs, which confirmed the kinetics of transcriptional inhibition following triptolide exposure (<xref rid="SD8" ref-type="supplementary-material">Figures S1B</xref> and <xref rid="SD8" ref-type="supplementary-material">S1C</xref>). Similar dose and time behavior was observed following exposure to &#9082;-amanitin (<xref rid="SD8" ref-type="supplementary-material">Figure S1D</xref>).</p><p id="P11">To characterize death in response to RNA Pol II inhibition, we used 1 &#956;M triptolide, which completely degraded Rbp1 within &#8764;4 h (<xref rid="F1" ref-type="fig">Figures 1A</xref> and <xref rid="F1" ref-type="fig">1B</xref>). Using the STACK assay to quantify live and dead cells,<sup><xref rid="R13" ref-type="bibr">13</xref></sup> we observed that live cells proliferated normally for only 4 h following triptolide exposure, followed by a complete loss of proliferation, coinciding with the initiation of cell death (<xref rid="F1" ref-type="fig">Figure 1C</xref>). Death kinetics at lower doses of triptolide were similar, but with a delay in death onset that matched the later degradation of RNA Pol II (<xref rid="SD8" ref-type="supplementary-material">Figure S1A</xref>). Similar results were observed with &#9082;-amanitin, suggesting that rapid onset of lethality is a general feature of drugs that degrade RNA Pol II (<xref rid="SD8" ref-type="supplementary-material">Figure S1D</xref>) and that cell death is the primary phenotypic outcome of complete transcriptional inhibition.</p><p id="P12">Since loss of RNA Pol II initiated cell death more rapidly than expected following transcriptional inhibition, we next aimed to characterize which death mechanism(s) are activated. At least 14 forms of regulated cell death have been characterized.<sup><xref rid="R14" ref-type="bibr">14</xref>&#8211;<xref rid="R16" ref-type="bibr">16</xref></sup> We reasoned that if cell death following loss of transcription resulted from passive protein loss, rather than active signaling, then inhibition of any single death pathway should fail to rescue viability. To test this, we genetically or chemically inhibited each death pathway, one at a time, and observed the effect on cell death following triptolide exposure. To inhibit apoptosis, we knocked out the mitochondrial pore-forming proteins, BAX and BAK (<italic toggle="yes">BAK1</italic>).<sup><xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup> Remarkably, BAX/BAK double-knockout (DKO) cells were completely resistant to the lethal effects of triptolide (<xref rid="F1" ref-type="fig">Figures 1D</xref> and <xref rid="SD8" ref-type="supplementary-material">S1E</xref>). While BAX/BAK DKO cells did not die, these cells were rendered completely non-proliferative within 4 h of triptolide exposure, suggesting that triptolide had completely inhibited transcription (<xref rid="F1" ref-type="fig">Figures 1D</xref>, <xref rid="SD8" ref-type="supplementary-material">S1F</xref>, and <xref rid="SD8" ref-type="supplementary-material">S1G</xref>). Triptolide-induced death was also suppressed using the caspase inhibitor, z-VAD, whereas selective inhibitors of other death pathways did not alter lethality (<xref rid="F1" ref-type="fig">Figure 1E</xref>). Similar effects were observed following &#9082;-amanitin treatment in U2OS cells (<xref rid="F1" ref-type="fig">Figures 1E</xref>, <xref rid="SD8" ref-type="supplementary-material">S1H</xref>, and <xref rid="SD8" ref-type="supplementary-material">S1I</xref>). Furthermore, inhibiting apoptosis suppressed the lethality of transcriptional inhibitors in a panel of genetically unrelated cell lines (<xref rid="F1" ref-type="fig">Figures 1E</xref>, <xref rid="SD8" ref-type="supplementary-material">S1J</xref>, and <xref rid="SD8" ref-type="supplementary-material">S1K</xref>; <xref rid="SD3" ref-type="supplementary-material">Table S1</xref>). These data reveal that transcriptional inhibition&#8212;even complete and prolonged transcriptional inhibition&#8212;exclusively activates a single cell death pathway, the cell-intrinsic apoptotic response.</p></sec><sec id="S4"><title>Apoptosis is activated prior to passive loss of apoptotic regulatory proteins</title><p id="P13">RNA Pol II was completely inhibited at the doses we used, and as expected, RNA levels decreased following loss of RNA Pol II (<xref rid="SD8" ref-type="supplementary-material">Figures S1L</xref>&#8211;<xref rid="SD8" ref-type="supplementary-material">S1N</xref>). However, at the time of death initiation, the RNA pool was only modestly decreased, with the total abundance of mRNAs decayed by &#8764;25% (<xref rid="SD8" ref-type="supplementary-material">Figures S1O</xref> and <xref rid="SD8" ref-type="supplementary-material">S1P</xref>). Furthermore, at the protein level, we observe no change in expression of canonical apoptotic regulatory proteins 4&#8211;8 h after triptolide exposure (<xref rid="SD8" ref-type="supplementary-material">Figure S2A</xref>). Thus, rapid initiation of apoptosis following loss of RNA Pol II could not be easily explained by the passive loss of mRNA or downstream decrease in protein expression.</p><p id="P14">Cellular behaviors did not appear to be dysregulated, even following a more substantial loss of RNAs. For instance, we observed similar RNA decay rates in U2OS and U2OS-BAX/BAK DKO cells (<xref rid="SD8" ref-type="supplementary-material">Figure S2B</xref>; <xref rid="SD2" ref-type="supplementary-material">Table S2</xref>). However, 4 days following triptolide exposure&#8212;when U2OS were completely dead&#8212;BAX/BAK DKO cells displayed no overt signs of dysregulation, despite having lost more than 90% of the mRNA pool (<xref rid="F1" ref-type="fig">Figures 1F</xref>&#8211;<xref rid="F1" ref-type="fig">1H</xref> and <xref rid="SD8" ref-type="supplementary-material">S2B</xref>&#8211;<xref rid="SD8" ref-type="supplementary-material">S2E</xref>). Even 4 days after triptolide exposure, BAX/BAK DKO cells were capable of re-adhering to plates following trypsinization, produced normal levels of ATP, and could activate DNA damage signaling (<xref rid="SD8" ref-type="supplementary-material">Figures S2F</xref>&#8211;<xref rid="SD8" ref-type="supplementary-material">S2K</xref>). Normal behaviors were maintained in BAX/BAK DKO cells through &#8764;10 days of triptolide exposure, after which cells began dying, with the entire population dying by 24 days (<xref rid="F1" ref-type="fig">Figures 1G</xref> and <xref rid="SD8" ref-type="supplementary-material">S2L</xref>). Notably, passive death observed in BAX/BAK DKO cells was coincident with complete loss of all mRNAs, evaluated using absolute mRNA quantification (<xref rid="F1" ref-type="fig">Figure 1H</xref>; <xref rid="SD2" ref-type="supplementary-material">Table S2</xref>). These data reveal that accidental cell death following loss of mRNA does indeed occur but is temporally distinct from the rapid death caused by RNA Pol II loss in cells that are proficient for activating apoptosis.</p><p id="P15">One potential explanation for these results is that lethality induced by triptolide and &#9082;-amanitin stems from an off-target mechanism, unrelated to RNA Pol II. To address this, we evaluated the effects of RNA Pol II degradation in HAP1 cells, in which the endogenous RPB1 gene (<italic toggle="yes">POL2RA</italic>) is tagged with an auxin-inducible degron (HAP1-RPB1-AID) (<xref rid="F1" ref-type="fig">Figure 1I</xref>, top).<sup><xref rid="R19" ref-type="bibr">19</xref></sup> While auxin had no effect on wild-type (WT) HAP1 cells, HAP1-RPB1-AID cells displayed rapid cell death that initiated shortly after RNA Pol II degradation (<xref rid="F1" ref-type="fig">Figure 1I</xref>). Furthermore, lethality of Rpb1 degradation could be potently suppressed by co-treatment with z-VAD, consistent with the results observed for triptolide and &#9082;-amanitin (<xref rid="F1" ref-type="fig">Figure 1I</xref>). Taken together, these data reveal that apoptosis following loss of RNA Pol II occurs in response to an active process that is distinct from the effects of global loss of mRNA.</p></sec><sec id="S5"><title>Loss of hypophosphorylated RNA Pol II&#8212;but not loss of RNA Pol II activity&#8212;correlates with initiation of apoptosis</title><p id="P16">While apoptotic-proficient cells die before experiencing global loss of mRNA, these cells still lose short-lived transcripts (<xref rid="SD8" ref-type="supplementary-material">Figure S2C</xref>). Mcl-1 is a potent negative regulator of apoptosis, unique among apoptotic regulators in that it is rapidly turned over at both the mRNA and protein levels.<sup><xref rid="R20" ref-type="bibr">20</xref>&#8211;<xref rid="R23" ref-type="bibr">23</xref></sup> Indeed, Mcl-1 is rapidly lost following transcriptional inhibition (<xref rid="SD8" ref-type="supplementary-material">Figures S3A</xref> and <xref rid="SD8" ref-type="supplementary-material">S3B</xref>). However, U2OS cells were insensitive to chemical inhibition or genetic knockout of <italic toggle="yes">MCL1</italic>, and loss of <italic toggle="yes">MCL1</italic> did not alter sensitivity to triptolide (<xref rid="SD8" ref-type="supplementary-material">Figures S3C</xref> and <xref rid="SD8" ref-type="supplementary-material">S3D</xref>).</p><p id="P17">We next sought to more generally test if loss of short-lived mRNAs following transcriptional inhibition causes apoptosis. One simple prediction of this model is that drugs inhibiting productive elongation faster will initiate death proportionally faster. To capture variation in RNA Pol II inhibition kinetics, we profiled transcriptional inhibitors that function with different inhibition timing: flavopiridol, THZ1, triptolide, actinomycin-D, &#945;-amanitin, and ethynylcytidine.<sup><xref rid="R24" ref-type="bibr">24</xref></sup> To quantify the kinetics of RNA Pol II inhibition, we first used immunoblotting of Rpb1 to distinguish between the levels of hyper- and hypo-phosphorylated RNA Pol II (<xref rid="F2" ref-type="fig">Figure 2A</xref>). The upper band, called RNA Pol IIO, migrates slowly due to hyper-phosphorylation of the carboxyl-terminal domain (CTD).<sup><xref rid="R25" ref-type="bibr">25</xref></sup> RNA Pol IIO is the productively elongating pool of RNA Pol II.<sup><xref rid="R26" ref-type="bibr">26</xref></sup> The lower band, called Pol IIA, represents all other forms of RNA Pol II that are not productively elongating, including preinitiation complex (PIC) bound, promoter paused, early pause released, and free RNA Pol II.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> We observed significant variation in the timing of RNA Pol IIO loss, with some drugs, such as the Cdk9 inhibitor flavopiridol, causing IIO loss within minutes, while other inhibitors required several hours to completely lose RNA Pol IIO (<xref rid="F2" ref-type="fig">Figure 2B</xref>; <xref rid="SD4" ref-type="supplementary-material">Table S3</xref>). However, drugs inducing the fastest loss of IIO were not particularly fast at activating cell death. The two fastest inhibitors, flavopiridol and THZ1, were, in fact, the two slowest activators of cell death (<xref rid="F2" ref-type="fig">Figure 2B</xref>; <xref rid="SD4" ref-type="supplementary-material">Table S3</xref>). Overall, we found no correlation between the timing of cell death and the timing of RNA Pol IIO loss (<xref rid="F2" ref-type="fig">Figures 2C</xref> and <xref rid="F2" ref-type="fig">2D</xref>; <xref rid="SD4" ref-type="supplementary-material">Table S3</xref>).</p><p id="P18">While RNA Pol IIO is the hyperphosphorylated form of RNA Pol II, it is not a precise measure of RNA Pol II transcriptional activity, particularly following transcriptional perturbations. Thus, we also used EU incorporation into nascent RNAs to explore the relationship between the timing of transcriptional inhibition and the timing of cell death (<xref rid="SD8" ref-type="supplementary-material">Figure S3E</xref>). No correlation was observed when comparing the timing of cell death to transcriptional inhibition quantified using EU incorporation (<xref rid="F2" ref-type="fig">Figures 2D</xref> and <xref rid="SD8" ref-type="supplementary-material">S3F</xref>). These data suggest that death induced by RNA Pol II inhibition does not result from loss of short-lived mRNAs.</p><p id="P19">The effects of transcriptional inhibitors could be phenocopied using auxin-inducible degradation of Rpb1 (<xref rid="F1" ref-type="fig">Figure 1I</xref>). Thus, we considered other mechanisms by which loss of RNA Pol II could activate death. While previous studies have generally focused on how transcriptional inhibitors affect RNA Pol IIO, our data highlight an underappreciated ability of these drugs to modulate hypophosphorylated RNA Pol IIA as well (<xref rid="F2" ref-type="fig">Figure 2A</xref>). Notably, while loss of IIO was not correlated with activation of death, we observed a strong positive correlation between timing of cell death and timing of decay for RNA Pol IIA, the forms of RNA Pol II that are not actively elongating mRNA (<xref rid="F2" ref-type="fig">Figures 2E</xref>, <xref rid="F2" ref-type="fig">2F</xref>, and <xref rid="SD8" ref-type="supplementary-material">S3G</xref>&#8211;<xref rid="SD8" ref-type="supplementary-material">S3I</xref>). Furthermore, the relationship between IIA decay and cell death was directly proportional, such that loss of RNA Pol IIA consistently preceded death by a fixed amount of time (<xref rid="F2" ref-type="fig">Figure 2F</xref>). While only a correlative result, these data propose an alternative model whereby death following transcriptional inhibition is not related to inhibition of RNA Pol II activity and the subsequent loss of mRNA but instead may result directly from loss of the hypophosphorylated RNA Pol IIA protein.</p></sec><sec id="S6"><title>Loss of hypophosphorylated RNA Pol II initiates apoptosis</title><p id="P20">A critical challenge for determining causality in this context is the mutual dependence between RNA Pol II protein and its enzymatic function: degrading RNA Pol II invariably inhibits RNA Pol II activity, and the existence of RNA Pol II protein relies on RNA Pol II-mediated transcription. To overcome this challenge, we developed three complementary strategies for uncoupling inhibition of RNA Pol II activity and the loss of RNA Pol II protein (<xref rid="F3" ref-type="fig">Figure 3A</xref>). First, we sought to acutely degrade RNA Pol II without inducing subsequent loss of mRNAs by inhibiting mediators of RNA degradation (<xref rid="F3" ref-type="fig">Figure 3Ai</xref>). NUP93 and EXOSC5 are critical mediators of mRNA concentration homeostasis, and acute knockdown of these proteins leads to an accumulation of mRNA.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> As expected, the mRNA pool in NUP93-KO cells was stabilized and significantly more resistant to triptolide-induced mRNA loss than control cells (<xref rid="F3" ref-type="fig">Figure 3B</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S4</xref>). Despite the stabilized mRNA pool, triptolide activated death to similar levels&#8212;and with similar kinetics&#8212;in control and NUP93-KO cells (<xref rid="F3" ref-type="fig">Figure 3C</xref>). Similar results were observed in EXOSC5-KO cells (<xref rid="SD8" ref-type="supplementary-material">Figures S3J</xref> and <xref rid="SD8" ref-type="supplementary-material">S3K</xref>). Notably, some rapidly degraded transcripts&#8212;including MYC, WEE1, and JUN&#8212;continue to be rapidly degraded in NUP93-KO cells (<xref rid="SD8" ref-type="supplementary-material">Figure S3L</xref>). However, knocking out these genes did not kill U2OS cells, nor did knocking out these genes exacerbate triptolide-induced lethality (<xref rid="SD8" ref-type="supplementary-material">Figures S3M</xref> and <xref rid="SD8" ref-type="supplementary-material">S3N</xref>). These data again suggest that death following RNA Pol II inhibition cannot be explained by the passive loss of mRNA alone.</p><p id="P21">Second, we sought to buffer against triptolide-induced degradation of RNA Pol IIA while maintaining transcriptional inhibition (<xref rid="F3" ref-type="fig">Figure 3Aii</xref>). Triptolide inhibits XPB, the helicase subunit of TFIIH.<sup><xref rid="R11" ref-type="bibr">11</xref></sup> Triptolide-induced degradation of RNA Pol II requires Cdk7 activity, presumably because Cdk7 facilitates removal of the PIC and release of RNA Pol II from chromatin, enabling RNA Pol II degradation.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> Consistent with this, co-treatment with the Cdk7 inhibitor, THZ1, blocks triptolide-induced RNA Pol IIA degradation (<xref rid="F3" ref-type="fig">Figures 3D</xref> and <xref rid="F3" ref-type="fig">3E</xref>). Importantly, THZ1 is itself a transcriptional inhibitor, and the combination of triptolide and THZ1 was as good at inducing RNA Pol IIO loss as either drug alone (<xref rid="F3" ref-type="fig">Figures 3D</xref> and <xref rid="F3" ref-type="fig">3F</xref>). Despite the complete loss of hyperphosphorylated RNA Pol IIO, the addition of THZ1 suppressed the lethality of triptolide (<xref rid="F3" ref-type="fig">Figures 3D</xref> and <xref rid="F3" ref-type="fig">3G</xref>). This paradox&#8212;in which the lethal effects of transcriptional inhibition can be suppressed by adding another transcriptional inhibitor&#8212;is in line with a model whereby lethality results from the degradation of hypophosphorylated RNA Pol II protein.</p><p id="P22">Finally, we asked if exogenous expression of a functionally inactive RNA Pol II mutant protein could rescue viability following degradation of endogenous RNA Pol II (<xref rid="F3" ref-type="fig">Figure 3Aiii</xref>). To accomplish this, we designed an RNA Pol II &#8220;switchover&#8221; system (<xref rid="F3" ref-type="fig">Figure 3H</xref>). This system features a doxycycline-inducible <italic toggle="yes">RPB1</italic> transgene completely devoid of the 52 heptapeptide repeat CTD.<sup><xref rid="R28" ref-type="bibr">28</xref>&#8211;<xref rid="R31" ref-type="bibr">31</xref></sup> Truncated versions of the CTD can still initiate in some settings but have defects in splicing and termination, and a completely CTD-less Rbp1 cannot initiate transcription.<sup><xref rid="R32" ref-type="bibr">32</xref>,<xref rid="R33" ref-type="bibr">33</xref></sup> In this CTD-less <italic toggle="yes">RBP1</italic> fragment, we also encoded an &#9082;-amanitin resistance mutation, N792D, allowing the selective degradation of endogenous RNA Pol II.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> Conceptually, this system allows us to directly compare cell death outcomes, using isogenic cells that either have or do not have a pool of non-functional RNA Pol II protein (<xref rid="F3" ref-type="fig">Figure 3I</xref>). As expected, &#9082;-amanitin induced complete loss of endogenous RNA Pol II in both doxycycline-pretreated and untreated conditions (<xref rid="F3" ref-type="fig">Figure 3J</xref>). However, only cells pretreated with doxycycline expressed a truncated, &#9082;-amanitin-unresponsive Rpb1 protein (<xref rid="F3" ref-type="fig">Figure 3J</xref>). Expression of Rpb1-N792D-&#916;CTD did not inhibit &#9082;-amanitin-induced loss of mRNA, validating that the CTD is required for transcription initiation (<xref rid="F3" ref-type="fig">Figures 3K</xref> and <xref rid="SD8" ref-type="supplementary-material">S3O</xref>; <xref rid="SD1" ref-type="supplementary-material">Table S4</xref>). Importantly, expression of Rpb1-N792D-&#916;CTD potently suppressed &#9082;-amanitin-induced cell death (<xref rid="F3" ref-type="fig">Figure 3L</xref>). Expression of Rpb1-N792D-&#916;CTD had no effect on the lethality of unrelated apoptotic agents, and rendering Rpb1-&#916;CTD sensitive to &#9082;-amanitin abolished its ability to suppress death (<xref rid="SD8" ref-type="supplementary-material">Figures S3P</xref> and <xref rid="SD8" ref-type="supplementary-material">S3Q</xref>). These experiments demonstrate that cell death following transcriptional inhibition is caused by degradation of the hypophosphorylated form of RNA Pol II and not loss of RNA Pol II transcriptional activity.</p></sec><sec id="S7"><title>Chemogenetic profiling identifies regulators of triptolide-induced cell death</title><p id="P23">RNA Pol II is a nuclear protein, but apoptosis is regulated at mitochondria. Thus, we next aimed to characterize how decreased levels of RNA Pol IIA are sensed and communicated to initiate apoptosis. Considering the lack of prior knowledge for which processes respond to loss of RNA Pol IIA, we evaluated this question using an unbiased genome-wide screening approach. We used Cas9-expressing U2OS cells to evaluate the effect of gene knockouts on triptolide-induced lethality.<sup><xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R35" ref-type="bibr">35</xref></sup> To identify genes that specifically regulate cell death, rather than proliferation, we developed a simple experimental approach to agitate plates, facilitating a mechanical separation of apoptotic corpses from live cells, such that both populations could be sequenced independently (<xref rid="F4" ref-type="fig">Figures 4A</xref> and <xref rid="SD8" ref-type="supplementary-material">S4A</xref>&#8211;<xref rid="SD8" ref-type="supplementary-material">S4F</xref>).</p><p id="P24">Our screen identified more than 100 genes whose knockout reduced triptolide-induced cell death (<xref rid="F4" ref-type="fig">Figures 4B</xref> and <xref rid="SD8" ref-type="supplementary-material">S4G</xref>; <xref rid="SD7" ref-type="supplementary-material">Table S5</xref>). Remarkably, this cohort included every gene encoding an essential pro-apoptotic regulatory protein (<xref rid="F4" ref-type="fig">Figures 4B</xref> and <xref rid="F4" ref-type="fig">4C</xref>). We also identified key negative regulators of apoptosis, such as <italic toggle="yes">XIAP</italic> and BCL-xL (<italic toggle="yes">BCL2L1</italic>), which increased triptolide-induced lethality when deleted (<xref rid="F4" ref-type="fig">Figures 4B</xref> and <xref rid="F4" ref-type="fig">4C</xref>). Furthermore, we identified triptolide-specific genetic dependencies, including <italic toggle="yes">CDK7</italic>, in line with our finding that THZ1 suppresses triptolide-induced death (<xref rid="F3" ref-type="fig">Figures 3G</xref> and <xref rid="F4" ref-type="fig">4B</xref>). Importantly, regulators of triptolide-induced death were not enriched for genes encoding short half-life mRNAs, further highlighting the specificity of our screen and that mRNA decay does not drive cell death in this context (<xref rid="F4" ref-type="fig">Figure 4D</xref>).</p><p id="P25">To clarify how RNA Pol II degradation activates apoptosis, we began by exploring if regulators of triptolide-induced death were enriched for genes involved in known stress response pathways. As expected, our screen was strongly enriched for apoptotic regulatory genes (<xref rid="F4" ref-type="fig">Figure 4E</xref>). However, we did not identify any other stress response pathways that might facilitate activation of apoptosis (<xref rid="F4" ref-type="fig">Figures 4E</xref> and <xref rid="F4" ref-type="fig">4F</xref>). Due to the proximity of RNA Pol II to DNA, we paid special attention to the DNA damage response (DDR). However, the DDR did not appear to be involved in triptolide-induced death: no regulators of DDR were hits in our screen, triptolide failed to activate DDR signaling, and knocking out TP53, an essential regulator of DDR-induced apoptosis,<sup><xref rid="R36" ref-type="bibr">36</xref></sup> had no effect on triptolide-induced death (<xref rid="F4" ref-type="fig">Figures 4F</xref>&#8211;<xref rid="F4" ref-type="fig">4H</xref>).</p></sec><sec id="S8"><title>Apoptosis following RNA Pol II degradation requires PTBP1</title><p id="P26">The gene whose deletion most strongly suppressed triptolide-induced death was not a core apoptotic effector, but PTBP1 (<xref rid="F4" ref-type="fig">Figure 4B</xref>). PTBP1 is a multi-functional RNA-binding protein with well-established roles in alternative splicing and activation of internal ribosome entry segments (IRESs).<sup><xref rid="R37" ref-type="bibr">37</xref>&#8211;<xref rid="R39" ref-type="bibr">39</xref></sup> We validated in U2OS cells that knocking out <italic toggle="yes">PTBP1</italic> suppressed triptolide-induced death, and re-expressing <italic toggle="yes">PTBP1</italic> in PTBP1-KO cells restored triptolide sensitivity (<xref rid="F5" ref-type="fig">Figures 5A</xref>, <xref rid="SD8" ref-type="supplementary-material">S5A</xref>, and <xref rid="SD8" ref-type="supplementary-material">S5B</xref>). A similar phenotype was observed following exposure to &#945;-amanitin and following <italic toggle="yes">PTBP1</italic> deletion in a panel of genetically diverse cell lines (<xref rid="F5" ref-type="fig">Figures 5B</xref> and <xref rid="SD8" ref-type="supplementary-material">S5C</xref>). By contrast, canonical apoptotic agents, such as ABT-199 or staurosporine, were not affected by knocking out <italic toggle="yes">PTBP1</italic> (<xref rid="F5" ref-type="fig">Figure 5B</xref>). Together, these data reveal that PTBP1 is required for apoptosis specifically in the context of RNA Pol II degradation.</p><p id="P27">Knocking out <italic toggle="yes">PTBP1</italic> suppressed lethality without altering RNA Pol II degradation, triptolide-induced loss of transcriptional activity, or triptolide-induced decay of mRNAs (<xref rid="SD8" ref-type="supplementary-material">Figures S5A</xref>&#8211;<xref rid="SD8" ref-type="supplementary-material">S5E</xref>). These data rule out the trivial explanation that loss of <italic toggle="yes">PTBP1</italic> inhibits triptolide activity. Furthermore, triptolide-induced changes in gene expression in U2OS and PTBP1-KO cells were nearly indistinguishable, further supporting our general finding that rapid loss of mRNA cannot explain the lethality of transcriptional inhibition (<xref rid="F5" ref-type="fig">Figures 5C</xref>, <xref rid="SD8" ref-type="supplementary-material">S5E</xref>, and <xref rid="SD8" ref-type="supplementary-material">S5F</xref>).</p><p id="P28">We next explored mechanisms by which PTBP1 could regulate apoptosis following RNA Pol II degradation. Prior studies report a post-transcriptional function in which PTBP1 promotes tumor necrosis factor (TNF)-induced apoptosis by activating IRESs, facilitating translation of the apoptotic effector, APAF1.<sup><xref rid="R40" ref-type="bibr">40</xref>,<xref rid="R41" ref-type="bibr">41</xref></sup> However, APAF1 protein expression was not altered during triptolide exposure, and APAF1 was expressed to similar levels in WT and PTBP1-KO cells (<xref rid="SD8" ref-type="supplementary-material">Figure S5F</xref>). PTBP1 is best described as a regulator of alternative splicing.<sup><xref rid="R42" ref-type="bibr">42</xref>&#8211;<xref rid="R45" ref-type="bibr">45</xref></sup> Intriguingly, the influence of PTBP1 on triptolide-induced lethality also appears to be unrelated to its role in alternative splicing: other regulators of alternative splicing did not suppress triptolide-induced lethality, triptolide did not affect PTBP1-dependent splicing, triptolide-induced splicing changes were unaffected in PTBP1-KO cells, and differentially spliced genes in PTBP1-KO cells did not affect triptolide-induced death when knocked out (<xref rid="F5" ref-type="fig">Figures 5D</xref> and <xref rid="SD8" ref-type="supplementary-material">S5G</xref>&#8211;<xref rid="SD8" ref-type="supplementary-material">S5I</xref>; <xref rid="SD7" ref-type="supplementary-material">Tables S5</xref> and <xref rid="SD6" ref-type="supplementary-material">S6</xref>).<sup><xref rid="R37" ref-type="bibr">37</xref></sup></p><p id="P29">To further explore how PTBP1 facilitates activation of apoptosis, we used immunoprecipitation to determine if PTBP1 interacts with RNA Pol II. Importantly, we found that only hypophosphorylated RNA Pol IIA co-immunoprecipitated with PTBP1 (<xref rid="F5" ref-type="fig">Figure 5E</xref>). Reciprocal immunoprecipitations targeting specific post-translationally modified forms of Rbp1 confirm that PTBP1 does not interact with the productively elongating RNA Pol IIO but does interact with hypophosphorylated RNA Pol IIA (<xref rid="F5" ref-type="fig">Figure 5F</xref>).</p><p id="P30">Many RNA-binding proteins localize to the nucleus and accumulate in the cytoplasm following transcriptional inhibition, though the reason for this is unclear.<sup><xref rid="R46" ref-type="bibr">46</xref>,<xref rid="R47" ref-type="bibr">47</xref></sup> Curiously, triptolide-induced death was rescued by knocking out the nuclear exporter <italic toggle="yes">XPO1</italic>; conversely, knocking out nuclear importers, <italic toggle="yes">RANGAP1</italic> or <italic toggle="yes">KPNB1</italic>, exacerbated triptolide-induced lethality (<xref rid="SD7" ref-type="supplementary-material">Table S5</xref>). Thus, we next explored whether loss of RNA Pol IIA stimulated nuclear-to-cytoplasmic translocation of PTBP1. Using fluorescence microscopy and cell fractionation, we confirmed that PTBP1 is a nuclear protein in healthy cells (<xref rid="F5" ref-type="fig">Figures 5G</xref>&#8211;<xref rid="F5" ref-type="fig">5I</xref>). However, PTBP1 translocated to the cytoplasm following triptolide- or &#945;-amanitin-induced RNA Pol II degradation (<xref rid="F5" ref-type="fig">Figures 5G</xref>&#8211;<xref rid="F5" ref-type="fig">5I</xref>, <xref rid="SD8" ref-type="supplementary-material">S5J</xref>, and <xref rid="SD8" ref-type="supplementary-material">S5K</xref>). Expression of CTD-less RNA Pol II blocked cytoplasmic translocation of PTBP1 and suppressed the lethality of &#945;-amanitin (<xref rid="F5" ref-type="fig">Figures 5J</xref>, <xref rid="SD8" ref-type="supplementary-material">S5J</xref>, and <xref rid="SD8" ref-type="supplementary-material">S5L</xref>). These data suggest that cytoplasmic trafficking of PTBP1 is critical for its death regulatory function.</p><p id="P31">We performed RNA sequencing (RNA-seq) on cytoplasmic and nuclear fractions in WT and PTBP1-KO cells. We found no evidence that altered localization of PTBP1 is associated with a change in mRNA localization that can causally explain triptolide-induced cell death: a cross-comparison of our RNA-seq and chemogenetic profiling datasets revealed no PTBP1-dependent changes to transcript expression or localization among genes that are required for triptolide-induced death (<xref rid="SD8" ref-type="supplementary-material">Figures S5M</xref> and <xref rid="SD8" ref-type="supplementary-material">S5N</xref>; <xref rid="SD6" ref-type="supplementary-material">Table S6</xref>). These data, again, support our observation that altered mRNA expression cannot causally explain cell death following transcriptional inhibition.</p><p id="P32">Given that PTBP1 binds to RNA Pol IIA in the nucleus, we presumed that PTBP1 translocation is an early event, upstream of key regulatory steps, such as mitochondrial outer membrane permeabilization (MOMP). Indeed, knocking out <italic toggle="yes">PTBP1</italic> blocked triptolide-induced activation of BAX and the release of cytochrome <italic toggle="yes">c</italic> from mitochondria (<xref rid="SD8" ref-type="supplementary-material">Figures S6A</xref>&#8211;<xref rid="SD8" ref-type="supplementary-material">S6C</xref>). These data confirm that PTBP1 translocation is an early event, upstream of MOMP. Taken together, these data support that PTBP1 is a genuine regulator of apoptosis, specifically following loss of RNA Pol IIA.</p></sec><sec id="S9"><title>BCL2L12 activates MOMP following RNA Pol II degradation and PTBP1 translocation</title><p id="P33">We next aimed to address how apoptosis is activated following RNA Pol II degradation and PTBP1 translocation. Apoptosis is typically initiated by BH3 domain-containing proteins in the Bcl-2 family.<sup><xref rid="R48" ref-type="bibr">48</xref>,<xref rid="R49" ref-type="bibr">49</xref></sup> Notably, our genetic screen identified every essential apoptotic effector downstream of MOMP; however, <italic toggle="yes">BCL2L12</italic> was the only Bcl-2 homology (BH) domain-containing gene that was required for triptolide-induced death, aside from BAX and BAK themselves (<xref rid="F6" ref-type="fig">Figure 6A</xref>). BCL2L12 is a poorly understood protein that has previously been characterized as having an anti-apoptotic function.<sup><xref rid="R50" ref-type="bibr">50</xref>,<xref rid="R51" ref-type="bibr">51</xref></sup> Nonetheless, we validated our genetic screening results, confirming that knocking out <italic toggle="yes">BCL2L12</italic> strongly suppresses triptolide-induced death in U2OS and other cell lines (<xref rid="F6" ref-type="fig">Figures 6B</xref>, <xref rid="SD8" ref-type="supplementary-material">S6D</xref>, and <xref rid="SD8" ref-type="supplementary-material">S6E</xref>). <italic toggle="yes">BCL2L12</italic> was specifically required for the lethality of RNA Pol II degraders but not other apoptotic drugs (<xref rid="F6" ref-type="fig">Figure 6C</xref>). Also, knocking out <italic toggle="yes">BCL2L12</italic> blocked triptolide-induced activation of BAX and release of cytochrome <italic toggle="yes">c</italic> (<xref rid="SD8" ref-type="supplementary-material">Figures S6F</xref> and <xref rid="SD8" ref-type="supplementary-material">S6G</xref>). These data confirm that, like PTBP1, BCL2L12 is required for activation of apoptosis downstream of RNA Pol II degradation and upstream of MOMP.</p><p id="P34">Notably, although many isoforms of BCL2L12 have been reported,<sup><xref rid="R52" ref-type="bibr">52</xref></sup> we did not observe any PTBP1-dependent changes in splicing of BCL2L12 (<xref rid="SD8" ref-type="supplementary-material">Figures S5H</xref>, <xref rid="SD8" ref-type="supplementary-material">S5I</xref>, and <xref rid="SD8" ref-type="supplementary-material">S6H</xref>; <xref rid="SD6" ref-type="supplementary-material">Table S6</xref>). Thus, we next aimed to clarify the functional relationship between BCL2L12 and PTBP1. We began by exploring if PTBP1 translocation alters BCL2L12 localization. To visualize BCL2L12, we created an hemagglutinin (HA)-tagged BCL2L12, which was capable of restoring triptolide sensitivity in BCL2L12-KO cells (<xref rid="SD8" ref-type="supplementary-material">Figure S6I</xref>). Using fluorescence microscopy, we found that BCL2L12 has a predominately nuclear localization, although some staining was also observed at the mitochondria (<xref rid="F6" ref-type="fig">Figure 6D</xref>). Following triptolide exposure, BCL2L12 lost nuclear localization and accumulated at mitochondria (<xref rid="F6" ref-type="fig">Figures 6D</xref>, <xref rid="F6" ref-type="fig">6E</xref>, and <xref rid="SD8" ref-type="supplementary-material">S6J</xref>). Furthermore, triptolide-induced re-localization of BCL2L12 was blocked in PTBP1-KO cells (<xref rid="F6" ref-type="fig">Figures 6D</xref> and <xref rid="F6" ref-type="fig">6E</xref>). Knocking out <italic toggle="yes">BCL2L12</italic> did not affect RNA Pol II degradation-induced translocation of PTBP1 (<xref rid="SD8" ref-type="supplementary-material">Figures S6K</xref>&#8211;<xref rid="SD8" ref-type="supplementary-material">S6M</xref>). These data suggest that PTBP1 is upstream of BCL2L12 and facilitates the release of BCL2L12 from the nucleus.</p><p id="P35">BCL2L12 is atypical within the Bcl2 family, as it contains only the BH2 homology domain, but not the BH1 or BH4 domains that typically exist in anti-apoptotic Bcl2 family proteins, or the BH3 domain that exists in all pro-apoptotic members of the Bcl2 family. Thus, it was unclear how BCL2L12 can function as an activator of apoptosis in the context of RNA Pol II degradation. However, prior studies note that BCL2L12 contains a non-canonical &#8220;BH3-like&#8221; domain.<sup><xref rid="R53" ref-type="bibr">53</xref></sup> Given that BH3 domains are critical for the pro-apoptotic functions of apoptotic activators/sensitizers, we next determined if the BH3-like domain within BCL2L12 has pro-apoptotic activity. To address this, we mutated E220, a critical residue required for the function of other pro-apoptotic BH3 proteins (<xref rid="F6" ref-type="fig">Figure 6F</xref>).<sup><xref rid="R49" ref-type="bibr">49</xref>,<xref rid="R54" ref-type="bibr">54</xref></sup> BCL2L12-E220A failed to activate cell death following exposure to triptolide but did not affect the lethality of other apoptotic drugs (<xref rid="F6" ref-type="fig">Figures 6G</xref> and <xref rid="SD8" ref-type="supplementary-material">S6N</xref>). These data suggest that the BH3-like domain of BCL2L12 is critical for its pro-apoptotic function.</p><p id="P36">To further characterize the pro-apoptotic function of BCL2L12, we used iBH3 profiling to test if the BH3-like peptide in BCL2L12 could induce MOMP.<sup><xref rid="R55" ref-type="bibr">55</xref></sup> We found that the BCL2L12 BH3-like peptide induces MOMP with an EC<sub>50</sub> of 20&#8211;30 &#956;M, which was less potent than the strong activator BIM and in line with potencies of other BH3 proteins when tested in unprimed/untreated cells (<xref rid="F6" ref-type="fig">Figures 6H</xref> and <xref rid="SD8" ref-type="supplementary-material">S6O</xref>).<sup><xref rid="R56" ref-type="bibr">56</xref>&#8211;<xref rid="R58" ref-type="bibr">58</xref></sup> The activity of the BH3-like peptide was similar in WT and PTBP1-KO cells, consistent with our observation that BCL2L12 functions downstream of PTBP1 (<xref rid="SD8" ref-type="supplementary-material">Figure S6P</xref>). Taken together, these data reveal a basic framework for how apoptosis is activated upon RNA Pol II degradation. In healthy cells, PTBP1 and BCL2L12 are largely localized to the nucleus, and PTBP1 interacts with the hypophosphorylated forms of RNA Pol II. Upon loss of hypophosphorylated RNA Pol II, PTBP1 promotes the cytoplasmic translocation of BCL2L12, which initiates MOMP and cell death using the conventional intrinsic apoptotic pathway (<xref rid="F6" ref-type="fig">Figure 6I</xref>).</p></sec><sec id="S10"><title>Multiple anti-cancer drugs owe their lethality to loss of RNA Pol IIA</title><p id="P37">We next aimed to investigate if RNA Pol II degradation-dependent death could be valuable in a therapeutic context. To address this question, we tested commonly used lethal compounds&#8212;including clinically relevant drugs that are not conventionally considered transcriptional inhibitors&#8212;and determined if the lethality of these drugs depended on genes required for triptolide-induced death: <italic toggle="yes">PTBP1</italic>, <italic toggle="yes">BCL2L12</italic>, and <italic toggle="yes">BAX</italic>/<italic toggle="yes">BAK1</italic> DKO. We generated a simple &#8220;Pol II degrader similarity&#8221; (PDS) score, which quantifies the extent to which a drug shares the genetic dependency profile of triptolide (<xref rid="F7" ref-type="fig">Figures 7A</xref> and <xref rid="F7" ref-type="fig">7B</xref>). We applied this signature-based strategy across 46 diverse compounds, covering 16 drug classes (<xref rid="F7" ref-type="fig">Figure 7C</xref>; <xref rid="SD5" ref-type="supplementary-material">Table S7</xref>). Strikingly, a wide array of PDS scores were observed, with variation both across and within drug classes (<xref rid="F7" ref-type="fig">Figure 7C</xref>). High PDS scores were observed for most drugs that directly target RNA Pol II or transcriptional Cdk proteins (<xref rid="F7" ref-type="fig">Figure 7C</xref>). By contrast, drugs inducing proteotoxic stress, such as brefeldin A, thapsigargin, or tunicamycin, were quite lethal but featured low PDS scores, confirming that RNA Pol II degradation activates death in a manner that is distinct from general dysregulation of protein levels (<xref rid="SD5" ref-type="supplementary-material">Table S7</xref>). Collectively, these data highlight that many drugs covering disparate mechanisms share the genetic dependencies observed for RNA Pol II degraders.</p><p id="P38">Each drug was evaluated across a range of doses, and we observed a large variation in PDS scores across doses of a drug. To more precisely categorize drug-dose pairs, we developed a binary classifier to evaluate our PDS data. We used a conservative probabilistic nearest neighbors-based machine-learning approach, in which a drug-dose pair was classified as &#8220;Pol II degradation-like&#8221; (PD-like) only if its proximity to validated RNA Pol II degrading drugs is within the neighborhood occupied by triptolide and &#945;-amanitin (<xref rid="SD8" ref-type="supplementary-material">Figures S7A</xref> and <xref rid="SD8" ref-type="supplementary-material">S7B</xref>).<sup><xref rid="R59" ref-type="bibr">59</xref>,<xref rid="R60" ref-type="bibr">60</xref></sup> Our classifier identified significant variation in drug classification across lethal doses of a drug (<xref rid="F7" ref-type="fig">Figure 7D</xref>). For instance, idarubicin was lethal at the highest 4 tested doses but was only PD-like at the highest dose (<xref rid="F7" ref-type="fig">Figure 7D</xref>). Conversely, 4-NQO was lethal at nearly all tested doses but, strikingly, only PD-like at intermediate doses (<xref rid="F7" ref-type="fig">Figure 7D</xref>).</p><p id="P39">We next validated if key features of RNA Pol II degradation-dependent death are also observed for PD-like drugs. For some PD-like drugs, it appeared that the mechanism of activation must differ from what is observed for conventional transcriptional inhibitors. For instance, the proteasome inhibitor bortezomib inhibits RNA Pol II degradation; however, RNA Pol II should still be ubiquitinated and recruited to the proteasome<sup><xref rid="R61" ref-type="bibr">61</xref></sup> and thus may no longer be available to sequester PTBP1. Thus, we first tested if PD-like compounds also cause PTBP1 translocation to the cytoplasm. Like triptolide, PD-like compounds 4-NQO, bortezomib, and cisplatin cause nuclear-to-cytoplasmic translocation of PTBP1 (<xref rid="F7" ref-type="fig">Figure 7E</xref>).</p><p id="P40">We next sought to validate if PD-like drugs also cause loss of RNA Pol IIA, as information about RNA Pol IIO/A levels or RNA Pol II activity is not included in the classifier. We focused initially on drugs such as abemaciclib, which are classified as PD-like at an intermediate dose but, paradoxically, not at higher doses (<xref rid="F7" ref-type="fig">Figure 7D</xref>). As predicted by our classifier, RNA Pol IIA is lost following exposure to 1 &#956;M abemaciclib but not when exposed to a 10-fold higher dose (<xref rid="F7" ref-type="fig">Figure 7F</xref>). Similar paradoxical dose-dependent loss of RNA Pol IIA was observed for other drugs, including the Cdk2/4/6 inhibitor PF3600 and idarubicin (<xref rid="SD8" ref-type="supplementary-material">Figures S7C</xref>&#8211;<xref rid="SD8" ref-type="supplementary-material">S7G</xref>). Thus, PD-like compounds also lose RNA Pol IIA, and this behavior was restricted to doses classified as PD-like.</p><p id="P41">Due to its widespread clinical use, we paid special attention to cisplatin, a chemotherapy used in the treatment of lung, ovarian, and testicular cancers, among others.<sup><xref rid="R62" ref-type="bibr">62</xref></sup> Our classifier predicts a PD-like mechanism for cisplatin at all doses, causing high levels of death (<xref rid="F7" ref-type="fig">Figure 7D</xref>). This was surprising, given that DNA damage can independently activate apoptosis through the DDR, which is observed for other drugs in this dataset. Consistent with our classifier, however, we observe RNA Pol IIA loss following cisplatin exposure at all doses inducing substantial lethality (<xref rid="F7" ref-type="fig">Figures 7G</xref> and <xref rid="SD8" ref-type="supplementary-material">S7H</xref>&#8211;<xref rid="SD8" ref-type="supplementary-material">S7J</xref>). Furthermore, cisplatin retains high PDS scores across several genetically unrelated cell types (<xref rid="F7" ref-type="fig">Figure 7H</xref>). These data suggest that the lethality of several DNA-damaging agents may hinge upon an RNA Pol II degradation-dependent death in both a drug- and dose-dependent manner.</p><p id="P42">Compounds that create bulky DNA lesions, such as 4-NQO and cisplatin, actually stall and degrade elongating RNA Pol IIO, and RNA Pol IIA is not directly degraded but rather &#8220;lost&#8221; due to being converted to RNA Pol IIO following initiation.<sup><xref rid="R63" ref-type="bibr">63</xref></sup> Thus, considering that some PD-like compounds preferentially target RNA Pol IIO, we explored if the lethality of PD-like compounds is still kinetically coupled to the loss of hypophosphorylated RNA Pol IIA. For PD-like drugs, cell death kinetics were also well correlated with the loss of RNA Pol IIA, with timing consistent with what we observe for canonical transcriptional inhibitors (<xref rid="F7" ref-type="fig">Figure 7I</xref>). Cell death kinetics for negative control drugs showed no relationship, and no correlation was observed between cell death timing and loss of RNA Pol IIO, even for drugs that preferentially target RNA Pol IIO (<xref rid="F7" ref-type="fig">Figure 7I</xref>; <xref rid="SD5" ref-type="supplementary-material">Table S7</xref>). Taken together, these data reveal that mechanisms of drug-induced lethality vary in non-trivial ways across doses, and more specifically, that loss of RNA Pol IIA is a common mechanism of lethality across many unrelated drug classes.</p></sec></sec><sec id="S11"><title>DISCUSSION</title><p id="P43">The fact that transcriptional inhibition is lethal to cells is hardly surprising. However, a common assumption has been that loss of transcription is toxic due to passive decay of mRNA and protein. We show that death following transcriptional inhibition initiates rapidly, well before cells experience stress from loss of mRNA or protein. Furthermore, we demonstrate that death occurs in response to an active signaling process, which is initiated by loss of the hypophosphorylated (i.e., not actively transcribing) form of RNA Pol II, not loss of RNA Pol II transcriptional activity. We also identify the critical events that signal loss of RNA Pol IIA to initiate apoptosis, specifically PTBP1/BCL2L12 translocation from the nucleus to the cytoplasm and BCL2L12-dependent activation of MOMP. Therefore, we propose that this process be termed the Pol II degradation-dependent apoptotic response (PDAR).</p><p id="P44">Why has this phenotype not been observed previously? Notably, the central issue is simply related to analytical resolution. Specifically, while apoptotic-deficient cells remain 100% viable following RNA Pol II degradation, these cells also cannot proliferate. Common drug response metrics misinterpret the level of lethality in this context because a non-proliferative drug-treated population is already very small compared with a rapidly dividing untreated population (<xref rid="SD8" ref-type="supplementary-material">Figure S1G</xref>).<sup><xref rid="R64" ref-type="bibr">64</xref></sup> Furthermore, given the lack of mechanistic insight provided by conventional analysis methods, any observed difference could reasonably be interpreted as evidence that apoptosis makes a partial/negligible contribution to the lethality of transcriptional inhibition (<xref rid="SD8" ref-type="supplementary-material">Figure S1G</xref>). Our evaluations of transcriptional inhibitors used the growth rate-adjusted for death (GRADE) method,<sup><xref rid="R65" ref-type="bibr">65</xref></sup> and mechanistic clarity provided by GRADE revealed that apoptotic-deficient cells completely arrest cell proliferation without activating any cell death (<xref rid="SD8" ref-type="supplementary-material">Figure S1F</xref>).</p><p id="P45">Prior to this discovery, substantial attention was focused on targeting transcription in cancer treatment. However, mechanisms promoting selective killing of cancer cells remained unclear and were generally presumed to be dependent on loss of rapidly turned-over proteins, such as Myc or Mcl-1.<sup><xref rid="R66" ref-type="bibr">66</xref></sup> Our study highlights that many of these drugs owe their lethality to activation of PDAR. This begs the question, <italic toggle="yes">why are cancer cells uniquely vulnerable to transcriptional inhibitors</italic>? While our study does not answer this question, possibilities may include altered RNA Pol II dynamics,<sup><xref rid="R67" ref-type="bibr">67</xref>,<xref rid="R68" ref-type="bibr">68</xref></sup> which may enable more flexible gene expression while sensitizing cells to PDAR. Alternatively, it is well-described that cancer cells are closer than normal cells to the threshold of apoptotic activation, also called mitochondrial priming.<sup><xref rid="R69" ref-type="bibr">69</xref>,<xref rid="R70" ref-type="bibr">70</xref></sup> Given that transcriptional inhibition exclusively activates mitochondrially regulated apoptosis, the selectivity of transcriptional inhibition may also stem from differences in mitochondrial priming.</p><p id="P46">Notably, the definitions we used for classifying PDAR-dependent cell death are conservative, as a drug was only characterized as PDAR-dependent if no alternative mechanisms exist to facilitate death in the absence of this pathway. Our study also highlights that selective killing is possible for PDAR-dependent drugs, as we identified several conventional DNA-damaging chemotherapies, which have long-standing clinical utility, that also score as PDAR-dependent using our conservative criteria. Thus, future studies of PDAR are likely to reveal new biomarkers that improve our ability to use a wide array of anti-cancer drugs and also may reveal new ways to selectively kill cancer cells.</p><sec id="S12"><title>Limitations of the study</title><p id="P47">Several mechanistic details of the PDAR pathway remain unclear. For instance, we did not clarify how much of the nuclear PTBP1 pool translocates to the cytoplasm upon loss of RNA Pol IIA, nor the amount that is required to propagate the PDAR signal. Additionally, it remains unclear how PTBP1 facilitates mitochondrial targeting of BCL2L12. Furthermore, because we lacked reagents for studying endogenous BCL2L12, our understanding of BCL2L12 localization was generated using an exogenous expression construct, and we were unable to evaluate how its level of expression and localization compare to the endogenous protein. Deeper mechanistic studies on endogenous BCL2L12 will help to understand the abundance of BCL2L12 in the nucleus/mitochondria and the relative contributions of these two pools. Our study demonstrates that loss of gene expression is not sufficient to activate apoptosis: knocking out PTBP1 or expressing a non-functional RNA Pol II rescued viability without altering the loss of gene expression. However, it is possible that altered gene expression cooperates with BCL2L12 to activate death by priming cells for apoptosis. The effect of transcriptional inhibition on priming was not explored in this study. Finally, we found that PDAR is the dominant form of death activated by many drugs. However, the extent to which PDAR contributes to the therapeutic efficacy of PD-like drugs has not been clarified. It remains possible that cell-autonomous killing is not required for the efficacy of some compounds or that mechanisms of lethality vary across cancer types or <italic toggle="yes">in vivo</italic>.</p></sec></sec><sec id="S13"><title>RESOURCE AVAILABILITY</title><sec id="S14"><title>Lead contact</title><p id="P48">Further information and requests for resources and reagents should be directed to the lead contact, Michael Lee (<email>michael.lee@umassmed.edu</email>).</p></sec><sec id="S15"><title>Materials availability</title><p id="P49">Requests for materials will be made available by the lead contact with a materials transfer agreement.</p></sec><sec sec-type="data-availability" id="S16"><title>Data and code availability</title><p id="P50">Custom scripts for curve fitting, LED kinetics, and drug GRADE are deposited on GitHub (<ext-link xlink:href="https://github.com/MJLee-Lab" ext-link-type="uri">https://github.com/MJLee-Lab</ext-link>). Custom scripts for other analyses are available upon request. RNA-seq data can be found in supplemental tables and as FASTQ files from the Gene Expression Omnibus (GEO) under accession numbers GEO: <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE283148">GSE283148</ext-link> (triptolide time course), GEO: <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE283149">GSE283149</ext-link> (NUP93-KO or EXOSC5-KO), GEO: <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE283150">GSE283150</ext-link> (nuclear:cytoplasmic fractionation), and GEO: <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE283151">GSE283151</ext-link> (RNA Pol II switchover system). Chemogenetic profiling data can be found as FASTQ files (GEO: <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE283147">GSE283147</ext-link>) and in <xref rid="SD7" ref-type="supplementary-material">Table S5</xref>. All other data are available in the main text or <xref rid="SD8" ref-type="supplementary-material">supplemental information</xref>.</p></sec></sec><sec id="S17"><title>STAR&#9733;METHODS</title><sec id="S18"><title>EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS</title><sec id="S19"><title>Cell Lines Culturing Conditions</title><p id="P51">U2OS, MDA-MB-157, A375, Hs578T, MDA-MB-453, MCF7, and HeLa cells were grown in DMEM (Corning, Cat# 10-017-CV) supplemented with 2mM glutamine (Corning, Cat# 25-005-CI). HT-29 cells were grown in McCoy&#8217;s 5A medium (Corning, Cat# 10-050-CV). WI-38 cells were grown in MEM medium (Thermo Fisher Scientific, Cat# 10370088) supplemented with 2mM glutamine. H1650 and PC9 cells were grown in RPMI medium (Thermo Fisher Scientific, Cat# 11875119). RPE-1 cells were grown in low glucose DMEM (Gibco, Cat# 11885-092) and Hams F-12 (Thermo Fisher Scientific, Cat# 11765054) mixed at a 1:1 ratio. HAP1 cells were grown in IMDM medium (Thermo Fisher Scientific, Cat# 12440053). MCF10A cells were grown in DMEM-F12 medium (Thermo Fisher Scientific, Cat# 11320033) supplemented with 5% horse serum (Thermo Fisher Scientific, Cat# 26050088), 20 ng/ml epidermal growth factor (EGF), 0.5 &#956;g/ml hydrocortisone, 100 ng/ml cholera toxin (Sigma-Aldrich, Cat# C8052-2MG), 10 &#956;g/ml insulin (Life Technologies, Cat# 12585014), and penicillin-streptomycin (Corning, Cat# 30-002-CI). Each media (expect that for MCF10A) was supplemented with 10% FBS (Peak Serum, Cat# PS-FB2, lot no. 21E1202) and penicillin-streptomycin (Corning, Cat# 30-002-CI). Hs578T cells were supplemented with 10&#956;g/mL insulin (Thermo Fisher Scientific, Cat# 12585014). Cell lines were cultured in incubators at 37C with 5% CO2. Cell lines were maintained at low (&lt;25) passage number from the original vial. U2OS, HT-29, WI-38, Hs578T, MDA-MB-453, MCF7, MDA-MB-157, A375, RPE-1, MCF10A and HeLa cells lines originated from female patients. H1650, PC9, HAP1 and HAP1-RPB1-AID cells originated from male patients. A375 cells were a gift from the Green laboratory (UMass Chan Medical School). HAP1 and HAP1-RPB1-AID cells were a gift from the Dekker laboratory (UMass Chan Medical School). RPE-1 cells were a gift from the Pazour laboratory (UMass Chan Medical School). PC9 cells were a gift from the Pritchard laboratory (Penn State University). All other cell lines mentioned above were purchased from ATCC and were authenticated using STR profiling with their identity confirmed.</p><p id="P52">U2OS-BAX/BAK1 double knockout cells (DKO) were generated previously.<sup><xref rid="R71" ref-type="bibr">71</xref></sup> U2OS cells expressing Nuc::mKate2 (U2OS-mKate2+) were generated previously.<sup><xref rid="R71" ref-type="bibr">71</xref></sup> All mKate2+ cells were generated by lentiviral infection with NucLight Red Lentivirus (Sartorius, 4627), followed by FACS selection. HAP1-RPB1-AID cells were treated with 450 &#956;g/mL hygromycin for one week prior to use. U2OS-Cas9 expressing and U2OS-TP53 knockout cells were generated previously.<sup><xref rid="R36" ref-type="bibr">36</xref></sup></p></sec><sec id="S20"><title>Cell Line Engineering</title><sec id="S21"><title>U2OS-BAX/BAK-DKO-mKate2+ cells</title><p id="P53">All mKate2+ cells were generated by lentiviral infection with NucLight Red Lentivirus in U2OS-BAX/BAK-DKO cells, followed by FACS selection.</p></sec><sec id="S22"><title>U2OS-PTBP1 and -BCL2L12 clonal knockout cells</title><p id="P54">U2OS-PTBP1 and U2OS-BCL2L12 clonal knockout cells were generated using CRISPR. For each gene, the highest-scoring sgRNA (see <xref rid="SD3" ref-type="supplementary-material">Table S1</xref>) was selected from the TKOv3 library and cloned into the pX330-puro plasmid using the single-step digestion-ligation protocol from the Zhang laboratory (available on the Zhang laboratory Addgene page). U2OS cells were then transiently transfected with the respective pX330-sgRNA-puro constructs using the FuGENE HD Transfection Reagent. Transfected cells were then selected with 1 &#956;g/mL puromycin for 3 days, followed by replating and recovery for 2 days. Single cell clones were generated using limiting dilution. Clones were validated by sequencing and TIDE analysis,<sup><xref rid="R72" ref-type="bibr">72</xref></sup> and for PTBP1 knockouts, immunoblotting.</p></sec></sec><sec id="S23"><title>Pooled single gene knockout cells using px330</title><p id="P55">U2OS-NUP93, -EXOSC5, -MCL1, -MYC, -WEE1, -TICRR, -JUN, -FBXO5, -DTL, -DBR1, -BCL2A1, and -NONT (nontargeting) knockout cells were generated using a transient transfection strategy. Briefly, sgRNA (see <xref rid="SD3" ref-type="supplementary-material">Table S1</xref>) were cloned into pX330-puro as described above. All constructs were sequence confirmed through Genewiz. U2OS cells were plated in six-well plates (300,000 cells per well) and left to adhere overnight. The following day, cells were transiently transfected with 2 &#956;g of respective pX330-sgRNA-puro construct using FuGene HD Transfection Reagent. Cells were then selected using 1 &#956;g/mL puromycin for either 2 days (for NUP93 and EXOSC5) or 3 days (for all others), followed by replating and expansion for either 1 day (for NUP93 and EXOSC5) or 2 days (for all others) prior to seeding for subsequent assays.</p></sec><sec id="S24"><title>Knockout cells using the in4mer Cas12a system</title><p id="P56">To determine the genetic dependence of cell death on BAX, BAK1, PTBP1, and BCL2L12 across a panel of normal and cancer cell lines, the Cas12a in4mer system was used, as described previously.<sup><xref rid="R82" ref-type="bibr">82</xref></sup> The in4mer systems allows for 4 independent guide RNAs to be co-infected with EnAsCas12a, allowing for both single- and multi-gene knockouts. Constructs were designed to target PTBP1 (with four guide RNAs), BCL2L12 (with four guide RNAs), or BAX and BAK1 (with two guide RNAs per gene). An intergenic-targeting construct (with four guide RNAs) was used as a control. Guide RNAs from the Inzolia library were designed into gBlocks (see <xref rid="SD3" ref-type="supplementary-material">Table S1</xref>) and synthesized through Integrated DNA Technologies. gBlocks were then individually cloned into the pRDA-550 vector (Addgene, Cat# 203398) using the NEBridge Golden Gate Assembly Kit (BsmBI-v2). All constructs were sequence confirmed through Genewiz and packaged into virus using Lenti-X 293T cells. Cell lines (U2OS, RPE-1, MCF10A, A375 and HeLa) were infected with virus and selected with puromycin.</p></sec><sec id="S25"><title>RPB1 switchover cells</title><p id="P57">For the RPB1 switchover system, a FLAG-RPB1-N792D-&#916;CTD fragment was PCR amplified (primers in <xref rid="T1" ref-type="table">key resources table</xref>) from FLAG-Pol2-WT (Addgene, Cat# 35175).<sup><xref rid="R83" ref-type="bibr">83</xref></sup> The PCR fragment resulted in a RPB1 mutant that lacked the entire C-terminal domain (repeats 1&#8211;52) and included an N-terminal FLAG tag, an &#9082;-amanitin resistance mutation, and homology regions to facilitate insertion into pLVX-Tre3G-IRES&#8212;a lentiviral vector for doxycycline-inducible gene expression. pLVX-Tre3G-IRES (Clontech, Cat# 631362) was digested with BamHI and NotI, gel extracted using the QIAquick Gel Extraction kit and purified. The PCR product was then inserted into the MCS1 of pLVX-Tre3G-IRES using Gibson Assembly. The resulting plasmid, pLVX-Tre3G-FLAG-RPB1-N792D-&#916;CTD, was packaged into virus using Lenti-X 293T cells, along with a vector expressing the Tet-On 3G transactivator protein, pLVX-Tet3G. U2OS cells were infected with pLVX-Tet3G lentivirus, followed by selection with 600 &#956;g/mL G418. Tet-3G expressing cells were then infected with pLVX-Tre3G-FLAG-RPB1-N792D-&#916;CTD virus, and selected with 1 &#956;g/mL puromycin. Single cell clones were generated using limiting dilution. Clones were selected for transgene expression levels approximating endogenous Rpb1 levels, determined using immunoblotting.</p></sec><sec id="S26"><title>mCherry-PTBP1 expressing cells</title><p id="P58">The PTBP1 ORF was obtained as a Gateway entry clone in the pDONR223 vector (DNASU Clone ID: 513885). The ORF was transferred into a lentiviral destination vector, pHAGE-nDEST-mCherry<sup><xref rid="R84" ref-type="bibr">84</xref></sup> using the Gateway LR Clonase II Enzyme Mix. The resulting plasmid, pHAGE-mCherry-PTBP1-IRES-PURO was sequence confirmed and packaged into lentivirus using Lenti-X 293T cells. U2OS-PTBP1-KO cells were infected with pHAGE-mCherry-PTBP1-IRES-PURO virus, and FACS sorted based on mCherry expression. Cells with exogenous Ptbp1 protein expression levels approximating that of wild-type cells, determined by immunoblotting, were used for further experiments. The resulting cells express exogenous PTBP1 with a N-terminal mCherry tag from a CMV promoter.</p></sec><sec id="S27"><title>BCL2L12-Flag-HA expressing cells</title><p id="P59">The full length BCL2L12 ORF (334 amino acids) was obtained from the human ORFeome collection and provided as a Gateway entry clone in the pDONR223.<sup><xref rid="R85" ref-type="bibr">85</xref></sup> The ORF was then transferred into a lentiviral destination vector, pHAGE-cDEST-FLAG-HA-IRES-PURO,<sup><xref rid="R86" ref-type="bibr">86</xref></sup> using the Gateway LR Clonase II Enzyme Mix. The resulting plasmid, pHAGE-BCL2L12-FLAG-HA-IRES-PURO was sequence confirmed and packaged into lentivirus using Lenti-X 293T cells. U2OS-BCL2L12-KO or U2OS-PTBP1-KO cells were infected with pHAGE-BCL2L12-FLAG-HA-IRES-PURO virus and selected with 1 &#956;g/mL puromycin. The resulting cells express exogenous BCL2L12 with a C-terminal Flag-HA tag.</p><p id="P60">To generate cells expressing BCL2L12 with a E220A mutation, the pHAGE-BCL2L12-FLAG-HA-IRES-PURO vector above was edited using the Q5 Site-Directed Mutagenesis kit with the primers: 5&#8217; - GCTGGAGGAGgcgGCAGAAGTCA - 3&#8217; and 5&#8217;- AGG GCCACCAGCCTC &#8211; 3&#8217;. The resulting plasmid, pHAGE-BCL2L12-E220A-FLAG-HA-IRES-PURO was sequence confirmed and packaged into lentivirus using Lenti-X 293T cells. U2OS-BCL2L12-KO cells were infected with pHAGE-BCL2L12-E220A-FLAG-HA-IRES-PURO virus and selected with 1 &#956;g/mL puromycin.</p></sec></sec><sec id="S28"><title>METHOD DETAILS</title><sec id="S29"><title>Immunoblotting</title><p id="P61">Cells were seeded in 6-well plates (300,000 cells per well) or 10-cm dishes (1.5 &#215; 10<sup>6</sup> cells per dish) and left to adhere overnight, unless otherwise stated. Cells were treated the next morning. At indicated timepoints, media were removed and collected. Samples were washed once with PBS, and the wash was added to the collected media. SDS-lysis buffer (50 mM Tris-HCl, 2% SDS, 5% glycerol, 5 mM EDTA, 1 mM NaF, 10 mM &#946;-glycerophosphate, 1 mM PMSF, 1 mM Na<sub>3</sub>VO<sub>4</sub>, protease inhibitor tablet and phosphatase inhibitor tablet) was used to lyse the cells, along with any dead cells that were pelleted from the media and wash. Lysates were centrifuged through an AcroPrep 96 well 3.0 &#956;m glass fiber/0.2 &#956;m Bio-Inert membrane filter plate. Protein content was quantified with a BCA assay and normalized for equal loading. Samples were boiled for 5 minutes at 95C in 6x Laemmli buffer. Denatured samples were run on hand-poured SDS-PAGE gels. Gels were subsequently wet transferred onto nitrocellulose membranes and blocked in 1:1 PBS: Intercept Blocking Buffer for 1 hour at room temperature. Membranes were then incubated overnight on a rocking shaker at 4C in primary antibody diluted in 1:1 PBS-0.1% Tween: Intercept Blocking Buffer at the following dilutions: Anti-Rpb1-NTD rabbit mAb (clone D8L4Y), 1:1,000; Anti-DYKDDDDK Tag (FLAG) rabbit mAb, 1:1,000; Anti-Ptbp1 rabbit mAb, 1:1,000; Anti-Histone-H3 rabbit mAb, 1:2,000; Anti-&#9082;-tubulin mouse mAb, 1:10,000; Anti-pH2A.X (Ser139) rabbit mAb, 1:1,000; Anti-Mcl-1 rabbit mAb, 1:1,000; Anti-Apaf-1 rabbit mAb, 1:1,000; Anti-Bax rabbit mAb (clone D2E11), 1:1000; Anti-mCherry rabbit polyclonal Ab, 1:1000; Anti-HA Tag mouse mAb, 1:5000; Anti-c-Myc rabbit mAb, 1:1000. The following day, membranes were incubated in primary anti&#8211;&#946;-actin antibody (diluted 1:15,000) for 1 hour at room temperature, followed by two 5-minute washes with PBS-0.1% Tween. Membranes were then incubated with secondary antibodies (diluted 1:15,000 in 1:1 PBS-0.1% Tween: Intercept Blocking Buffer) conjugated to infrared dyes (IRDye 680RD goat anti-mouse immunoglobulin G (IgG) secondary; IRDye 800CW goat anti-rabbit IgG secondary) for 1 hour at room temperature. Following four 5-minute washes with PBS-0.1% Tween and one 5-minute wash with PBS, blots were visualized using a LI-COR Odyssey CLx scanner. Raw protein expression levels were quantified in LI-COR&#8217;s ImageStudio software, background subtracted, divided by &#946;-actin signals to normalize for loading differences, then normalized per gel to a reference sample (generally, an untreated sample). All immunoblots for Rpb1 use Anti-Rpb1-NTD rabbit mAb (clone D8L4Y), unless otherwise stated.</p></sec><sec id="S30"><title>Immunoprecipitation and Co-immunoprecipitation</title><p id="P62">To measure activated Bax protein, an active conformation-specific Bax antibody (clone 6A7) was used.<sup><xref rid="R87" ref-type="bibr">87</xref></sup> U2OS, U2OS-BCL2L12-KO, or U2OS-PTBP1-KO cells were plated onto 10cm plates and left to adhere overnight. The following day, cells were treated with 1 &#956;M triptolide or vehicle, along with 50 &#956;M z-VAD-FMK, for 24 hours. Cells were washed once with PBS, and lysed on the plate in 500 &#956;L lysis buffer (10 mM HEPES pH 7.4, 150mM NaCl, 1% CHAPS, supplemented with protease and phosphatase inhibitor tablets). Replacement of 1% CHAPS with 1% Triton-X100 in the lysis buffer facilitates and active conformation of Bax and was used as a positive control. Cells were scraped in lysis buffer and pooled, then lysates were tumbled at 4C for 20 minutes. Lysates were then centrifuged at 16,100xg for 20 minutes at 4C. Supernatant was saved, and protein concentration was determined using the BCA assay. Samples were normalized to 450 &#956;g protein in 550 &#956;L, 50 &#956;L was saved as input, then samples were incubated with 4 &#956;g mouse anti-human Bax clone 6A7 (active Bax), or concentration matched mouse IgG1, &#954; isotype control, overnight at 4C. The following morning, samples were added to 25 &#956;L pre-washed protein G magnetic beads and rotated for 2 hours at 4C. Complexes were then magnetically separated and washed 3 times in lysis buffer. Proteins were eluted from the beads by boiling samples in Laemmli buffer for 5 minutes at 95C. Equal volumes of IPs were separated by SDS-PAGE as described above, and total Bax was detected using anti-Bax (clone D2E11).</p><p id="P63">To identify protein-protein interactions between Ptbp1 and Rpb1, reciprocal Co-Ips were performed. To pull down Ptbp1, U2OS-PTBP1-KO cells reconstituted with mCherry-PTBP1 (U2OS-mCherry-PTBP1, detailed above) were lysed on ice in lysis buffer (10 mM Tris-HCl, 100 mM NaCl, 2.5 mM MgCl<sub>2</sub>, 0.5% NP-40, 1 mM PMSF, and protease inhibitor tablets). Wild-type U2OS cells were used as a control. Cells were scraped and collected in lysis buffer and incubated on ice for 30 minutes. Indicated samples were then sonicated using a Sonics VCX 130 Vibra Cell sonicator (10 seconds on and 10 seconds off, for 3 cycles at 30% amplitude). Lysates were centrifuged at 12,000 xg for 20 minutes at 4C. Supernatant was saved, and protein concentration was determined using the BCA assay. Samples were normalized to 1200 &#956;g protein in 600 &#956;L each, 100 &#956;L was saved as input, then each sample was incubated with 25 &#956;L of pre-washed RFP-Trap magnetic agarose beads and incubated at 4C for 2 hours with rotation. Beads were then washed 4 times with lysis buffer. Proteins were eluted from the beads by boiling samples in Laemmli buffer for 5 minutes at 95C. Equal volumes of IPs were separated by SDS-PAGE as described above.</p><p id="P64">For co-immunoprecipitation with Rpb1 in various phosphorylated states, U2OS cells were lysed on ice in lysis buffer (10 mM Tris-HCl, 100 mM NaCl, 2.5 mM MgCl<sub>2</sub>, 0.5% NP-40, 1 mM PMSF, and protease inhibitor tablets). Cells were scraped and collected in lysis buffer and incubated on ice for 30 minutes. Indicated samples were then sonicated using a Sonics VCX 130 Vibra Cell sonicator (10 seconds on and 10 seconds off, for 3 cycles at 30% amplitude). Lysates were centrifuged at 12,000 xg for 20 minutes at 4C. Supernatant was saved, and protein concentration was determined using the BCA assay. Samples were normalized to 1200 &#956;g protein in 600 &#956;L each and 100 &#956;L was saved as input. To pull down hypo-phosphorylated Rpb1, samples were incubated with 8 &#956;g of anti-Rpb1 mouse mAb clone 8WG16. To pull down Rpb1 phosphorylated at serine 5 of the CTD, samples were incubated with anti-phospho-Rpb1 CTD (ser5) Rabbit mAb at a 1:100 dilution. To pull down Rpb1 phosphorylated at serine 7 of the CTD, samples were incubated with anti-phospho-Rpb1 CTD (ser7) Rabbit mAb at a 1:100 dilution. To pull down Rpb1 phosphorylated at serine 2 of the CTD, samples were incubated with anti-phospho-Rpb1 CTD (ser2) Rabbit mAb at a 1:50 dilution. Samples were incubated for 4 hours at 4C with rotation, then added to 25 &#956;L pre-washed protein G magnetic beads and rotated for 2 hours at 4C. Complexes were then magnetically separated and washed 4 times in lysis buffer. Proteins were eluted from the beads by boiling samples in Laemmli buffer for 5 minutes at 95C. Equal volumes of IPs were separated by SDS-PAGE as described above. To avoid interference with IgG heavy chain when blotting for PTBP1, the Quick Western Kit was used.</p></sec><sec id="S31"><title>Proteome profiler analysis of apoptotic proteins</title><p id="P65">Proteome Profiler Apoptosis Arrays were performed according to the manufacturer&#8217;s instructions. Briefly, U2OS cells were collected at 1.5 million cells per condition and lysed according to instructions. An equal volume of lysate (250 &#956;L) was loaded per array. Blot arrays were visualized using a LI-COR Odyssey CLx scanner, and protein expression was quantified in LI-COR&#8217;s ImageStudio software.</p></sec><sec id="S32"><title>Quantification of ATP molecules per cell</title><p id="P66">To quantify ATP amount per cell following prolonged triptolide treatment, an approach was taken to measure ATP amount using CellTiter Glo normalized for cell number measured using the FLICK assay (see below for details). WT or DKO cells were plated at 15,000 cells per well in 96-well plates. The following day, cells were treated with 1 &#956;M triptolide for 4 days. Untreated plates were also prepared such that all conditions could be processed at the same time. At assay endpoint, relative ATP amount was measured using CellTiter Glo, according to manufacturer&#8217;s recommendations. In parallel, relative cell number (both live and dead) was measured using FLICK. Absolute ATP amount was determined by generating an ATP standard curve. Similarly, absolute cell number was determined by generating a cell titration in FLICK. Thus, quantifying both cell number and total molar ATP amount enabled an average estimate of ATP molecules per cell.</p></sec><sec id="S33"><title>Labelling and measurement of nascent transcription</title><p id="P67">Methods for labelling and quantification of nascent transcription were adapted from methods described previously.<sup><xref rid="R88" ref-type="bibr">88</xref></sup> Cells treated with transcriptional inhibitors were labeled with 1 mM 5-ethynyl uridine for 1 hour in existing media. Cells were then washed with PBS, trypsinized, pelleted, and washed with cold PBS. Cells were then fixed in 4% fresh formaldehyde in PBS at room temperature for 15 minutes. Fixed cells were washed with cold PBS, pelleted, resuspended in ice-cold 100% methanol, and stored at &#8722;20C overnight. The following day, the methanol was removed, and the cells were washed twice with PBS-0.1% Tween. Cells were then incubated for 30 minutes at room temperature with 86.5 &#956;L Click-iT reaction buffer, 4 &#956;L CuSO<sub>4</sub> buffer, 0.125 &#956;L Alexa Fluor-azide-488 and 10.3 &#956;L Click-iT reaction buffer additive (all from Thermo Fisher Scientific, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="C10329">C10329</ext-link>). Cells were washed once with 100 &#956;L Click-iT reaction rinse buffer (from Thermo Fisher Scientific, <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="C10329">C10329</ext-link>), then washed two more times with PBS-0.1% Tween. Samples were resuspended in PBS-0.1% Tween, filtered, and run on a Miltenyi MACSQuant VYB cytometer with laser and filter settings appropriate for reading Alexa-488. Data were analyzed using FlowJo software.</p></sec><sec id="S34"><title>RNA sequencing</title><p id="P68">For evaluation of mRNA abundance following long-term triptolide exposure in DKO cells, DKO and WT cells were seeded onto six-well plates (300,000 cells per well) and left to adhere overnight. Cells were then drugged the next day (D0). To evaluate the transcriptome of WT cells after 1 day of triptolide, cells were cotreated with 50 &#956;M z-VAD to inhibit loss of material from cell death. Due to the long assay length, plating and drugging was staggered for each condition, such that the assay endpoint for each sample occurred simultaneously. For analyses that defined the 50 shortest or 50 longest half-life RNAs, these lists of RNAs were based on prior studies.<sup><xref rid="R89" ref-type="bibr">89</xref></sup></p><p id="P69">For evaluation of mRNA abundance in the context of NUP93 or EXOSC5 knockout, knockout and nontargeting cells were seeded onto six-well plates (300,000 cells per well) and left to adhere overnight. Cells were then drugged the next day.</p><p id="P70">For evaluation of mRNA abundance in Pol II switchover cells, Rpb1-N792D-&#916;CTD expressing cells were seeded onto six-well plates (100,000 cells per well) and left to adhere overnight. The following day, the media was removed and replaced with fresh media with or without 2 &#956;g/mL doxycycline. 48 hours later, drug or vehicle was gently added to the existing media.</p><p id="P71">For the extraction of mRNA for the experiments above, at assay endpoint cells were trypsinized, counted using a hemacytometer, pelleted, washed with PBS, and moved immediately to RNA extraction. Total RNA was extracted using the RNeasy Plus Mini Kit according to manufacturer protocol. To facilitate absolute RNA quantification, polyadenylated ERCC standards were diluted 1:100 in nuclease-free water, and added to each sample at 1 &#956;L/100,000 cells. ERCC spike-ins were added immediately following lysis of cells in RLT-plus buffer, and prior to all subsequent total RNA extraction steps using the RNeasy Plus kit. All RNA integrity numbers (RIN) were greater than 9, as measured on a 4150 Tapestation System. mRNA was isolated using the NEBNext poly(A) mRNA Magnetic Isolation Module. RNAseq libraries were prepared with the NEBNext Ultra II Directional RNA Library Prep Kit using the NEBNext Multiplex Oligos for Illumina. Paired-end 2 &#215; 50nt sequencing of libraries was performed in-house on the Illumina NextSeq2000 using the NextSeq 1000/2000 P<sup>2</sup> XLEAP-SBS Reagent Kit.</p></sec><sec id="S35"><title>Nuclear and cytoplasmic fractionation</title><p id="P72">Nuclear-cytoplasmic fractionation was performed in such a way to facilitate extraction of RNA and protein from the same cellular lysate. A similar protocol, excluding the RNA extraction steps, was used in fractionation experiments that only examined protein expression. Cells were plated at 6 million cells per condition (3 million cells per 15 cm plate) and left to adhere overnight. Cells were then drugged the next day. At assay endpoint cells were trypsinized, counted using a hemacytometer, pelleted, washed with PBS, and moved immediately to cellular fractionation. Cells were first resuspended in 900 &#956;L hypotonic lysis buffer (50 mM HEPES pH 7.2, 150mM NaCl, 0.5 mM EDTA, 0.15% Triton X-100, 1 mM PMSF, protease inhibitor tablet, phosphatase inhibitor tablet, 20 U/mL SUPERase-In RNase inhibitor). Cells were pipet up and down 10 times, 1/3 of the lysate was taken as a whole-cell lysate (WCL) sample, and the cells were left to swell on ice for 10 minutes. Samples were centrifuged at 12,000xg for 30 seconds at 4C. The supernatant was collected as the cytoplasmic fraction (CYT). The nuclear pellet was washed once with 500 &#956;L wash buffer (PBS containing 0.1% Triton X-100, 1mM EDTA and 20 U/mL SUPERase-In), centrifuged at 12,000xg for 30 seconds at 4C, and the wash buffer was completely removed. The nuclear pellet was then lysed in 400&#956;L 1x nuclear lysis buffer (50 mM HEPES pH 7.2, 150mM NaCl, 0.5 mM EDTA, 1% Triton X-100, 0.5% Sodium Deoxycholate, 0.2% SDS, 1 mM PMSF, protease inhibitor tablet, phosphatase inhibitor tablet, 20 U/mL SUPERase-In). 10x nuclear lysis buffer was added to WCL and CYT fractions to equalize surfactant amounts to that of the nuclear fraction. Each resulting lysate was divided in half to facilitate either downstream protein analysis or RNA extraction.</p><p id="P73">For protein fractions, 100x Benzonase buffer (50 mM Tris-HCl, 20 mM NaCl, 2 mM MgCl<sub>2</sub>, 2000 U/mL Benzonase Nuclease) was added to lysates. Lysates were kept on ice for 30 minutes with periodic vortexing. The BCA assay was performed on all cellular fractions, and 10 &#956;g of each lysate was subjected to immunoblotting as described above. Total protein was detected using the Revert 700 Total Protein Stain Kit prior to incubation with primary antibody.</p><p id="P74">For extraction of total RNA from RNA fractions, samples were subjected to the RNeasy Plus manufacturer protocol with the following modifications. 3.5x sample volume of RLT-plus buffer was added to cellular fractions. Prior to removal of genomic DNA using the gDNA Eliminator spin column, ERCC standards (diluted 1:10) were added to each lysate at a concentration of 1 &#956;L/1 million cells (or similarly, 1 million nuclei or 1 million cell cytoplasm&#8217;s). Following genomic DNA removal, 2.5x original lysate volume of 100% ethanol was added to each flowthrough, and subsequent steps of the RNeasy Plus protocol were followed as standard. mRNA was isolated as above. Sequencing libraries were prepared with the NEBNext Ultra II Directional RNA Library Prep Kit, using manufacturer recommended modifications to generate large (&#8764;450nt) inserts. Paired-end 2 &#215; 150nt sequencing of libraries was performed in-house on the Illumina NextSeq2000 using the NextSeq 2000 P3 Reagent Kit.</p></sec><sec id="S36"><title>STACK assay for kinetic evaluation of drug responses</title><p id="P75">The STACK assay was used to evaluate cell proliferation and cell death continuously over time using microscopy, as previously described.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> mKate2+ cells were seeded into 96-well black-sided optical-bottom plates, and left to adhere overnight. The following day, cells were given drugged media containing 50 nM SYTOX Green, and imaged over time time-lapsed images were collected using an IncuCyte S3 (Essen Biosciences). Images were collected with a 10x objective with acquisition in the green channel ex: 460 &#177; 20, em: 524 &#177; 20, acquisition time: 300ms; and red channel ex:585 &#177; 20, em: 635 &#177; 70, acquisition time: 400ms. Counts of dead (green) and live (red) cells were determined using the built-in IncuCyte software (Essen Biosciences) and exported for analysis using a custom MATLAB script.</p><p id="P76">For the long-term evaluation of BAX/BAK DKO cells following triptolide, accurate dead cell measurements using STACK as described above are insufficient, as identification of a dead cell from an image is no longer possible after the dead cell fully degrades away. To overcome this technical confound, a modified STACK assay was used, taking advantage of the FLICK assay (described in detail below), which does not rely on image segmentation for cell quantification. Cells were seeded and drugged as above, at a high density (15,000 cells per well). Separate plates were prepared for each timepoint, whereby cells were first imaged using an EVOS FL Auto 2 automated microscope. Images were acquired using a 10x objective (EVOS 10x objective, Cat #: AMEP4681). Sytox images were acquired using a GFP filter cube (EVOS LED Cube, GFP, Cat #: AMEP4651, ex: 470/22, em: 525/50). Mkate2+ images were acquired using a TexasRed filter cube (EVOS LED Cube TxRed, Cat #: AMEP4655, ex: 585/29, em: 628/32). Following imaging, FLICK was performed as an endpoint measurement to obtain lethal fraction values, as described below. Images were linearly adjusted using a custom MATLAB script.</p></sec><sec id="S37"><title>FLICK assay for quantification of cell death</title><p id="P77">The FLICK assay was performed as described.<sup><xref rid="R71" ref-type="bibr">71</xref>,<xref rid="R90" ref-type="bibr">90</xref></sup> Briefly, 90 &#956;L of cells were seeded at a density of 2,000&#8211;5,000 cells per well in black-sided optical-bottom 96-well plates (Greiner Bio-One, 655090) and left to adhere overnight. The following day, cells were treated with 10 &#956;L of media containing the indicated compound/s along with SYTOX Green, resulting in a final SYTOX concentration of 2 &#956;M. Fluorescence was monitored at various times following drugging with a Tecan Spark (running SparkControl software version 2.2) microplate reader (ex: 503, em: 524). Gain was set to achieve a linear relationship between SYTOX signal and dead cell number. To obtain the total cell number at the time of drugging, a duplicate &#8220;T0&#8221; plate was lysed in 0.15% Triton X-100 and 2 &#956;M SYTOX for 2&#8211;4 hours at 37C prior to taking a fluorescence reading. Total cell number for each condition at the end of the assay was similarly determined by lysing cells in 0.15% Triton X-100.</p></sec><sec id="S38"><title>Pol II Switch over system</title><p id="P78">For experiments involving the RPB1 switchover system, cells were seeded as described for the respective experiment. The following day, cells we treated with or without 2 &#956;g/mL doxycycline for 48 hours to induce the expression of FLAG-RPB1-N792D-&#916;CTD. 10 &#956;M &#9082;-amanitin was added to the cells without removing the conditioned media to degrade the endogenous Rbp1.</p></sec><sec id="S39"><title>Chemo-genetic profiling of triptolide</title><p id="P79">Conventional approaches used for these &#8220;chemo-genetic profiling&#8221; studies are unable to accurately identify death-regulatory genes due to the confounding effects of varied proliferation rates between cells harboring different gene knockouts.<sup><xref rid="R36" ref-type="bibr">36</xref></sup> In general, specialized analytical methods are required to identify death-regulatory genes when drug-induced lethality occurs in a proliferative population, at low rates relative to proliferation, or via non-apoptotic mechanisms. However, in this case, we recognized that triptolide-induced death is: 1) exclusively apoptotic, 2) occurring rapidly (before the effects of varied proliferation can be observed in the population), and 3) activated at high rates (such that large numbers of dead cells accumulate before apoptotic corpses have decayed). Thus, we mechanically separate live cells from apoptotic corpses simply by agitating and rinsing plates to collect floating dead cells, prior to trypsinization and collection of the live cells. Both populations could then be sequenced independently.</p><p id="P80">The genome-wide CRISPR screen was performed using the Toronto KnockOut Library v3 (TKOv3), which contains 4 sgRNA per gene, along with 142 non-targeting sgRNA.<sup><xref rid="R91" ref-type="bibr">91</xref></sup> U2OS-Cas9 expressing cells were selected with 5 &#956;g/mL blasticidin for 5 days. Following selection, cells were divided into two replicates, which would be handled separately for the remainder of the assay. Cells were then transduced with the TKOv3 viral library using a &#8216;spinfection&#8217; method. To maintain sufficient library coverage, more than 200 million cells were transduced per replicate, at an MOI of 0.3. To do this, cells were divided into 12-well plates at a density of 2 million cells per along with 75 &#956;L virus and 0.8 &#956;g/mL polybrene. Plates were centrifuged at 37 &#176;C for 2 h at 830x<italic toggle="yes">g</italic>. Following spinfection, virus-containing media was gently removed and replaced with fresh media, and cells were returned to the incubator overnight. The following morning, cells were moved out of the 12-well plates and onto 15 cm dishes. The following day, cells were treated with 1 &#956;g/mL puromycin for 3 days, followed by a two-day expansion without selection. Cells were then seeded onto 15cm plates and let to adhere overnight prior to drugging. At the time of drugging, a T0 sample was taken from the cell population and frozen, at a population size 650x that of the library size. The rest of the cells were treated with either 1 &#956;M triptolide or DMSO. Cells were incubated for 32 hours in drug, resulting in approximately 50% cell death. Apoptotic corpses, which become non-adherent, were removed and saved. Plates were washed with PBS to dislodge any remaining dead cells, and PBS wash was added with the separated dead cell fraction. The adherent cells remaining on the plate were the live cell population. The live cells were trypsinized and collected. Each condition was collected such that a minimum of 650x library coverage was achieved per replicate.</p><p id="P81">Genomic DNA was extracted using the Wizard Genomic DNA Purification Kit. sgRNA sequences were PCR amplified out of the genomic DNA, and gel-extracted and purified. A second round of PCR added sequencing adaptors and multiplexing barcodes, and libraries were pooled and sequenced on a HiSeq 4000 at 500x coverage.</p></sec><sec id="S40"><title>Immunofluorescence microscopy</title><p id="P82">For imaging of PTBP1 localization following drug exposure, mCherry-PTBP1 expressing cells were seeded onto round glass coverslips in 12-well plates. The following day, media was removed and replaced with media containing drug or vehicle control, along with 50 &#956;M z-VAD-FMK. At assay endpoint, cells were washed once with PBS and fixed in 4% formaldehyde (in PBS) for 15 minutes. Cells were washed 3 times with PBS, and permeabilized in PBS-0.2% Triton-X100 for 10 minutes. Following 3 washes in PBS, cells were blocked in blocking buffer (3% BSA, 0.1% Tween20, in PBS) for 30 minutes at room temperature. Cells were then incubated at 4C overnight with anti-mCherry polyclonal Ab diluted 1:800 in blocking buffer. The following day, cells were washed 3 times with blocking buffer and incubated at room temperature for 2 hours with goat anti-rabbit IgG Alexa Fluor 594 diluted 1:1000 in blocking buffer. Cells were washed 3 times with blocking buffer, once with PBS, then incubated at room temperature for 20 minutes with CoraLite Plus 488-Phalloidin (1:200 in PBS). Following 2 washes with PBS, cells were stained with DAPI and mounted on glass slides with Prolong Diamond.</p><p id="P83">For imaging of BCL2L12 localization following Rpb1 degradation, BCL2L12-Flag-HA expressing cells were seeded onto round glass coverslips in 12-well plates. The following day, media was removed and replaced with media containing drug or vehicle control, along with 50 &#956;M z-VAD-FMK. At assay endpoint cells were fixed and permeabilized as above. Cells were then incubated at 4C overnight with anti-HA Tag mAb and anti-Tom20 mAb diluted 1:500 and 1:200 in blocking buffer, respectively. The following day, cells were washed 3 times with blocking buffer and incubated at room temperature for 2 hours with goat anti-mouse IgG1 Alexa Fluor 488 and goat anti-rabbit IgG Alexa Fluor 594 diluted 1:2000 and 1:1000 in blocking buffer, respectively. Cells were washed 3 times with blocking buffer, stained with DAPI, and mounted on glass slides with Prolong Diamond.</p><p id="P84">IF slides were imaged using an EVOS FL Auto 2 automated microscope. Images were acquired using a 40x objective (EVOS 40x objective, Cat #: AMEP4699). Images were acquired using a GFP filter cube (EVOS LED Cube GFP, Cat #: AMEP4651, ex: 470/22, em: 525/50), a TexasRed filter cube (EVOS LED Cube TxRed, Cat #: AMEP4655, ex: 585/29, em: 628/32), and a DAPI filter cube (EVOS LED Cube DAPI, Cat #: AMEP4650, ex: 357/44, em: 447/60).</p></sec><sec id="S41"><title>iBH3 profiling assay</title><p id="P85">Cytochrome C release in cells following exposure to peptides was performed using the iBH3 profiling assay.<sup><xref rid="R55" ref-type="bibr">55</xref></sup> Human BIM-BH3 (N term &#8211; MRPEIWIAQELRRIGDEFNA &#8211; C term), and human W-BCL2L12-BH3-like (N term &#8211; WEAILRRLVALLEEEAEVINQ &#8211; C term) peptides were synthesized through Genscript (purity &gt;= 95%; N-term acetylation; C-term amidation). A tryptophan (W) residue was added to the N-terminus of the BCL2L12-BH3-like sequence (as shown above) to facilitate UV absorbance measurements. Peptides were dissolved in DMSO, and quantified by UV absorption at 280 nm. U2OS, U2OS-BAX/BAK-DKO, U2OS-PTBP1-KO, and U2OS-BCL2L12-KO cells were collected through trypsinization and pelleting, and resuspended at 2 million cells per mL in MEB2 buffer (150mM Mannitol, 10mM HEPES-KOH pH 7.5, 150mM KCl, 1mM EGTA, 1mM EDTA, 0.1% BSA, 5mM Succinate). 50 &#956;L cells were then added to 50 &#956;L of treatment, diluted in MEB2 buffer containing 0.002% digitonin. 15 &#956;M alamethicin was used as a positive control, and 0.1% DMSO was used as a negative control. Treatment was terminated after 1 hour by addition of 33 &#956;L of 4% formaldehyde (in PBS) for 10 minutes. Fixation was terminated by addition of 33 &#956;L of N2 buffer (1.7 M Tris base, 1.25 M Glycine, pH 9.1) for 5 minutes. 20&#956;L of Alexa Fluor 488 anti-cytochrome c (clone 6H2.B4) diluted in 10X CytoC stain buffer (10% BSA and 2% Tween20 in PBS) was then added to samples, reaching a final antibody dilution of 1:400. Samples were incubated with antibody overnight at 4C, washed once with PBS-0.1% Tween, filtered, and run on a Miltenyi MACSQuant VYB cytometer with laser and filter settings appropriate for reading Alexa-488. Data were analyzed using FlowJo software.</p></sec><sec id="S42"><title>Flow Cytometry</title><p id="P86">For the quantification of cytochrome C release following treatment with triptolide, U2OS, U2OS-PTBP1-KO, and U2OS-BCL2L12-KO cells were plated in 6-well plates such that there would be 300,000 cells at the time of collection. After adhering overnight, cells were treated with 1 &#956;M tripolide or vehicle control, along with 50 &#956;M z-VAD-FMK, for 24 hours. Cells were then collected through trypsinization and pelleting. Cells were resuspended in MEB2 buffer containing 0.001% digitonin and incubated for 10 minutes. Cells were then fixed, stained, and analyzed as described for the iBH3 protocol above.</p><p id="P87">For the quantification of exogenous BCL2L12-Flag-HA protein expression in U2OS-BCL2L12-KO cells, 300,000 cells expressing either BCL2L12-Flag-HA or BCL2L12-E220A-Flag-HA were trypsinized and pelleted. Cells were washed with PBS, fixed in 4% formaldehyde (in PBS) for 15 minutes, washed once with PBS, and permeabilized with 100% cold methanol. Cells were stored overnight at &#8722;20C. The following day, cells were washed twice with PBS-0.1% Tween, then incubated at 4C overnight with anti-HA Tag mAb (2-2.2.14) diluted 1:500 in 1% BSA (in PBS). The following day, cells were washed once with PBS-0.1% Tween, then incubated for 2 hours with goat anti-mouse IgG Alexa Fluor 488 (diluted 1:500 in 1% BSA). Cells were washed two more times with PBS-0.1% Tween, resuspended in PBS-0.1% Tween, filtered, and run on a Miltenyi MACSQuant VYB cytometer with laser and filter settings appropriate for reading Alexa-488. Data were analyzed using FlowJo software.</p></sec><sec id="S43"><title>Evaluation of drug PDS score</title><p id="P88">FLICK was used to determine lethal fraction kinetics in U2OS, PTBP1-KO, BCL2L12-KO, and BAX/BAK DKO cells across a panel of 46 drugs, across 7 half-log dilutions, and spanning the following 16 classes. Pol II degraders (Triptolide, 1 &#8211; 0.001 &#956;M; &#9082;-amanitin, 10 &#8211; 0.01 &#956;M). RNA synthesis inhibitors (Actinomycin-D, 1 &#8211; 0.001 &#956;M; Ethynylcytidine, 10 &#8211; 0.01 &#956;M; Cordycepin, 100 &#8211; 0.1 &#956;M). Transcriptional CDK inhibitors (Flavopiridol, 10 &#8211; 0.01 &#956;M; DRB, 100 &#8211; 0.1 &#956;M; THZ1, 10 &#8211; 0.01 &#956;M; THZ531, 10 &#8211; 0.01 &#956;M; YKL-5-124, 31.6 &#8211; 0.0316 &#956;M). Cell cycle CDK inhibitors (Abemaciclib, 10 &#8211; 0.01 &#956;M; Palbociclib, 10 &#8211; 0.01 &#956;M; Ribociclib, 10 &#8211; 0.01 &#956;M; PF3600, 31.6 &#8211; 0.0316 &#956;M; PF4091, 31.6 &#8211; 0.0316 &#956;M). DNA crosslinking and nucleotide damaging (4-NQO, 31.6 &#8211; 0.0316 &#956;M; Cisplatin, 100 &#8211; 0.1 &#956;M; Carboplatin, 316 &#8211; 0.316 &#956;M). Topoisomerase I inhibitors (Camptothecin, 10 &#8211; 0.01 &#956;M; Topotecan, 31.6 &#8211; 0.0316 &#956;M). Topoisomerase II inhibitors (Idarubicin, 1 &#8211; 0.001 &#956;M; Etoposide, 31.6 &#8211; 0.0316 &#956;M; Teniposide, 31.6 &#8211; 0.0316 &#956;M). PARP inhibitors (Niraparib, 100 &#8211; 0.1 &#956;M; Rucaparib, 100 &#8211; 0.1 &#956;M). Translational inhibitors (Cycloheximide, 100 &#8211; 0.1 &#956;M; Homoharringtonine, 10 &#8211; 0.01 &#956;M; Anisomycin 316 &#8211; 0.316 &#956;M). Proteasome inhibitors (Bortezomib, 1 &#8211; 0.001 &#956;M; MG132, 10 &#8211; 0.01 &#956;M). ER- and proteotoxic-stress inducers (Brefeldin A, 31.6 &#8211; 0.0316 &#956;M; Thapsigargin, 31.6 &#8211; 0.0316 &#956;M; Tuni-camycin, 10 &#8211; 0.01 &#956;M). BH3 mimetics (ABT-199, 100 &#8211; 0.1 &#956;M; ABT-263, 100 &#8211; 0.1 &#956;M; ABT-737, 31.6 &#8211; 0.0316 &#956;M). HDAC inhibitors (Panobinostat, 1 &#8211; 0.001 &#956;M; Vorinostat, 100 &#8211; 0.1 &#956;M). mTOR inhibitors (Torin2, 31.6 &#8211; 0.0316 &#956;M; Rapamycin, 10 &#8211; 0.01 &#956;M). MEK/PI3K/AKT inhibitors (Mirdametinib, 31.6 &#8211; 0.0316 &#956;M; Buparlisib, 31 &#8211; 0.0316 &#956;M; Capivasertib, 31.6 &#8211; 0.0316 &#956;M). Others (SGI-1027, 31.6 &#8211; 0.0316 &#956;M; JQ1, 100 &#8211; 0.1 &#956;M; Staurosporine, 10 &#8211; 0.01 &#956;M).</p><p id="P89">Lethal fraction kinetics were fit to a lag exponential death (LED) equation. Non-lethal conditions were defined as those having a maximum observed lethal fraction less than 0.16, approximately double the death observed in untreated cells. Cells were further classified as apoptotic or non-apoptotic by thresholding a 50% reduction in maximum lethal fraction in the BAX/BAK DKO background compared to U2OS cells. To determine the &#8220;Pol II Degrader Similarity&#8221; (PDS) score for a particular drug-dose pair, the area under the LED fit (AUC) was determined, and the baseline cell death was removed by subtracting out the AUC of untreated cells. The difference in drug response between KO and U2OS cells was defined as 1 minus the AUC ratio of KO over U2OS. This value, determined for PTBP1-KO and BCL2L12-KO separately, was summed. Finally, scores were divided by that of 1 &#956;M triptolide, such that a score of one denotes a functional genetic signature equal to that of triptolide.</p></sec><sec id="S44"><title>Evaluation of genetic dependencies across cells</title><p id="P90">In order to evaluate the dependence of cell death on BAX/BAK1, PTBP1, and BCL2L12 across different cell lines, the in4mer system was used to generate genetic knockouts (described above). 90 &#956;L of selected cells were seeded at a density of 2,000&#8211;5,000 cells per well in black-sided optical-bottom 96-well plates (Greiner Bio-One, 655090) and left to adhere overnight. The following day, cells were treated with 10 &#956;L of media containing the indicated compound/s along with 5 &#956;M SYTOX Green, and subjected to the FLICK assay (described above). Assay length was varied based on the cell death kinetics of each cell line, such that greater than 50% cell death was observed by assay endpoint.</p></sec></sec><sec id="S45"><title>QUANTIFICATION AND STATISTICAL ANALYSIS</title><sec id="S46"><title>RNA sequencing analysis</title><p id="P91">Quality control for the RNAseq datasets were performed using FastQC. Transcript abundance was estimated using Kallisto with parameters &#8211;bootstrap-samples 30 &#8211;single-overhang &#8211;rf-stranded. The Ensembl GRCh38 cDNA transcriptome build, appended with ERCC control transcript sequences, was used to build a Kallisto index. Gene-level counts were generated in R using the txim-port package. Counts were normalized to ERCC spike-ins using DESeq2, implemented with the function &#8220;estimateSizeFactors&#8221; with the option &#8220;controlGenes&#8221; set to the identities of the 92 ERCC transcripts. Counts were filtered for protein coding genes in R using AnnotationHub. Differential gene expression was performed with DESeq2, and fold change shrinkage was performed using the function lfcShrink with the adaptive shrinkage estimator &#8220;ashr.&#8221;<sup><xref rid="R92" ref-type="bibr">92</xref></sup> For comparative gene-level analysis between U2OS cells and PTBP1-KO whole cell extracts, the cytoplasmic and nuclear RNAseq FASTQ files corresponding to the same biological samples were pooled. For all analysis related to the quantification of mRNA decay following transcriptional inhibition, genes were filtered to include those with reliably detectable expression in untreated cells (cutoff determined from ERCC spike-ins, mean normalized count of 10).</p><p id="P92">To facilitate detection of splice-level events, cytoplasmic and nuclear RNAseq FASTQ files corresponding to the same biological samples (above) were pooled. Regulated splicing events were detected and analyzed with VAST-TOOLS. Briefly, reads were aligned to the human genome (hg38) using the align function. Differential splicing events were identified using the diff function (with parameters -S 2). Events were filtered for adequate coverage using the tidy function (with parameters -min_N 4, &#8211;noVLOW, &#8211;min_SD 5, and &#8211;p_IR). Splicing events were considered significantly different if the VAST-TOOLS reported expected absolute &#916;PSI value was greater than 0.1 and if the minimum value (95% confidence) of the absolute &#916;PSI value was greater than 0.</p></sec><sec id="S47"><title>Analysis of growth and death data from the FLICK assay</title><p id="P93">From measurements made from FLICK (dead cells at each timepoint, along with total cell numbers at the beginning and end of the assay), live cell numbers over time can be inferred and all calculations to determine LF, FV, RV and GR can be made<sup><xref rid="R65" ref-type="bibr">65</xref></sup>:
<disp-formula id="FD1"><mml:math id="M1" display="block"><mml:mi>L</mml:mi><mml:mi>F</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>D</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mi>F</mml:mi><mml:mi>V</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>L</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>L</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mo>+</mml:mo><mml:mi>D</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mi>R</mml:mi><mml:mi>V</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>L</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>r</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>L</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>U</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mi>G</mml:mi><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>L</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>r</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>L</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>L</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>U</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>L</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow></mml:msup><mml:mo>&#8722;</mml:mo><mml:mn>1</mml:mn></mml:math></disp-formula></p><p id="P94">All analyses were performed using custom MATLAB scripts. Dose-response curves were fit using a 4-parameter sigmoidal equation. Lethal fraction (LF) kinetics were fit using the lag-exponential death (LED) equation, where LF<sub>0</sub> is the initial LF in the absence of drug, LF<sub>p</sub> is the asymptotic LF in the exponential fit, D<sub>R</sub> is the initial death rate, D<sub>O</sub> is the death onset time, and <italic toggle="yes">t</italic> is time in hours<sup><xref rid="R13" ref-type="bibr">13</xref></sup>:
<disp-formula id="FD2"><mml:math id="M2" display="block"><mml:mi>L</mml:mi><mml:mi>F</mml:mi><mml:mfenced separators="|"><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mfenced><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>L</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>L</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>&#8722;</mml:mo><mml:msub><mml:mrow><mml:mi>L</mml:mi><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#8722;</mml:mo><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>&#8722;</mml:mo><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>(</mml:mo><mml:mi>t</mml:mi><mml:mo>&#8722;</mml:mo><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>O</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:math></disp-formula></p><p id="P95">All analyses were performed using custom MATLAB scripts. All data were fit with the &#8220;fit&#8221; function in MATLAB using nonlinear least-squares.</p></sec><sec id="S48"><title>Drug GRADE-based analysis of drug responses</title><p id="P96">True proliferation rates and death rates were calculated using the GRADE method using STACK data, as previously described.<sup><xref rid="R65" ref-type="bibr">65</xref></sup> Conceptually, the GRADE method infers the true, underlying cell proliferation rates and death rates of cell population by cross-referencing experimentally measured death rates (FV or LF) and net population growth rates (GR) with computational simulations. To begin, we simulated all pairwise combinations of 500 proliferation rates and 500 death rates using the following equations where <italic toggle="yes">C</italic><sub><italic toggle="yes">0</italic></sub> = initial cell number, <italic toggle="yes">t</italic> = assay length, <italic toggle="yes">&#964;</italic> = proliferation rate, and <italic toggle="yes">D</italic><sub><italic toggle="yes">R</italic></sub> = death rate.</p><disp-formula id="FD3"><mml:math id="M3" display="block"><mml:mi>L</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>e</mml:mi><mml:mspace width="0.5em"/><mml:mi>C</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mspace width="0.5em"/><mml:mi>N</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msup><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>&#964;</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow></mml:msup></mml:mrow></mml:mfenced><mml:mo>&#8722;</mml:mo><mml:mo>(</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msup><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>&#964;</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow></mml:msup><mml:mo>*</mml:mo><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:math></disp-formula><disp-formula id="FD4"><mml:math id="M4" display="block"><mml:mi>D</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>d</mml:mi><mml:mspace width="0.5em"/><mml:mi>C</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mspace width="0.5em"/><mml:mi>N</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msup><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mfenced separators="|"><mml:mrow><mml:mfrac><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mi>&#964;</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:mrow></mml:msup><mml:mo>*</mml:mo><mml:msub><mml:mrow><mml:mi>D</mml:mi></mml:mrow><mml:mrow><mml:mi>R</mml:mi></mml:mrow></mml:msub></mml:math></disp-formula><p id="P97">FV and GR values (defined above) were then calculated for each simulated proliferation rate and death rate pair. Next, for a given condition, experimentally determined FV and GR values were calculated (as above). The simulated proliferation rate and death rate that yield the empirically determined FV and GR values was then found.</p></sec><sec id="S49"><title>Quantification of Pol II half-life</title><p id="P98">Half-lives for Pol IIA and Pol IIO were determined using temporally resolved quantitating immunoblotting using an antibody recognizing the N terminal domain of Rpb1 (anti-Rpb1-NTD, clone D8L4Y), as described above. Pol II protein primarily exists in two forms. Pol IIO is hyper-phosphorylated along the carboxy-terminal domain (CTD) of the protein and is the actively elongating pool of Pol II. The hypo-phosphorylated form, called Pol IIA, represents all other forms of Pol II that are not actively elongating RNA, including preinitiation complex (PIC) bound, promoter paused, early pause released, and free Pol II. Pol IIO and Pol llA can be distinguished by a band shift on a gel. Immunoblots were quantified in ImageStudio, normalized to &#946;-actin, then normalized to the untreated sample (time 0) on each gel respectively, generating an abundance value relative to steady state. Data were fit to a two-term exponential decay function in MATLAB, relative to the highest Rpb1 signal observed over the time course. Half-lives determined from the fits, as the time at which half-maximal signal was reached. To correlate Pol II half-lives with cell death timing, the LF50 time was similarly found from lag-exponential death (LED) fits to STACK data. LF50 was defined as the time at which half of the maximum observed LF (measured or inferred after 72 hours) was reached. For identifying the timing of loss of nascent transcription, EU measurements (as described above), were fit to a 4-parameter hill function. The EU t<sub>1/2</sub> values were determined from the fits as the time at which 50% of cells were EU negative.</p></sec><sec id="S50"><title>Chemo-genetic profiling analysis</title><p id="P99">The FASTX-Toolkit was used to trim reads to get just CRISPR guide sequences (parameters: -f 23 -l 42). Trimmed reads were mapped to the TKOv3 library with Bowtie allowing for 2 mismatches (parameters: -v 2 -m 1). Samples were normalized for sequencing depth using median of ratios method implemented in DESeq2. Guides with low counts (approximately the bottom 2% of guides) were removed from the library. sgRNA-level log<sub>2</sub> fold-changes were determined using DESeq2 and were then z-scored to the distribution of nontargeting sgRNA. The median sgRNA-level z-score was determined for each gene to collapse scores to the gene level. An empiric <italic toggle="yes">P</italic> value was determined for each gene by bootstrapping from the sgRNA-level fold change scores of all guides, and was FDR corrected using the Benjamini&#8211;Hochberg procedure. An FDR cutoff of 0.1 was used to determine genes that significantly alter the cell death rate following triptolide. Gene set enrichment using an FDR-corrected one-tailed Fishers Exact test was performed to test if any apoptotic-related pathways from the Molecular Signatures Database (MSigDB) were overrepresented among genes whose knockout significantly reduced triptolide-induced death. To avoid confounded results, core apoptotic regulators (defined as those in the Biocarta Mitochondrial Pathway gene set) were removed from all other gene sets analyzed. To identify if fast or slow decaying mRNAs are preferentially enriched at the extreme ends of our chemo-genetic profiling data, GSEA was run with a pre-ranked list of the relative death rate scores. Gene sets were defined at the top 1% fastest or slowest decaying mRNAs (133 genes each), based on our RNAseq data.</p></sec><sec id="S51"><title>Drug PDS score definition</title><p id="P100">Lethal fraction kinetics were fit to a lag exponential death (LED) equation. Non-lethal conditions were defined as those having a maximum observed lethal fraction less than 0.16, approximately double the death observed in untreated cells. To determine the &#8220;Pol II Degrader Similarity&#8221; (PDS) score for a particular drug-dose pair, the area under the LED fit (AUC) was determined, and the baseline cell death was removed by subtracting out the AUC of untreated cells. The difference in drug response between KO and U2OS cells was defined as 1 minus the AUC ratio of KO over U2OS. This value, determined for PTBP1-KO and BCL2L12-KO separately, was summed. Finally, scores were divided by that of 1 &#956;M triptolide, such that a score of one denotes a functional genetic signature equal to that of triptolide.</p><p id="P101">Evaluation of genetic dependance across cell lines using the in4mer system of cell death on BAX/BAK1, on PTBP1, on BCL2L12, as well as PDS scores across cell lines, followed an identical approach. Scores were further normalized to that of triptolide in U2OS cells as a validated control.</p></sec><sec id="S52"><title>Probabilistic drug classifier</title><p id="P102">Drugs were classified as &#8220;triptolide-like&#8221; based on their dependency on PTBP1, BCL2L12, BAX, and BAK1 for causing cell death. To perform this functional genetic classification, we adapted an established approach used previously.<sup><xref rid="R59" ref-type="bibr">59</xref>,<xref rid="R60" ref-type="bibr">60</xref></sup> Briefly, for each drug-dose pair, AUC ratios between each KO and U2OS were determined. This places each drug-dose pair in a 3-dimensional functional genetic space, defined by the relative AUCs observed in PTBP1-KO vs. WT, BCL2L12-KO vs. WT, and BAX/BAK DKO vs. WT. The &#8220;neighborhood&#8221; of transcriptional inhibitors was calculated as the mean of pairwise Euclidean distances between validated Pol II degraders (triptolide and &#9082;-amanitin) in this 3-dimensional space. The linkage ratio describes the similarity of a query compound to triptolide and &#9082;-amanitin and defines how much the neighborhood expands or shrinks after the query compound is included in it. A set of negative controls, defined as a set of drugs with known mechanism of action distinct from transcriptional inhibition, is then forced to be included in the transcriptional inhibitor neighborhood, iteratively, causing the neighborhood to expand or shrink. BH3 mimetics (ABT-199, ABT-263, ABT-737), Topoisomerase inhibitors (Etoposide, Camptothecin, Idarubicin, Topotecan, and Teniposide), and ER-stress inducers (Thapsigargin, Tunicamycin, and Brefeldin A) were used to generate the false expansion. This process of &#8220;false expansion&#8221; generates an empirically defined null distribution of linkage ratios. A linkage ratio for each drug-dose pair is then determined and compared to the null distribution to derive a <italic toggle="yes">P</italic> value. <italic toggle="yes">P</italic> values are then FDR corrected using the Benjamini&#8211;Hochberg procedure.</p></sec><sec id="S53"><title>IF image analysis</title><p id="P103">Images were analyzed in Fiji. DAPI staining was used to mask nuclei, and a cytoplasmic area was drawn for each analyzed cell using actin staining. Images were quantified in a double-blinded fashion. Raw intensities within each region of interest were area normalized, and cytoplasmic/nuclear ratios for each cell were calculated. For quantifying nuclear versus mitochondrial intensity, Tom20 staining was used to mask mitochondria.</p></sec><sec id="S54"><title>Data analysis and statistics</title><p id="P104">Unless otherwise noted, data analysis and statistics was performed in MATLAB (version R2024b) using built-in functions. Bar plots were generated in GraphPad Prism 10. ImageStudio 3.1.4 was used to analyze western blots. Flow cytometry analysis was performed using FlowJo version 10.8.1 software. Details of statistical tests&#8212;including type of test used, exact values of <italic toggle="yes">n</italic>, definition of center, dispersion and precision measurements, and definitions of significance&#8212;are indicated in the respective figure legends and methods section.</p></sec></sec></sec><sec sec-type="supplementary-material" id="SM1"><title>Supplementary Material</title><supplementary-material id="SD1" position="float" content-type="local-data" orientation="portrait"><label>MMC4</label><media xlink:href="NIHMS2100174-supplement-MMC4.xlsx" id="d67e2122" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD2" position="float" content-type="local-data" orientation="portrait"><label>MMC2</label><media xlink:href="NIHMS2100174-supplement-MMC2.xlsx" id="d67e2125" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD3" position="float" content-type="local-data" orientation="portrait"><label>MMC1</label><media xlink:href="NIHMS2100174-supplement-MMC1.xlsx" id="d67e2128" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD4" position="float" content-type="local-data" orientation="portrait"><label>MMC3</label><media xlink:href="NIHMS2100174-supplement-MMC3.xlsx" id="d67e2131" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD5" position="float" content-type="local-data" orientation="portrait"><label>MMC7</label><media xlink:href="NIHMS2100174-supplement-MMC7.xlsx" id="d67e2134" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD6" position="float" content-type="local-data" orientation="portrait"><label>MMC6</label><media xlink:href="NIHMS2100174-supplement-MMC6.xlsx" id="d67e2137" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD7" position="float" content-type="local-data" orientation="portrait"><label>MMC5</label><media xlink:href="NIHMS2100174-supplement-MMC5.xlsx" id="d67e2140" position="anchor" orientation="portrait"/></supplementary-material><supplementary-material id="SD8" position="float" content-type="local-data" orientation="portrait"><label>8</label><media xlink:href="NIHMS2100174-supplement-8.pdf" id="d67e2143" position="anchor" orientation="portrait"/></supplementary-material><p id="P105">Supplemental information can be found online at <ext-link xlink:href="10.1016/j.cell.2025.07.034" ext-link-type="doi">https://doi.org/10.1016/j.cell.2025.07.034</ext-link>.</p></sec></body><back><ack id="S55"><title>ACKNOWLEDGMENTS</title><p id="P106">We thank Marian Walhout, Tom Fazzio, Eric Baehrecke, Roger Davis, Caryn Navarro, Tiana Naylor, Mika Wesley, and all members of the UMass Chan DSB community for their suggestions throughout the execution of this study. We especially thank Ezequiel Calvo-Roitberg for advice related to evaluating PTBP1-dependent splicing and RNA location and Job Dekker for providing the HAP1-RPB1-AID cells. Funding provided by NIGMS grant R35GM15 2194 (to M.J.L.) and NCI fellowship F31CA284879 (to N.W.H.).</p></ack><fn-group><fn fn-type="COI-statement" id="FN2"><p id="P107">DECLARATION OF INTERESTS</p><p id="P108">The authors declare no competing interests.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tsherniak</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Vazquez</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Montgomery</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Weir</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Kryukov</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Cowley</surname><given-names>GS</given-names></name>, <name name-style="western"><surname>Gill</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Harrington</surname><given-names>WF</given-names></name>, <name name-style="western"><surname>Pantel</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Krill-Burger</surname><given-names>JM</given-names></name>, <etal/> (<year>2017</year>). <article-title>Defining a Cancer Dependency Map</article-title>. <source>Cell</source><volume>170</volume>, <fpage>564</fpage>&#8211;<lpage>576.e16</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.06.010</pub-id>.<pub-id pub-id-type="pmid">28753430</pub-id><pub-id pub-id-type="pmcid">PMC5667678</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Vervoort</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Devlin</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Kwiatkowski</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Teng</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gray</surname><given-names>NS</given-names></name>, and <name name-style="western"><surname>Johnstone</surname><given-names>RW</given-names></name> (<year>2022</year>). <article-title>Targeting transcription cycles in cancer</article-title>. <source>Nat. Rev. Cancer</source><volume>22</volume>, <fpage>5</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1038/s41568-021-00411-8</pub-id>.<pub-id pub-id-type="pmid">34675395</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Green</surname><given-names>DR</given-names></name> (<year>2019</year>). <article-title>The Coming Decade of Cell Death Research: Five Riddles</article-title>. <source>Cell</source><volume>177</volume>, <fpage>1094</fpage>&#8211;<lpage>1107</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2019.04.024</pub-id>.<pub-id pub-id-type="pmid">31100266</pub-id><pub-id pub-id-type="pmcid">PMC6534278</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tang</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Kang</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Berghe</surname><given-names>TV</given-names></name>, <name name-style="western"><surname>Vandenabeele</surname><given-names>P</given-names></name>, and <name name-style="western"><surname>Kroemer</surname><given-names>G</given-names></name> (<year>2019</year>). <article-title>The molecular machinery of regulated cell death</article-title>. <source>Cell Res</source><volume>29</volume>, <fpage>347</fpage>&#8211;<lpage>364</lpage>. <pub-id pub-id-type="doi">10.1038/s41422-019-0164-5</pub-id>.<pub-id pub-id-type="pmid">30948788</pub-id><pub-id pub-id-type="pmcid">PMC6796845</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Haimovich</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Medina</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Causse</surname><given-names>SZ</given-names></name>, <name name-style="western"><surname>Garber</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Mill&#225;n-Zambrano</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Barkai</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Ch&#225;vez</surname><given-names>S</given-names></name>, <name name-style="western"><surname>P&#233;rez-Ort&#237;n</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Darzacq</surname><given-names>X</given-names></name>, and <name name-style="western"><surname>Choder</surname><given-names>M</given-names></name> (<year>2013</year>). <article-title>Gene Expression Is Circular: Factors for mRNA Degradation Also Foster mRNA Synthesis</article-title>. <source>Cell</source><volume>153</volume>, <fpage>1000</fpage>&#8211;<lpage>1011</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2013.05.012</pub-id>.<pub-id pub-id-type="pmid">23706738</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sun</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Schwalb</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Pirkl</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Maier</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Schenk</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Failmezger</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Tresch</surname><given-names>A</given-names></name>, and <name name-style="western"><surname>Cramer</surname><given-names>P</given-names></name> (<year>2013</year>). <article-title>Global Analysis of Eukaryotic mRNA Degradation Reveals Xrn1-Dependent Buffering of Transcript Levels</article-title>. <source>Mol. Cell</source><volume>52</volume>, <fpage>52</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2013.09.010</pub-id>.<pub-id pub-id-type="pmid">24119399</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Berry</surname><given-names>S</given-names></name>, <name name-style="western"><surname>M&#252;ller</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rai</surname><given-names>A</given-names></name>, and <name name-style="western"><surname>Pelkmans</surname><given-names>L</given-names></name> (<year>2022</year>). <article-title>Feedback from nuclear RNA on transcription promotes robust RNA concentration homeostasis in human cells</article-title>. <source>Cell Syst</source><volume>13</volume>, <fpage>454</fpage>&#8211;<lpage>470.e15</lpage>. <pub-id pub-id-type="doi">10.1016/j.cels.2022.04.005</pub-id>.<pub-id pub-id-type="pmid">35613616</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Slobodin</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Bahat</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sehrawat</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Becker-Herman</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zuckerman</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Weiss</surname><given-names>AN</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Elkon</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Agami</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ulitsky</surname><given-names>I</given-names></name>, <etal/> (<year>2020</year>). <article-title>Transcription Dynamics Regulate Poly(A) Tails and Expression of the RNA Degradation Machinery to Balance mRNA Levels</article-title>. <source>Mol. Cell</source><volume>78</volume>, <fpage>434</fpage>&#8211;<lpage>444.e5</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2020.03.022</pub-id>.<pub-id pub-id-type="pmid">32294471</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hartenian</surname><given-names>E</given-names></name>, and <name name-style="western"><surname>Glaunsinger</surname><given-names>BA</given-names></name> (<year>2019</year>). <article-title>Feedback to the central dogma: cytoplasmic mRNA decay and transcription are interdependent processes</article-title>. <source>Crit. Rev. Biochem. Mol. Biol</source><volume>54</volume>, <fpage>385</fpage>&#8211;<lpage>398</lpage>. <pub-id pub-id-type="doi">10.1080/10409238.2019.1679083</pub-id>.<pub-id pub-id-type="pmid">31656086</pub-id><pub-id pub-id-type="pmcid">PMC6871655</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Swaffer</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Marinov</surname><given-names>GK</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Fuentes Valenzuela</surname><given-names>LF</given-names></name>, <name name-style="western"><surname>Tsui</surname><given-names>CY</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>AW</given-names></name>, <name name-style="western"><surname>Greenwood</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kundaje</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Greenleaf</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Reyes-Lamothe</surname><given-names>R</given-names></name>, <etal/> (<year>2023</year>). <article-title>RNA polymerase II dynamics and mRNA stability feedback scale mRNA amounts with cell size</article-title>. <source>Cell</source><volume>186</volume>, <fpage>5254</fpage>&#8211;<lpage>5268.e26</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2023.10.012</pub-id>.<pub-id pub-id-type="pmid">37944513</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Titov</surname><given-names>DV</given-names></name>, <name name-style="western"><surname>Gilman</surname><given-names>B</given-names></name>, <name name-style="western"><surname>He</surname><given-names>Q-L</given-names></name>, <name name-style="western"><surname>Bhat</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Low</surname><given-names>W-K</given-names></name>, <name name-style="western"><surname>Dang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Smeaton</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Demain</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Kugel</surname><given-names>JF</given-names></name>, <etal/> (<year>2011</year>). <article-title>XPB, a subunit of TFIIH, is a target of the natural product triptolide</article-title>. <source>Nat. Chem. Biol</source><volume>7</volume>, <fpage>182</fpage>&#8211;<lpage>188</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.522</pub-id>.<pub-id pub-id-type="pmid">21278739</pub-id><pub-id pub-id-type="pmcid">PMC3622543</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Nguyen</surname><given-names>VT</given-names></name>, <name name-style="western"><surname>Giannoni</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Dubois</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Seo</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Vigneron</surname><given-names>M</given-names></name>, <name name-style="western"><surname>K&#233;-dinger</surname><given-names>C</given-names></name>, and <name name-style="western"><surname>Bensaude</surname><given-names>O</given-names></name> (<year>1996</year>). <article-title>In Vivo Degradation of RNA Polymerase II Largest Subunit Triggered by &#945;-Amanitin</article-title>. <source>Nucleic Acids Res</source><volume>24</volume>, <fpage>2924</fpage>&#8211;<lpage>2929</lpage>. <pub-id pub-id-type="doi">10.1093/nar/24.15.2924</pub-id>.<pub-id pub-id-type="pmid">8760875</pub-id><pub-id pub-id-type="pmcid">PMC146057</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Forcina</surname><given-names>GC</given-names></name>, <name name-style="western"><surname>Conlon</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wells</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Cao</surname><given-names>JY</given-names></name>, and <name name-style="western"><surname>Dixon</surname><given-names>SJ</given-names></name> (<year>2017</year>). <article-title>Systematic Quantification of Population Cell Death Kinetics in Mammalian Cells</article-title>. <source>Cell Syst</source><volume>4</volume>, <fpage>600</fpage>&#8211;<lpage>610.e6</lpage>. <pub-id pub-id-type="doi">10.1016/j.cels.2017.05.002</pub-id>.<pub-id pub-id-type="pmid">28601558</pub-id><pub-id pub-id-type="pmcid">PMC5509363</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Galluzzi</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Vitale</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Aaronson</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Abrams</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Adam</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Agostinis</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Alnemri</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Altucci</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Amelio</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Andrews</surname><given-names>DW</given-names></name>, <etal/> (<year>2018</year>). <article-title>Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018</article-title>. <source>Cell Death Differ</source><volume>25</volume>, <fpage>486</fpage>&#8211;<lpage>541</lpage>. <pub-id pub-id-type="doi">10.1038/s41418-017-0012-4</pub-id>.<pub-id pub-id-type="pmid">29362479</pub-id><pub-id pub-id-type="pmcid">PMC5864239</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Holze</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Michaudel</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mackowiak</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Haas</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Benda</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hubel</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Pennemann</surname><given-names>FL</given-names></name>, <name name-style="western"><surname>Schnepf</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Wettmarshausen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Braun</surname><given-names>M</given-names></name>, <etal/> (<year>2018</year>). <article-title>Oxeiptosis, a ROS-induced caspase-independent apoptosis-like cell-death pathway</article-title>. <source>Nat. Immunol</source><volume>19</volume>, <fpage>130</fpage>&#8211;<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1038/s41590-017-0013-y</pub-id>.<pub-id pub-id-type="pmid">29255269</pub-id><pub-id pub-id-type="pmcid">PMC5786482</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tsvetkov</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Coy</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Petrova</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Dreishpoon</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Verma</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Abdusamad</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rossen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Joesch-Cohen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Humeidi</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Spangler</surname><given-names>RD</given-names></name>, <etal/> (<year>2022</year>). <article-title>Copper induces cell death by targeting lipoylated TCA cycle proteins</article-title>. <source>Science</source><volume>375</volume>, <fpage>1254</fpage>&#8211;<lpage>1261</lpage>. <pub-id pub-id-type="doi">10.1126/science.abf0529</pub-id>.<pub-id pub-id-type="pmid">35298263</pub-id><pub-id pub-id-type="pmcid">PMC9273333</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Wei</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Zong</surname><given-names>WX</given-names></name>, <name name-style="western"><surname>Cheng</surname><given-names>EH</given-names></name>, <name name-style="western"><surname>Lindsten</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Panoutsakopoulou</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Ross</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Roth</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>MacGregor</surname><given-names>GR</given-names></name>, <name name-style="western"><surname>Thompson</surname><given-names>CB</given-names></name>, and <name name-style="western"><surname>Korsmeyer</surname><given-names>SJ</given-names></name> (<year>2001</year>). <article-title>Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death</article-title>. <source>Science</source><volume>292</volume>, <fpage>727</fpage>&#8211;<lpage>730</lpage>. <pub-id pub-id-type="doi">10.1126/science.1059108</pub-id>.<pub-id pub-id-type="pmid">11326099</pub-id><pub-id pub-id-type="pmcid">PMC3049805</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lindsten</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ross</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>King</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Zong</surname><given-names>WX</given-names></name>, <name name-style="western"><surname>Rathmell</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Shiels</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Ulrich</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Waymire</surname><given-names>KG</given-names></name>, <name name-style="western"><surname>Mahar</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Frauwirth</surname><given-names>K</given-names></name>, <etal/> (<year>2000</year>). <article-title>The Combined Functions of Proapoptotic Bcl-2 Family Members Bak and Bax Are Essential for Normal Development of Multiple Tissues</article-title>. <source>Mol. Cell</source><volume>6</volume>, <fpage>1389</fpage>&#8211;<lpage>1399</lpage>. <pub-id pub-id-type="doi">10.1016/s1097-2765(00)00136-2</pub-id>.<pub-id pub-id-type="pmid">11163212</pub-id><pub-id pub-id-type="pmcid">PMC3057227</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Valton</surname><given-names>A-L</given-names></name>, <name name-style="western"><surname>Venev</surname><given-names>SV</given-names></name>, <name name-style="western"><surname>Mair</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Khokhar</surname><given-names>ES</given-names></name>, <name name-style="western"><surname>Tong</surname><given-names>AHY</given-names></name>, <name name-style="western"><surname>Usaj</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Pai</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Moffat</surname><given-names>J</given-names></name>, and <name name-style="western"><surname>Dekker</surname><given-names>J</given-names></name> (<year>2022</year>). <article-title>A cohesin traffic pattern genetically linked to gene regulation</article-title>. <source>Nat. Struct. Mol. Biol</source><volume>29</volume>, <fpage>1239</fpage>&#8211;<lpage>1251</lpage>. <pub-id pub-id-type="doi">10.1038/s41594-022-00890-9</pub-id>.<pub-id pub-id-type="pmid">36482254</pub-id><pub-id pub-id-type="pmcid">PMC10228515</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cidado</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Boiko</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Proia</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ferguson</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Criscione</surname><given-names>SW</given-names></name>, <name name-style="western"><surname>San Martin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Pop-Damkov</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Roamio Franklin</surname><given-names>VN</given-names></name>, <name name-style="western"><surname>Sekhar Reddy Chila-makuri</surname><given-names>C</given-names></name>, <etal/> (<year>2020</year>). <article-title>AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells</article-title>. <source>Clin. Cancer Res</source><volume>26</volume>, <fpage>922</fpage>&#8211;<lpage>934</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-1853</pub-id>.<pub-id pub-id-type="pmid">31699827</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sancho</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Leiva</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Lucendo</surname><given-names>E</given-names></name>, and <name name-style="western"><surname>Orz&#225;ez</surname><given-names>M</given-names></name> (<year>2022</year>). <article-title>Understanding MCL1: from cellular function and regulation to pharmacological inhibition</article-title>. <source>FEBS Journal</source><volume>289</volume>, <fpage>6209</fpage>&#8211;<lpage>6234</lpage>. <pub-id pub-id-type="doi">10.1111/febs.16136</pub-id>.<pub-id pub-id-type="pmid">34310025</pub-id><pub-id pub-id-type="pmcid">PMC9787394</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Widden</surname><given-names>H</given-names></name>, and <name name-style="western"><surname>Placzek</surname><given-names>WJ</given-names></name> (<year>2021</year>). <article-title>The multiple mechanisms of MCL1 in the regulation of cell fate</article-title>. <source>Commun. Biol</source><volume>4</volume>, <fpage>1029</fpage>. <pub-id pub-id-type="doi">10.1038/s42003-021-02564-6</pub-id>.<pub-id pub-id-type="pmid">34475520</pub-id><pub-id pub-id-type="pmcid">PMC8413315</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kotschy</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Szlavik</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Murray</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Davidson</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Maragno</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Le Toumelin-Braizat</surname><given-names>GL</given-names></name>, <name name-style="western"><surname>Chanrion</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kelly</surname><given-names>GL</given-names></name>, <name name-style="western"><surname>Gong</surname><given-names>J-N</given-names></name>, <name name-style="western"><surname>Moujalled</surname><given-names>DM</given-names></name>, <etal/> (<year>2016</year>). <article-title>The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models</article-title>. <source>Nature</source><volume>538</volume>, <fpage>477</fpage>&#8211;<lpage>482</lpage>. <pub-id pub-id-type="doi">10.1038/nature19830</pub-id>.<pub-id pub-id-type="pmid">27760111</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bensaude</surname><given-names>O</given-names></name> (<year>2011</year>). <article-title>Inhibiting eukaryotic transcription: Which compound to choose? How to evaluate its activity?</article-title><source>Transcription</source><volume>2</volume>, <fpage>103</fpage>&#8211;<lpage>108</lpage>. <pub-id pub-id-type="doi">10.4161/trns.2.3.16172</pub-id>.<pub-id pub-id-type="pmid">21922053</pub-id><pub-id pub-id-type="pmcid">PMC3173647</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name>, and <name name-style="western"><surname>Corden</surname><given-names>JL</given-names></name> (<year>1991</year>). <article-title>Phosphorylation causes a conformational change in the carboxyl-terminal domain of the mouse RNA polymerase II largest subunit</article-title>. <source>J. Biol. Chem</source><volume>266</volume>, <fpage>2297</fpage>&#8211;<lpage>2302</lpage>. <pub-id pub-id-type="doi">10.1016/s0021-9258(18)52243-2</pub-id>.<pub-id pub-id-type="pmid">1989983</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cadena</surname><given-names>DL</given-names></name>, and <name name-style="western"><surname>Dahmus</surname><given-names>ME</given-names></name> (<year>1987</year>). <article-title>Messenger RNA synthesis in mammalian cells is catalyzed by the phosphorylated form of RNA polymerase II</article-title>. <source>J. Biol. Chem</source><volume>262</volume>, <fpage>12468</fpage>&#8211;<lpage>12474</lpage>. <pub-id pub-id-type="doi">10.1016/s0021-9258(18)45229-5</pub-id>.<pub-id pub-id-type="pmid">3624268</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Steurer</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Janssens</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Geverts</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Geijer</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Wienholz</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Theil</surname><given-names>AF</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Dealy</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pothof</surname><given-names>J</given-names></name>, <name name-style="western"><surname>van Cappellen</surname><given-names>WA</given-names></name> van, <etal/> (<year>2018</year>). <article-title>Live-cell analysis of endogenous GFP-RPB1 uncovers rapid turnover of initiating and promoter-paused RNA Polymerase II</article-title>. <source>Proc. Natl. Acad. Sci. USA</source><volume>115</volume>, <fpage>E4368</fpage>&#8211;<lpage>E4376</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1717920115</pub-id>.<pub-id pub-id-type="pmid">29632207</pub-id><pub-id pub-id-type="pmcid">PMC5948963</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jacobs</surname><given-names>EY</given-names></name>, <name name-style="western"><surname>Ogiwara</surname><given-names>I</given-names></name>, and <name name-style="western"><surname>Weiner</surname><given-names>AM</given-names></name> (<year>2004</year>). <article-title>Role of the C-Terminal Domain of RNA Polymerase II in U2 snRNA Transcription and 3<sup>&#8242;</sup> Processing</article-title>. <source>Mol. Cell. Biol</source><volume>24</volume>, <fpage>846</fpage>&#8211;<lpage>855</lpage>. <pub-id pub-id-type="doi">10.1128/MCB.24.2.846-855.2004</pub-id>.<pub-id pub-id-type="pmid">14701755</pub-id><pub-id pub-id-type="pmcid">PMC343789</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dahmus</surname><given-names>ME</given-names></name> (<year>1996</year>). <article-title>Reversible Phosphorylation of the C-terminal Domain of RNA Polymerase II</article-title>. <source>J. Biol. Chem</source><volume>271</volume>, <fpage>19009</fpage>&#8211;<lpage>19012</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.271.32.19009</pub-id>.<pub-id pub-id-type="pmid">8759772</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>McCracken</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fong</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Yankulov</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ballantyne</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Greenblatt</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Patterson</surname><given-names>SD</given-names></name>, <name name-style="western"><surname>Wickens</surname><given-names>M</given-names></name>, and <name name-style="western"><surname>Bentley</surname><given-names>DL</given-names></name> (<year>1997</year>). <article-title>The C-terminal domain of RNA polymerase II couples mRNA processing to transcription</article-title>. <source>Nature</source><volume>385</volume>, <fpage>357</fpage>&#8211;<lpage>361</lpage>. <pub-id pub-id-type="doi">10.1038/385357a0</pub-id>.<pub-id pub-id-type="pmid">9002523</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Egloff</surname><given-names>S</given-names></name>, <name name-style="western"><surname>O&#8217;Reilly</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Chapman</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tanzhaus</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Pitts</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Eick</surname><given-names>D</given-names></name>, and <name name-style="western"><surname>Murphy</surname><given-names>S</given-names></name> (<year>2007</year>). <article-title>Serine-7 of the RNA Polymerase II CTD Is Specifically Required for snRNA Gene Expression</article-title>. <source>Science</source><volume>318</volume>, <fpage>1777</fpage>&#8211;<lpage>1779</lpage>. <pub-id pub-id-type="doi">10.1126/science.1145989</pub-id>.<pub-id pub-id-type="pmid">18079403</pub-id><pub-id pub-id-type="pmcid">PMC2263945</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Gerber</surname><given-names>A</given-names></name>, and <name name-style="western"><surname>Roeder</surname><given-names>RG</given-names></name> (<year>2020</year>). <article-title>The CTD Is Not Essential for the Post-Initiation Control of RNA Polymerase II Activity</article-title>. <source>J. Mol. Biol</source><volume>432</volume>, <fpage>5489</fpage>&#8211;<lpage>5498</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2020.07.010</pub-id>.<pub-id pub-id-type="pmid">32707132</pub-id><pub-id pub-id-type="pmcid">PMC7502503</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lux</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Albiez</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Chapman</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Heidinger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Meininghaus</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Brack-Werner</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Lang</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ziegler</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Cremer</surname><given-names>T</given-names></name>, and <name name-style="western"><surname>Eick</surname><given-names>D</given-names></name> (<year>2005</year>). <article-title>Transition from initiation to promoter proximal pausing requires the CTD of RNA polymerase II</article-title>. <source>Nucleic Acids Res</source><volume>33</volume>, <fpage>5139</fpage>&#8211;<lpage>5144</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gki802</pub-id>.<pub-id pub-id-type="pmid">16157863</pub-id><pub-id pub-id-type="pmcid">PMC1214543</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Mair</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Tomic</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Masud</surname><given-names>SN</given-names></name>, <name name-style="western"><surname>Tonge</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Weiss</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Usaj</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tong</surname><given-names>AHY</given-names></name>, <name name-style="western"><surname>Kwan</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Titus</surname><given-names>E</given-names></name>, <etal/> (<year>2019</year>). <article-title>Essential Gene Profiles for Human Pluripotent Stem Cells Identify Uncharacterized Genes and Substrate Dependencies</article-title>. <source>Cell Rep</source><volume>27</volume>, <fpage>599</fpage>&#8211;<lpage>615.e12</lpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2019.02.041</pub-id>.<pub-id pub-id-type="pmid">30970261</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hart</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Tong</surname><given-names>AHY</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Van Leeuwen</surname><given-names>JV</given-names></name>, <name name-style="western"><surname>Seetharaman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Aregger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Chandrashekhar</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Hustedt</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Seth</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Noonan</surname><given-names>A</given-names></name>, <etal/> (<year>2017</year>). <article-title>Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens</article-title>. <source>G3 (Bethesda)</source><volume>7</volume>, <fpage>2719</fpage>&#8211;<lpage>2727</lpage>. <pub-id pub-id-type="doi">10.1534/g3.117.041277</pub-id>.<pub-id pub-id-type="pmid">28655737</pub-id><pub-id pub-id-type="pmcid">PMC5555476</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Honeywell</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Isidor</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Harper</surname><given-names>NW</given-names></name>, <name name-style="western"><surname>Fontana</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Birdsall</surname><given-names>GA</given-names></name>, <name name-style="western"><surname>Cruz-Gordillo</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Porto</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Jerome</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fraser</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Sarosiek</surname><given-names>KA</given-names></name>, <etal/> (<year>2024</year>). <article-title>Functional genomic screens with death rate analyses reveal mechanisms of drug action</article-title>. <source>Nat. Chem. Biol</source><volume>20</volume>, <fpage>1443</fpage>&#8211;<lpage>1452</lpage>. <pub-id pub-id-type="doi">10.1038/s41589-024-01584-7</pub-id>.<pub-id pub-id-type="pmid">38480981</pub-id><pub-id pub-id-type="pmcid">PMC11393183</pub-id></mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Iannone</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kainov</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhuravskaya</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hamid</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Nojima</surname><given-names>T</given-names></name>, and <name name-style="western"><surname>Makeyev</surname><given-names>EV</given-names></name> (<year>2023</year>). <article-title>PTBP1-activated co-transcriptional splicing controls epigenetic status of pluripotent stem cells</article-title>. <source>Mol. Cell</source><volume>83</volume>, <fpage>203</fpage>&#8211;<lpage>218.e9</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2022.12.014</pub-id>.<pub-id pub-id-type="pmid">36626906</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Zhu</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Rong</surname><given-names>LJ</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yan</surname><given-names>XJ</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L</given-names></name>, <etal/> (<year>2020</year>). <article-title>Roles of PTBP1 in alternative splicing, glycolysis, and oncogensis</article-title>. <source>J. Zhejiang Univ. Sci. B</source><volume>21</volume>, <fpage>122</fpage>&#8211;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1631/jzus.B1900422</pub-id>.<pub-id pub-id-type="pmid">32115910</pub-id><pub-id pub-id-type="pmcid">PMC7076342</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Sawicka</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Bushell</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Spriggs</surname><given-names>KA</given-names></name>, and <name name-style="western"><surname>Willis</surname><given-names>AE</given-names></name> (<year>2008</year>). <article-title>Polypyrimidine-tract-binding protein: a multifunctional RNA-binding protein</article-title>. <source>Biochem. Soc. Trans</source><volume>36</volume>, <fpage>641</fpage>&#8211;<lpage>647</lpage>. <pub-id pub-id-type="doi">10.1042/BST0360641</pub-id>.<pub-id pub-id-type="pmid">18631133</pub-id></mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bushell</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Stoneley</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kong</surname><given-names>YW</given-names></name>, <name name-style="western"><surname>Hamilton</surname><given-names>TL</given-names></name>, <name name-style="western"><surname>Spriggs</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Dobbyn</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Qin</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Sarnow</surname><given-names>P</given-names></name>, and <name name-style="western"><surname>Willis</surname><given-names>AE</given-names></name> (<year>2006</year>). <article-title>Polypyrimidine Tract Binding Protein Regulates IRES-Mediated Gene Expression during Apoptosis</article-title>. <source>Mol. Cell</source><volume>23</volume>, <fpage>401</fpage>&#8211;<lpage>412</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2006.06.012</pub-id>.<pub-id pub-id-type="pmid">16885029</pub-id></mixed-citation></ref><ref id="R41"><label>41.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>King</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Cobbold</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Pichon</surname><given-names>X</given-names></name>, <name name-style="western"><surname>P&#246;yry</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Booden</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Jukes-Jones</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Cain</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Lilley</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Bushell</surname><given-names>M</given-names></name>, <etal/> (<year>2014</year>). <article-title>Remodelling of a polypyrimidine tract-binding protein complex during apoptosis activates cellular IRESs</article-title>. <source>Cell Death Differ</source><volume>21</volume>, <fpage>161</fpage>&#8211;<lpage>171</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2013.135</pub-id>.<pub-id pub-id-type="pmid">24141718</pub-id><pub-id pub-id-type="pmcid">PMC3857619</pub-id></mixed-citation></ref><ref id="R42"><label>42.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kafasla</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Mickleburgh</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Llorian</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Coelho</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Gooding</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Cherny</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Joshi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kotik-Kogan</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Curry</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Eperon</surname><given-names>IC</given-names></name>, <etal/> (<year>2012</year>). <article-title>Defining the roles and interactions of PTB</article-title>. <source>Biochem. Soc. Trans</source><volume>40</volume>, <fpage>815</fpage>&#8211;<lpage>820</lpage>. <pub-id pub-id-type="doi">10.1042/BST20120044</pub-id>.<pub-id pub-id-type="pmid">22817740</pub-id></mixed-citation></ref><ref id="R43"><label>43.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Xue</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ji</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Kwon</surname><given-names>Y-S</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Yeo</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Black</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>H</given-names></name>, <etal/> (<year>2009</year>). <article-title>Genome-wide Analysis of PTB-RNA Interactions Reveals a Strategy Used by the General Splicing Repressor to Modulate Exon Inclusion or Skipping</article-title>. <source>Mol. Cell</source><volume>36</volume>, <fpage>996</fpage>&#8211;<lpage>1006</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2009.12.003</pub-id>.<pub-id pub-id-type="pmid">20064465</pub-id><pub-id pub-id-type="pmcid">PMC2807993</pub-id></mixed-citation></ref><ref id="R44"><label>44.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Keppetipola</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Sharma</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Q</given-names></name>, and <name name-style="western"><surname>Black</surname><given-names>DL</given-names></name> (<year>2012</year>). <article-title>Neuronal regulation of pre-mRNA splicing by polypyrimidine tract binding proteins, PTBP1 and PTBP2</article-title>. <source>Crit. Rev. Biochem. Mol. Biol</source><volume>47</volume>, <fpage>360</fpage>&#8211;<lpage>378</lpage>. <pub-id pub-id-type="doi">10.3109/10409238.2012.691456</pub-id>.<pub-id pub-id-type="pmid">22655688</pub-id><pub-id pub-id-type="pmcid">PMC3422667</pub-id></mixed-citation></ref><ref id="R45"><label>45.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Llorian</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Schwartz</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Clark</surname><given-names>TA</given-names></name>, <name name-style="western"><surname>Hollander</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Tan</surname><given-names>L-Y</given-names></name>, <name name-style="western"><surname>Spellman</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Gordon</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Schweitzer</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>de la Grange</surname><given-names>P</given-names></name> de la, Ast, G., <etal/> (<year>2010</year>). <article-title>Position-dependent alternative splicing activity revealed by global profiling of alternative splicing events regulated by PTB</article-title>. <source>Nat. Struct. Mol. Biol</source><volume>17</volume>, <fpage>1114</fpage>&#8211;<lpage>1123</lpage>. <pub-id pub-id-type="doi">10.1038/nsmb.1881</pub-id>.<pub-id pub-id-type="pmid">20711188</pub-id><pub-id pub-id-type="pmcid">PMC2933513</pub-id></mixed-citation></ref><ref id="R46"><label>46.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Pi&#241;ol-Roma</surname><given-names>S</given-names></name>, and <name name-style="western"><surname>Dreyfuss</surname><given-names>G</given-names></name> (<year>1992</year>). <article-title>Shuttling of pre-mRNA binding proteins between nucleus and cytoplasm</article-title>. <source>Nature</source><volume>355</volume>, <fpage>730</fpage>&#8211;<lpage>732</lpage>. <pub-id pub-id-type="doi">10.1038/355730a0</pub-id>.<pub-id pub-id-type="pmid">1371331</pub-id></mixed-citation></ref><ref id="R47"><label>47.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Pi&#241;ol-Roma</surname><given-names>S</given-names></name>, and <name name-style="western"><surname>Dreyfuss</surname><given-names>G</given-names></name> (<year>1991</year>). <article-title>Transcription-Dependent and Transcription-Independent Nuclear Transport of hnRNP Proteins</article-title>. <source>Science</source><volume>253</volume>, <fpage>312</fpage>&#8211;<lpage>314</lpage>. <pub-id pub-id-type="doi">10.1126/science.1857966</pub-id>.<pub-id pub-id-type="pmid">1857966</pub-id></mixed-citation></ref><ref id="R48"><label>48.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ni Chonghaile</surname><given-names>TN</given-names></name>, and <name name-style="western"><surname>Letai</surname><given-names>A</given-names></name> (<year>2008</year>). <article-title>Mimicking the BH3 domain to kill cancer cells</article-title>. <source>Oncogene</source><volume>27</volume>, <fpage>S149</fpage>&#8211;<lpage>S157</lpage>. <pub-id pub-id-type="doi">10.1038/onc.2009.52</pub-id>.<pub-id pub-id-type="pmid">19641500</pub-id><pub-id pub-id-type="pmcid">PMC3733265</pub-id></mixed-citation></ref><ref id="R49"><label>49.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Huang</surname><given-names>DCS</given-names></name>, and <name name-style="western"><surname>Strasser</surname><given-names>A</given-names></name> (<year>2000</year>). <article-title>BH3-Only Proteins&#8212;Essential Initiators of Apoptotic Cell Death</article-title>. <source>Cell</source><volume>103</volume>, <fpage>839</fpage>&#8211;<lpage>842</lpage>. <pub-id pub-id-type="doi">10.1016/s0092-8674(00)00187-2</pub-id>.<pub-id pub-id-type="pmid">11136969</pub-id></mixed-citation></ref><ref id="R50"><label>50.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kale</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Osterlund</surname><given-names>EJ</given-names></name>, and <name name-style="western"><surname>Andrews</surname><given-names>DW</given-names></name> (<year>2018</year>). <article-title>BCL-2 family proteins: changing partners in the dance towards death</article-title>. <source>Cell Death Differ</source><volume>25</volume>, <fpage>65</fpage>&#8211;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1038/cdd.2017.186</pub-id>.<pub-id pub-id-type="pmid">29149100</pub-id><pub-id pub-id-type="pmcid">PMC5729540</pub-id></mixed-citation></ref><ref id="R51"><label>51.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Stegh</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Bachoo</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Forloney</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Schulze</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hannon</surname><given-names>GJ</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Louis</surname><given-names>DN</given-names></name>, <etal/> (<year>2007</year>). <article-title>Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma</article-title>. <source>Genes Dev</source><volume>21</volume>, <fpage>98</fpage>&#8211;<lpage>111</lpage>. <pub-id pub-id-type="doi">10.1101/gad.1480007</pub-id>.<pub-id pub-id-type="pmid">17210792</pub-id><pub-id pub-id-type="pmcid">PMC1759904</pub-id></mixed-citation></ref><ref id="R52"><label>52.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Adamopoulos</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Kontos</surname><given-names>CK</given-names></name>, <name name-style="western"><surname>Tsiakanikas</surname><given-names>P</given-names></name>, and <name name-style="western"><surname>Scorilas</surname><given-names>A</given-names></name> (<year>2016</year>). <article-title>Identification of novel alternative splice variants of the BCL2L12 gene in human cancer cells using next-generation sequencing methodology</article-title>. <source>Cancer Lett</source><volume>373</volume>, <fpage>119</fpage>&#8211;<lpage>129</lpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2016.01.019</pub-id>.<pub-id pub-id-type="pmid">26797417</pub-id></mixed-citation></ref><ref id="R53"><label>53.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Chu</surname><given-names>C-W</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>M-C</given-names></name>, <name name-style="western"><surname>Chou</surname><given-names>C-H</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>W-S</given-names></name>, <name name-style="western"><surname>Hsiao</surname><given-names>B-X</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y-T</given-names></name>, <name name-style="western"><surname>Chiou</surname><given-names>S-J</given-names></name>, <name name-style="western"><surname>Loh</surname><given-names>J-K</given-names></name>, and <name name-style="western"><surname>Hong</surname><given-names>Y-R</given-names></name> (<year>2018</year>). <article-title>GSK3&#946;-mediated Ser156 phosphorylation modulates a BH3-like domain in BCL2L12 during TMZ-induced apoptosis and autophagy in glioma cells</article-title>. <source>Int. J. Mol. Med</source><volume>42</volume>, <fpage>905</fpage>&#8211;<lpage>918</lpage>. <pub-id pub-id-type="doi">10.3892/ijmm.2018.3672</pub-id>.<pub-id pub-id-type="pmid">29749471</pub-id><pub-id pub-id-type="pmcid">PMC6034918</pub-id></mixed-citation></ref><ref id="R54"><label>54.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Czabotar</surname><given-names>PE</given-names></name>, <name name-style="western"><surname>Westphal</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Dewson</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hockings</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Fairlie</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>EF</given-names></name>, <name name-style="western"><surname>Yao</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Robin</surname><given-names>AY</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>BJ</given-names></name>, <etal/> (<year>2013</year>). <article-title>Bax Crystal Structures Reveal How BH3 Domains Activate Bax and Nucleate Its Oligomerization to Induce Apoptosis</article-title>. <source>Cell</source><volume>152</volume>, <fpage>519</fpage>&#8211;<lpage>531</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.12.031</pub-id>.<pub-id pub-id-type="pmid">23374347</pub-id></mixed-citation></ref><ref id="R55"><label>55.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ryan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Montero</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Rocco</surname><given-names>J</given-names></name>, and <name name-style="western"><surname>Letai</surname><given-names>A</given-names></name> (<year>2016</year>). <article-title>iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry</article-title>. <source>Biol. Chem</source><volume>397</volume>, <fpage>671</fpage>&#8211;<lpage>678</lpage>. <pub-id pub-id-type="doi">10.1515/hsz-2016-0107</pub-id>.<pub-id pub-id-type="pmid">26910743</pub-id></mixed-citation></ref><ref id="R56"><label>56.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Kuwana</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Bouchier-Hayes</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Chipuk</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Bonzon</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Sullivan</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Green</surname><given-names>DR</given-names></name>, and <name name-style="western"><surname>Newmeyer</surname><given-names>DD</given-names></name> (<year>2005</year>). <article-title>BH3 Domains of BH3-Only Proteins Differentially Regulate Bax-Mediated Mitochondrial Membrane Permeabilization Both Directly and Indirectly</article-title>. <source>Mol. Cell</source><volume>17</volume>, <fpage>525</fpage>&#8211;<lpage>535</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2005.02.003</pub-id>.<pub-id pub-id-type="pmid">15721256</pub-id></mixed-citation></ref><ref id="R57"><label>57.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>L&#243;pez</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Llop-Hern&#225;ndez</surname><given-names>&#192;</given-names></name>, <name name-style="western"><surname>Verdura</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Serrano-Herv&#225;s</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Martinez-Balibrea</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bosch-Barrera</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Teixidor</surname><given-names>E</given-names></name>, <name name-style="western"><surname>L&#243;pez-Bonet</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Martin-Castillo</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Sardany&#233;s</surname><given-names>J</given-names></name>, <etal/> (<year>2025</year>). <article-title>Mitochondrial priming and response to BH3 mimetics in &#8220;one-two punch&#8221; senogenic-senolytic strategies</article-title>. <source>Cell Death Discov</source><volume>11</volume>, <fpage>91</fpage>. <pub-id pub-id-type="doi">10.1038/s41420-025-02379-y</pub-id>.<pub-id pub-id-type="pmid">40055336</pub-id><pub-id pub-id-type="pmcid">PMC11889205</pub-id></mixed-citation></ref><ref id="R58"><label>58.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Villalobos-Ortiz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ryan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mashaka</surname><given-names>TN</given-names></name>, <name name-style="western"><surname>Opferman</surname><given-names>JT</given-names></name>, and <name name-style="western"><surname>Letai</surname><given-names>A</given-names></name> (<year>2019</year>). <article-title>BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics</article-title>. <source>Cell Death Differ</source>, <fpage>1</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/s41418-019-0391-9</pub-id>.<pub-id pub-id-type="pmcid">PMC7205860</pub-id><pub-id pub-id-type="pmid">31332296</pub-id></mixed-citation></ref><ref id="R59"><label>59.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Pritchard</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Bruno</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Hemann</surname><given-names>MT</given-names></name>, and <name name-style="western"><surname>Lauffenburger</surname><given-names>DA</given-names></name> (<year>2013</year>). <article-title>Predicting cancer drug mechanisms of action using molecular network signatures</article-title>. <source>Mol. Biosyst</source><volume>9</volume>, <fpage>1604</fpage>&#8211;<lpage>1619</lpage>. <pub-id pub-id-type="doi">10.1039/c2mb25459j</pub-id>.<pub-id pub-id-type="pmid">23287973</pub-id><pub-id pub-id-type="pmcid">PMC3945388</pub-id></mixed-citation></ref><ref id="R60"><label>60.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Jiang</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Pritchard</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>RT</given-names></name>, <name name-style="western"><surname>Lauffenburger</surname><given-names>DA</given-names></name>, and <name name-style="western"><surname>Hemann</surname><given-names>MT</given-names></name> (<year>2011</year>). <article-title>A mammalian functional-genetic approach to characterizing cancer therapeutics</article-title>. <source>Nat. Chem. Biol</source><volume>7</volume>, <fpage>92</fpage>&#8211;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1038/nchembio.503</pub-id>.<pub-id pub-id-type="pmid">21186347</pub-id><pub-id pub-id-type="pmcid">PMC3070540</pub-id></mixed-citation></ref><ref id="R61"><label>61.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Cacioppo</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Gillis</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Shlamovitz</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Zeller</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Castiblanco</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Crisp</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Haworth</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Arabiotorre</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Abyaneh</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bao</surname><given-names>Y</given-names></name>, <etal/> (<year>2024</year>). <article-title>CRL3ARMC5 ubiquitin ligase and Integrator phosphatase form parallel mechanisms to control early stages of RNA Pol II transcription</article-title>. <source>Mol. Cell</source><volume>84</volume>, <fpage>4808</fpage>&#8211;<lpage>4823.e13</lpage>. <pub-id pub-id-type="doi">10.1016/j.molcel.2024.11.024</pub-id>.<pub-id pub-id-type="pmid">39667934</pub-id><pub-id pub-id-type="pmcid">PMC7617427</pub-id></mixed-citation></ref><ref id="R62"><label>62.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Dasari</surname><given-names>S</given-names></name>, and <name name-style="western"><surname>Tchounwou</surname><given-names>PB</given-names></name> (<year>2014</year>). <article-title>Cisplatin in cancer therapy: Molecular mechanisms of action</article-title>. <source>Eur. J. Pharmacol</source><volume>740</volume>, <fpage>364</fpage>&#8211;<lpage>378</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2014.07.025</pub-id>.<pub-id pub-id-type="pmid">25058905</pub-id><pub-id pub-id-type="pmcid">PMC4146684</pub-id></mixed-citation></ref><ref id="R63"><label>63.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tufegd&#382;i&#263; Vidakovi&#263;</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Mitter</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kelly</surname><given-names>GP</given-names></name>, <name name-style="western"><surname>Neumann</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Harreman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rodr&#237;guez-Mart&#237;nez</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Herlihy</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Weems</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Boeing</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Encheva</surname><given-names>V</given-names></name>, <etal/> (<year>2020</year>). <article-title>Regulation of the RNAPII Pool Is Integral to the DNA Damage Response</article-title>. <source>Cell</source><volume>180</volume>, <fpage>1245</fpage>&#8211;<lpage>1261.e21</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2020.02.009</pub-id>.<pub-id pub-id-type="pmid">32142654</pub-id><pub-id pub-id-type="pmcid">PMC7103762</pub-id></mixed-citation></ref><ref id="R64"><label>64.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hafner</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Niepel</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Chung</surname><given-names>M</given-names></name>, and <name name-style="western"><surname>Sorger</surname><given-names>PK</given-names></name> (<year>2016</year>). <article-title>Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs</article-title>. <source>Nat. Methods</source><volume>13</volume>, <fpage>521</fpage>&#8211;<lpage>527</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.3853</pub-id>.<pub-id pub-id-type="pmid">27135972</pub-id><pub-id pub-id-type="pmcid">PMC4887336</pub-id></mixed-citation></ref><ref id="R65"><label>65.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Schwartz</surname><given-names>HR</given-names></name>, <name name-style="western"><surname>Richards</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Fontana</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Joyce</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Honeywell</surname><given-names>ME</given-names></name>, and <name name-style="western"><surname>Lee</surname><given-names>MJ</given-names></name> (<year>2020</year>). <article-title>Drug GRADE: An Integrated Analysis of Population Growth and Cell Death Reveals Drug-Specific and Cancer Subtype-Specific Response Profiles</article-title>. <source>Cell Rep</source><volume>31</volume>, <fpage>107800</fpage>. <pub-id pub-id-type="doi">10.1016/j.celrep.2020.107800</pub-id>.<pub-id pub-id-type="pmid">32579927</pub-id><pub-id pub-id-type="pmcid">PMC7394473</pub-id></mixed-citation></ref><ref id="R66"><label>66.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bradner</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Hnisz</surname><given-names>D</given-names></name>, and <name name-style="western"><surname>Young</surname><given-names>RA</given-names></name> (<year>2017</year>). <article-title>Transcriptional Addiction in Cancer</article-title>. <source>Cell</source><volume>168</volume>, <fpage>629</fpage>&#8211;<lpage>643</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2016.12.013</pub-id>.<pub-id pub-id-type="pmid">28187285</pub-id><pub-id pub-id-type="pmcid">PMC5308559</pub-id></mixed-citation></ref><ref id="R67"><label>67.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Henikoff</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Paranal</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Greene</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Henikoff</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Russell</surname><given-names>ZR</given-names></name>, <name name-style="western"><surname>Szulzewsky</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Thirimanne</surname><given-names>HN</given-names></name>, <name name-style="western"><surname>Kugel</surname><given-names>S</given-names></name>, <etal/> (<year>2025</year>). <article-title>RNA polymerase II at histone genes predicts outcome in human cancer</article-title>. <source>Science</source><volume>387</volume>, <fpage>737</fpage>&#8211;<lpage>743</lpage>. <pub-id pub-id-type="doi">10.1126/science.ads2169</pub-id>.<pub-id pub-id-type="pmid">39946483</pub-id><pub-id pub-id-type="pmcid">PMC12184985</pub-id></mixed-citation></ref><ref id="R68"><label>68.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Lin</surname><given-names>CY</given-names></name>, <name name-style="western"><surname>Lov&#233;n</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Rahl</surname><given-names>PB</given-names></name>, <name name-style="western"><surname>Paranal</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Burge</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Bradner</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>TI</given-names></name>, and <name name-style="western"><surname>Young</surname><given-names>RA</given-names></name> (<year>2012</year>). <article-title>Transcriptional Amplification in Tumor Cells with Elevated c-Myc</article-title>. <source>Cell</source><volume>151</volume>, <fpage>56</fpage>&#8211;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2012.08.026</pub-id>.<pub-id pub-id-type="pmid">23021215</pub-id><pub-id pub-id-type="pmcid">PMC3462372</pub-id></mixed-citation></ref><ref id="R69"><label>69.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Montero</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sarosiek</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>DeAngelo</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Maertens</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Ryan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ercan</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Piao</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Horowitz</surname><given-names>NS</given-names></name>, <name name-style="western"><surname>Berkowitz</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Matulonis</surname><given-names>U</given-names></name>, <etal/> (<year>2015</year>). <article-title>Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy</article-title>. <source>Cell</source><volume>160</volume>, <fpage>977</fpage>&#8211;<lpage>989</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2015.01.042</pub-id>.<pub-id pub-id-type="pmid">25723171</pub-id><pub-id pub-id-type="pmcid">PMC4391197</pub-id></mixed-citation></ref><ref id="R70"><label>70.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Ni Chonghaile</surname><given-names>TN</given-names></name>, <name name-style="western"><surname>Sarosiek</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Vo</surname><given-names>TT</given-names></name>, <name name-style="western"><surname>Ryan</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Tammareddi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Moore</surname><given-names>VDG</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>KC</given-names></name>, <name name-style="western"><surname>Richardson</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Tai</surname><given-names>YT</given-names></name>, <etal/> (<year>2011</year>). <article-title>Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy</article-title>. <source>Science</source><volume>334</volume>, <fpage>1129</fpage>&#8211;<lpage>1133</lpage>. <pub-id pub-id-type="doi">10.1126/science.1206727</pub-id>.<pub-id pub-id-type="pmid">22033517</pub-id><pub-id pub-id-type="pmcid">PMC3280949</pub-id></mixed-citation></ref><ref id="R71"><label>71.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Richards</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Schwartz</surname><given-names>HR</given-names></name>, <name name-style="western"><surname>Honeywell</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Stewart</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Cruz-Gordillo</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Joyce</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Landry</surname><given-names>BD</given-names></name>, and <name name-style="western"><surname>Lee</surname><given-names>MJ</given-names></name> (<year>2020</year>). <article-title>Drug antagonism and single-agent dominance result from differences in death kinetics</article-title>. <source>Nat. Chem. Biol</source><volume>16</volume>, <fpage>791</fpage>&#8211;<lpage>800</lpage>. <pub-id pub-id-type="doi">10.1038/s41589-020-0510-4</pub-id>.<pub-id pub-id-type="pmid">32251407</pub-id><pub-id pub-id-type="pmcid">PMC7311243</pub-id></mixed-citation></ref><ref id="R72"><label>72.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Brinkman</surname><given-names>EK</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Amendola</surname><given-names>M</given-names></name>, and <name name-style="western"><surname>van Steensel</surname><given-names>B</given-names></name> (<year>2014</year>). <article-title>Easy quantitative assessment of genome editing by sequence trace decomposition</article-title>. <source>Nucleic Acids Res</source><volume>42</volume>, <fpage>e168</fpage>. <pub-id pub-id-type="doi">10.1093/nar/gku936</pub-id>.<pub-id pub-id-type="pmid">25300484</pub-id><pub-id pub-id-type="pmcid">PMC4267669</pub-id></mixed-citation></ref><ref id="R73"><label>73.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Bray</surname><given-names>NL</given-names></name>, <name name-style="western"><surname>Pimentel</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Melsted</surname><given-names>P</given-names></name>, and <name name-style="western"><surname>Pachter</surname><given-names>L</given-names></name> (<year>2016</year>). <article-title>Near-optimal probabilistic RNA-seq quantification</article-title>. <source>Nat. Biotechnol</source><volume>34</volume>, <fpage>525</fpage>&#8211;<lpage>527</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.3519</pub-id>.<pub-id pub-id-type="pmid">27043002</pub-id></mixed-citation></ref><ref id="R74"><label>74.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Soneson</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Love</surname><given-names>MI</given-names></name>, and <name name-style="western"><surname>Robinson</surname><given-names>MD</given-names></name> (<year>2015</year>). <article-title>Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences</article-title>. <source>F1000Res</source><volume>4</volume>, <fpage>1521</fpage>. <pub-id pub-id-type="doi">10.12688/f1000research.7563.2</pub-id>.<pub-id pub-id-type="pmid">26925227</pub-id><pub-id pub-id-type="pmcid">PMC4712774</pub-id></mixed-citation></ref><ref id="R75"><label>75.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Love</surname><given-names>MI</given-names></name>, <name name-style="western"><surname>Huber</surname><given-names>W</given-names></name>, and <name name-style="western"><surname>Anders</surname><given-names>S</given-names></name> (<year>2014</year>). <article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title>. <source>Genome Biol</source><volume>15</volume>, <fpage>550</fpage>. <pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id>.<pub-id pub-id-type="pmid">25516281</pub-id><pub-id pub-id-type="pmcid">PMC4302049</pub-id></mixed-citation></ref><ref id="R76"><label>76.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Morgan</surname><given-names>M</given-names></name>, and <name name-style="western"><surname>Shepherd</surname><given-names>L</given-names></name> (<year>2025</year>). <source>AnnotationHub: Client to access AnnotationHub resources. package version 3.99.6</source>. <pub-id pub-id-type="doi">10.18129/B9.bioc.AnnotationHub</pub-id>.</mixed-citation></ref><ref id="R77"><label>77.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Tapial</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ha</surname><given-names>KCH</given-names></name>, <name name-style="western"><surname>Sterne-Weiler</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Gohr</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Braunschweig</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Her-moso-Pulido</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Quesnel-Valli&#232;res</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Permanyer</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Sodaei</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Marquez</surname><given-names>Y</given-names></name>, <etal/> (<year>2017</year>). <article-title>An atlas of alternative splicing profiles and functional associations reveals new regulatory programs and genes that simultaneously express multiple major isoforms</article-title>. <source>Genome Res</source><volume>27</volume>, <fpage>1759</fpage>&#8211;<lpage>1768</lpage>. <pub-id pub-id-type="doi">10.1101/gr.220962.117</pub-id>.<pub-id pub-id-type="pmid">28855263</pub-id><pub-id pub-id-type="pmcid">PMC5630039</pub-id></mixed-citation></ref><ref id="R78"><label>78.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Irimia</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Weatheritt</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Ellis</surname><given-names>JD</given-names></name>, <name name-style="western"><surname>Parikshak</surname><given-names>NN</given-names></name>, <name name-style="western"><surname>Gonatopoulos-Pournatzis</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Babor</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Quesnel-Valli&#232;res</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tapial</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Raj</surname><given-names>B</given-names></name>, <name name-style="western"><surname>O&#8217;Hanlon</surname><given-names>D</given-names></name>, <etal/> (<year>2014</year>). <article-title>A Highly Conserved Program of Neuronal Microexons Is Misregulated in Autistic Brains</article-title>. <source>Cell</source><volume>159</volume>, <fpage>1511</fpage>&#8211;<lpage>1523</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2014.11.035</pub-id>.<pub-id pub-id-type="pmid">25525873</pub-id><pub-id pub-id-type="pmcid">PMC4390143</pub-id></mixed-citation></ref><ref id="R79"><label>79.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Langmead</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Trapnell</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Pop</surname><given-names>M</given-names></name>, and <name name-style="western"><surname>Salzberg</surname><given-names>SL</given-names></name> (<year>2009</year>). <article-title>Ultrafast and memory-efficient alignment of short DNA sequences to the human genome</article-title>. <source>Genome Biol</source><volume>10</volume>, <fpage>R25</fpage>. <pub-id pub-id-type="doi">10.1186/gb-2009-10-3-r25</pub-id>.<pub-id pub-id-type="pmid">19261174</pub-id><pub-id pub-id-type="pmcid">PMC2690996</pub-id></mixed-citation></ref><ref id="R80"><label>80.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Subramanian</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tamayo</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Mootha</surname><given-names>VK</given-names></name>, <name name-style="western"><surname>Mukherjee</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ebert</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Gillette</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Paulovich</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Pomeroy</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Golub</surname><given-names>TR</given-names></name>, <name name-style="western"><surname>Lander</surname><given-names>ES</given-names></name>, <etal/> (<year>2005</year>). <article-title>Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles</article-title>. <source>Proc. Natl. Acad. Sci. USA</source><volume>102</volume>, <fpage>15545</fpage>&#8211;<lpage>15550</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id>.<pub-id pub-id-type="pmid">16199517</pub-id><pub-id pub-id-type="pmcid">PMC1239896</pub-id></mixed-citation></ref><ref id="R81"><label>81.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Schindelin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Arganda-Carreras</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Frise</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Kaynig</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Longair</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Pietzsch</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Preibisch</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Rueden</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Saalfeld</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Schmid</surname><given-names>B</given-names></name>, <etal/> (<year>2012</year>). <article-title>Fiji: an open-source platform for biological-image analysis</article-title>. <source>Nat. Methods</source><volume>9</volume>, <fpage>676</fpage>&#8211;<lpage>682</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id>.<pub-id pub-id-type="pmid">22743772</pub-id><pub-id pub-id-type="pmcid">PMC3855844</pub-id></mixed-citation></ref><ref id="R82"><label>82.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Esmaeili Anvar</surname><given-names>NE</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Wilson</surname><given-names>LL</given-names></name>, <name name-style="western"><surname>Steger</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Sangree</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Colic</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>SH</given-names></name>, <name name-style="western"><surname>Doench</surname><given-names>JG</given-names></name>, and <name name-style="western"><surname>Hart</surname><given-names>T</given-names></name> (<year>2024</year>). <article-title>Efficient gene knockout and genetic interaction screening using the in4mer CRISPR/Cas12a multiplex knockout platform</article-title>. <source>Nat. Commun</source><volume>15</volume>, <fpage>3577</fpage>. <pub-id pub-id-type="doi">10.1038/s41467-024-47795-3</pub-id>.<pub-id pub-id-type="pmid">38678031</pub-id><pub-id pub-id-type="pmcid">PMC11055879</pub-id></mixed-citation></ref><ref id="R83"><label>83.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Rosonina</surname><given-names>E</given-names></name>, and <name name-style="western"><surname>Blencowe</surname><given-names>BJ</given-names></name> (<year>2004</year>). <article-title>Analysis of the requirement for RNA polymerase II CTD heptapeptide repeats in pre-mRNA splicing and 3<sup>&#8242;</sup> -end cleavage</article-title>. <source>RNA</source><volume>10</volume>, <fpage>581</fpage>&#8211;<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1261/rna.5207204</pub-id>.<pub-id pub-id-type="pmid">15037767</pub-id><pub-id pub-id-type="pmcid">PMC1370548</pub-id></mixed-citation></ref><ref id="R84"><label>84.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hickey</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Swarup</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>IR</given-names></name>, <name name-style="western"><surname>Paoli</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Miguel Whelan</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Paulo</surname><given-names>JA</given-names></name>, and <name name-style="western"><surname>Harper</surname><given-names>JW</given-names></name> (<year>2023</year>). <article-title>Proteome census upon nutrient stress reveals Golgiphagy membrane receptors</article-title>. <source>Nature</source><volume>623</volume>, <fpage>167</fpage>&#8211;<lpage>174</lpage>. <pub-id pub-id-type="doi">10.1038/s41586-023-06657-6</pub-id>.<pub-id pub-id-type="pmid">37757899</pub-id><pub-id pub-id-type="pmcid">PMC10620096</pub-id></mixed-citation></ref><ref id="R85"><label>85.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Boehm</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Salehi-Ashtiani</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hao</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Lubonja</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Thomas</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Alkan</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Bhimdi</surname><given-names>T</given-names></name>, <etal/> (<year>2011</year>). <article-title>A public genome-scale lentiviral expression library of human ORFs</article-title>. <source>Nat. Methods</source><volume>8</volume>, <fpage>659</fpage>&#8211;<lpage>661</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth.1638</pub-id>.<pub-id pub-id-type="pmid">21706014</pub-id><pub-id pub-id-type="pmcid">PMC3234135</pub-id></mixed-citation></ref><ref id="R86"><label>86.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Huttlin</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Ting</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Bruckner</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Gebreab</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Gygi</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Szpyt</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tam</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zarraga</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Colby</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Baltier</surname><given-names>K</given-names></name>, <etal/> (<year>2015</year>). <article-title>The BioPlex Network: A Systematic Exploration of the Human Interactome</article-title>. <source>Cell</source><volume>162</volume>, <fpage>425</fpage>&#8211;<lpage>440</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2015.06.043</pub-id>.<pub-id pub-id-type="pmid">26186194</pub-id><pub-id pub-id-type="pmcid">PMC4617211</pub-id></mixed-citation></ref><ref id="R87"><label>87.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hsu</surname><given-names>YT</given-names></name>, and <name name-style="western"><surname>Youle</surname><given-names>RJ</given-names></name> (<year>1998</year>). <article-title>Bax in Murine Thymus Is a Soluble Monomeric Protein That Displays Differential Detergent-induced Conformations</article-title>. <source>J. Biol. Chem</source><volume>273</volume>, <fpage>10777</fpage>&#8211;<lpage>10783</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.273.17.10777</pub-id>.<pub-id pub-id-type="pmid">9553144</pub-id></mixed-citation></ref><ref id="R88"><label>88.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Vervoort</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Welsh</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Devlin</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Barbieri</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Knight</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Offley</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bjelosevic</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Costacurta</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Todorovski</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Kearney</surname><given-names>CJ</given-names></name>, <etal/> (<year>2021</year>). <article-title>The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer</article-title>. <source>Cell</source><volume>184</volume>, <fpage>3143</fpage>&#8211;<lpage>3162.e32</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2021.04.022</pub-id>.<pub-id pub-id-type="pmid">34004147</pub-id><pub-id pub-id-type="pmcid">PMC8567840</pub-id></mixed-citation></ref><ref id="R89"><label>89.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Agarwal</surname><given-names>V</given-names></name>, and <name name-style="western"><surname>Kelley</surname><given-names>DR</given-names></name> (<year>2022</year>). <article-title>The genetic and biochemical determinants of mRNA degradation rates in mammals</article-title>. <source>Genome Biol</source><volume>23</volume>, <fpage>245</fpage>. <pub-id pub-id-type="doi">10.1186/s13059-022-02811-x</pub-id>.<pub-id pub-id-type="pmid">36419176</pub-id><pub-id pub-id-type="pmcid">PMC9684954</pub-id></mixed-citation></ref><ref id="R90"><label>90.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Richards</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Honeywell</surname><given-names>ME</given-names></name>, and <name name-style="western"><surname>Lee</surname><given-names>MJ</given-names></name> (<year>2021</year>). <article-title>FLICK: an optimized plate reader-based assay to infer cell death kinetics</article-title>. <source>Star Protoc</source><volume>2</volume>, <fpage>100327</fpage>. <pub-id pub-id-type="doi">10.1016/j.xpro.2021.100327</pub-id>.<pub-id pub-id-type="pmid">33659903</pub-id><pub-id pub-id-type="pmcid">PMC7890003</pub-id></mixed-citation></ref><ref id="R91"><label>91.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Hart</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Chandrashekhar</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Aregger</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Steinhart</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>MacLeod</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Mis</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Zimmermann</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fradet-Turcotte</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>S</given-names></name>, <etal/> (<year>2015</year>). <article-title>High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities</article-title>. <source>Cell</source><volume>163</volume>, <fpage>1515</fpage>&#8211;<lpage>1526</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2015.11.015</pub-id>.<pub-id pub-id-type="pmid">26627737</pub-id></mixed-citation></ref><ref id="R92"><label>92.</label><mixed-citation publication-type="journal"><name name-style="western"><surname>Stephens</surname><given-names>M</given-names></name> (<year>2017</year>). <article-title>False discovery rates: a new deal</article-title>. <source>Biostatistics</source><volume>18</volume>, <fpage>275</fpage>&#8211;<lpage>294</lpage>. <pub-id pub-id-type="doi">10.1093/biostatistics/kxw041</pub-id>.<pub-id pub-id-type="pmid">27756721</pub-id><pub-id pub-id-type="pmcid">PMC5379932</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig position="float" id="F1" orientation="portrait"><label>Figure 1.</label><caption><title>RNA Pol II inhibition activates apoptosis prior to passive decay of apoptotic mRNA and protein</title><p id="P109">(A) Immunoblot of Rpb1 in U2OS following 1 or 0.1 &#956;M triptolide (TRP). Blots representative of 3 biological replicates.</p><p id="P110">(B) Quantification of (A).</p><p id="P111">(C and D) Live/dead cell kinetics following 1 &#956;M TRP in Nuc::mKate2-expressing U2OS cells. mKate+ = live; Sytox+ = dead. (C) U2OS. (D) U2OS<sup>BAX&#8722;/&#8722;/BAK1&#8722;/&#8722;</sup> (BAX/BAK DKO). Scale bar, 100 &#956;m.</p><p id="P112">(E) Fractional viability (FV) following drugs &#177; pathway-specific inhibitors: z-VAD-FMK (z-VAD) inhibits apoptotic caspases; VX765 inhibits pyroptotic initiator, caspase-1; TTM inhibits cuproptosis (cupro); Rucaparib (Rucap.) inhibits parthanatos (parth); Nec-1 inhibits necroptosis (necro); and Fer-1 inhibits ferroptosis (ferro). RSL3, elesclomol (Eles.), MNNG, and TSZ are canonical activators of listed death pathways. M-157, MDA-MB-157. Heatmap scaled to the mean of 3 biological replicates.</p><p id="P113">(F and G) Long-term response to 1 &#956;M TRP. (F) Representative images from 3 biological replicates. Scale bar, 275 &#956;m. (G) Lethal fraction (LF).</p><p id="P114">(H) mRNA levels following 1 &#956;M TRP, relative to untreated cells. mRNA was quantified for times in which lethality had not yet occurred (4 h for WT; 10 days for DKO). Range for DKO represents 50 longest/shortest half-life mRNAs. Dashed lines denote extrapolation from fit. For WT, the median, 25<sup>th</sup>, and 75<sup>th</sup> percentiles are shown.</p><p id="P115">(I) (Top) Immunoblot of Rpb1 in HAP1, or HAP1-RPB1-AID, following 500 &#956;g/mL auxin (IAA, 3-indoleacetic acid). (Bottom) LF for HAP1-RPB1-AID cells +IAA, &#177;z-VAD. Data are mean &#177; SD of 9 biological replicates. For panels with error bars, data are mean &#177; SD of 3 biological replicates unless otherwise noted.</p><p id="P116">See also <xref rid="SD8" ref-type="supplementary-material">Figures S1</xref> and <xref rid="SD8" ref-type="supplementary-material">S2</xref> and <xref rid="SD3" ref-type="supplementary-material">Tables S1</xref> and <xref rid="SD2" ref-type="supplementary-material">S2</xref>.</p></caption><graphic position="float" orientation="portrait" xlink:href="nihms-2100174-f0002.jpg"/></fig><fig position="float" id="F2" orientation="portrait"><label>Figure 2.</label><caption><title>Loss of hypophosphorylated RNA Pol II correlates with onset of apoptotic death</title><p id="P117">(A) Immunoblots of Rpb1 following flavopiridol (10 &#956;M), THZ1 (1 &#956;M), TRP (0.1 &#956;M), or actinomycin-D (Act-D, 0.1 &#956;M). Blots representative of 3 biological replicates.</p><p id="P118">(B) (Top) Quantification of decay kinetics for RNA Pol IIO (hyperphosphorylated) and RNA Pol IIA (hypophosphorylated) from immunoblots in (A). t<sub>1/2</sub> denotes time to 50% decay. (Bottom) Cell death kinetics. LF<sub>50</sub> denotes time to 50% max observed death.</p><p id="P119">(C and D) Relationship between loss of RNA Pol IIO, or loss of transcriptional activity, and cell death. (C) Cell death kinetics for 17 unique drug-dose combinations, aligned to t<sub>1/2</sub> for loss of RNA Pol IIO (dashed vertical line). Mean of 3 biological replicates shown. (D) Correlation between LF<sub>50</sub> and t<sub>1/2</sub> for loss of RNA Pol IIO (left) or t<sub>1/2</sub> for loss of transcriptional activity measured using EU incorporation (right). Solid gray line denotes fit to a linear regression model. Black dashed line denotes direct x = y relationship, shifted by a constant to account for a lag time between drug activity and cell death.</p><p id="P120">(E and F) Relationship between loss of RNA Pol IIA and cell death. (E) Same as (C), except aligned to t<sub>1/2</sub> for loss of RNA Pol IIA (dashed vertical line). (F) Correlation between t<sub>1/2</sub> for loss of RNA Pol IIA and LF<sub>50</sub>. For panels with error bars, data are mean &#177; SD of 3 biological replicates.</p><p id="P121">See also <xref rid="SD8" ref-type="supplementary-material">Figure S3</xref> and <xref rid="SD4" ref-type="supplementary-material">Table S3</xref>.</p></caption><graphic position="float" orientation="portrait" xlink:href="nihms-2100174-f0003.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Figure 3.</label><caption><title>Loss of hypophosphorylated RNA Pol II initiates apoptosis</title><p id="P122">(A) Schematic describing approaches for uncoupling RNA Pol II activity from protein levels (Ai&#8211;Aiii).</p><p id="P123">(B) Absolute mRNA fold change following 1 &#956;M TRP in U2OS expressing sgRNA-NUP93 or nontargeting sgRNA. Two-sided KS test <italic toggle="yes">p</italic> value shown.</p><p id="P124">(C) LF for cells in (B) following TRP. Wilcoxon rank sum <italic toggle="yes">p</italic> value shown (n.s. <italic toggle="yes">p</italic> &gt; 0.05).</p><p id="P125">(D) Immunoblot of Rpb1 in U2OS following 1 &#956;M TRP, 0.316 &#956;M THZ1, or a combination of the two. Blots representative of 3 biological replicates.</p><p id="P126">(E and F) Quantification of Rpb1 after 4-h drug exposure, associated with (D). (E) Hypophosphorylated (RNA Pol IIA). (F) Hyperphosphorylated (RNA Pol IIO).</p><p id="P127">(G) LF at 24 h, measured in identical conditions to (D)&#8211;(F). Data are mean &#177; SD for 6 biological replicates.</p><p id="P128">(H&#8211;L) RNA Pol II switchover system (H) diagram of RNA Pol II construct. (I) Experimental logic of switchover system. (J) Immunoblot of Rpb1 following 10 &#956;M &#9082;-amanitin. (K) Absolute mRNA fold changes following &#9082;-amanitin. (L) LF following &#9082;-amanitin. Mean &#177; SD for 5 biological replicates. Unless otherwise noted, error bars represent mean &#177; SD of 3 biological replicates.</p><p id="P129">See also <xref rid="SD8" ref-type="supplementary-material">Figure S3</xref> and <xref rid="SD1" ref-type="supplementary-material">Table S4</xref>.</p></caption><graphic position="float" orientation="portrait" xlink:href="nihms-2100174-f0004.jpg"/></fig><fig position="float" id="F4" orientation="portrait"><label>Figure 4.</label><caption><title>Genome-wide screen identifies regulators of TRP-induced apoptosis</title><p id="P130">(A) Schematic of chemogenetic profiling to identify death regulatory genes.</p><p id="P131">(B) Gene-level chemogenetic profiling data. Key death regulatory genes and nontargeting controls highlighted.</p><p id="P132">(C) Simplified schematic of the cell-intrinsic apoptotic pathway. Bcl-2* denotes anti-apoptotic Bcl-2 family members. BH3* denotes pro-apoptotic BH3-only proteins. Regulators in blue/yellow were identified in chemogenetic profiling data.</p><p id="P133">(D) Running enrichment scores (ESs) from gene set enrichment analysis on rank-ordered death rates, evaluating short-lived RNAs or long-lived RNAs. Nominal <italic toggle="yes">p</italic> value shown (n.s. <italic toggle="yes">p</italic> &gt; 0.05).</p><p id="P134">(E) Enrichment for stress response pathways among death regulatory genes identified by chemogenetic profiling. Significance was determined using a false discovery rate (FDR)-corrected one-tailed Fisher&#8217;s exact test.</p><p id="P135">(F) Chemogenetic profiling data, highlighting genes associated with stress response pathways: Biocarta mitochondrial pathway (Mito. Pathway), unfolded protein response (UPR), integrated stress response (ISR), and DDR. Odds ratio for one-tailed Fisher&#8217;s exact test shown. Gray dashed lines: FDR = 0.1.</p><p id="P136">(G) Immunoblot of phosphorylated-H2A.X(Ser139) following 31.6 &#956;M etoposide or 1 &#956;M TRP in U2OS.</p><p id="P137">(H) LF following TRP in U2OS or U2OS-TP53-KO. Data are mean &#177; SD for 9 biological replicates.</p><p id="P138">See also <xref rid="SD8" ref-type="supplementary-material">Figure S4</xref> and <xref rid="SD7" ref-type="supplementary-material">Table S5</xref>.</p></caption><graphic position="float" orientation="portrait" xlink:href="nihms-2100174-f0005.jpg"/></fig><fig position="float" id="F5" orientation="portrait"><label>Figure 5.</label><caption><title>Apoptosis following RNA Pol II degradation depends on cytoplasmic translocation of PTBP1</title><p id="P139">(A) TRP-induced death in U2OS and PTBP1-KO. Data are mean &#177; SD for 6 biological replicates.</p><p id="P140">(B) PTBP1-dependence for RNA Pol II degraders, or canonical apoptotic agents: 1 &#956;M TRP, 10 &#956;M &#9082;-amanitin (&#9082;-ama.), 100 &#956;M ABT-199 (ABT), and 0.5 &#956;M staurosporine (STS). Drugs tested in U2OS, PTBP1-KO, or BAX/BAK DKO. LF kinetics with area under the curve colored: gray, WT; red, DKO or PTBP1-KO, as indicated. Areas based on mean of 6 biological replicates.</p><p id="P141">(C) RNA-seq comparing drug-induced transcriptional changes in U2OS (WT) and PTBP1-KO, 8 h after TRP. Data normalized using ERCC spike-ins. Dashed line, x = y. Pearson correlation coefficient shown. Anti-apoptotic (anti-APO) and pro-apoptotic (pro-APO) regulators highlighted.</p><p id="P142">(D) Chemogenetic profiling data, highlighting genes alternatively spliced in a TRP/PTBP1-KO dependent manner. Blue, increased in PTBP-KO; red, decreased in PTBP1-KO. See also <xref rid="SD8" ref-type="supplementary-material">Figure S5H</xref>.</p><p id="P143">(E) CoIP of RNA Pol IIA with mCherry-PTBP1.</p><p id="P144">(F) CoIP of PTBP1 with varied forms of RNA Pol II.</p><p id="P145">(G) Localization of mCherry-PTBP1 &#177; TRP for 48 h. Scale bar, 25 &#956;m.</p><p id="P146">(H) Quantification of PTBP1 cytoplasm/nuclear ratio following TRP.</p><p id="P147">(I and J) Fractionation to assess PTBP1 localization following exposure to &#9082;-ama. W, whole-cell lysate; C, cytoplasmic; N, nuclear. (I) U2OS-RBP1-N792D/&#916;CTD cells following 12-h 10 &#956;M &#9082;-amanitin. (J) As in (I), except with doxycycline (+Dox).</p><p id="P148">See also <xref rid="SD8" ref-type="supplementary-material">Figures S5</xref> and <xref rid="SD8" ref-type="supplementary-material">S6</xref> and <xref rid="SD6" ref-type="supplementary-material">Table S6</xref>.</p></caption><graphic position="float" orientation="portrait" xlink:href="nihms-2100174-f0006.jpg"/></fig><fig position="float" id="F6" orientation="portrait"><label>Figure 6.</label><caption><title>BCL2L12 activates apoptosis following PTBP1 translocation</title><p id="P149">(A) Chemogenetic profiling data, highlighting BCL-2 family.</p><p id="P150">(B) LF following TRP in U2OS and BCL2L12-KO. Data are mean &#177; SD of 6 biological replicates.</p><p id="P151">(C) BCL2L12-dependence for RNA Pol II degraders or canonical apoptotic agents, as in <xref rid="F5" ref-type="fig">Figure 5B</xref>.</p><p id="P152">(D) Localization of HA-tagged BCL2L12 following TRP or vehicle for 24 h. Scale bar, 25 &#956;m.</p><p id="P153">(E) Quantification of BCL2L12 mitochondria:nuclear ratio, 24 h after TRP or vehicle.</p><p id="P154">(F) Alignment of BH3 domains from established pro-apoptotic proteins and the BH3-like domain of BCL2L12. Conserved hydrophobic residues (h1&#8211;h4) and an invariant charged residue (blue) highlighted.</p><p id="P155">(G) LF after the indicated compounds, in U2OS or BCL2L12-KO, expressing either BCL2L12 (WT B-L12) or mutant BCL2L12 (E220A B-L12).</p><p id="P156">(H) iBH3 profiling of the BCL2L12 BH3-like domain. BIM is shown for comparison. (Left) Cytochrome <italic toggle="yes">c</italic> (CytoC) release in U2OS-BCL2L12-KO with 100 &#956;M BIM-BH3, 100 &#956;M BCL2L12-BH3-like peptide, or vehicle. (Right) iBH3 profiling across doses of BIM or BCL2L12 peptides. Data are mean &#177; SD of 3 biological replicates.</p><p id="P157">(I) Schematic of PDAR.</p><p id="P158">See also <xref rid="SD8" ref-type="supplementary-material">Figure S6</xref>.</p></caption><graphic position="float" orientation="portrait" xlink:href="nihms-2100174-f0007.jpg"/></fig><fig position="float" id="F7" orientation="portrait"><label>Figure 7.</label><caption><title>Commonly used anti-cancer drugs owe their lethality to RNA Pol II degradation</title><p id="P159">(A) Strategy to identify PDAR-dependent drugs. KO refers to genetic dependencies observed for RNA Pol II degraders.</p><p id="P160">(B) Cell death in U2OS for a high-scoring drug (10 &#956;M &#9082;-ama) and low-scoring drug (3.16 &#956;M STS). Data are mean &#177; SD of 3 biological replicates.</p><p id="P161">(C) Heatmap depicting PDS score across a 7-point, half-log dose range for 46 compounds. Data collected in U2OS. Gray boxes, non-lethal doses. ***Clinically approved; *clinically investigated.</p><p id="P162">(D) Binary classifier, ordered as in (C). Red circles denote PD-like mechanisms.</p><p id="P163">(E) mCherry-PTBP1 cytoplasmic-nuclear (Cyto/Nuc.) ratio following indicated compounds.</p><p id="P164">(F) Immunoblot of Rpb1 in U2OS following 1 &#956;M abemaciclib (PD-like) or a 10-fold higher dose (low PDS).</p><p id="P165">(G) As in (F), but for cisplatin.</p><p id="P166">(H) PDS across a panel of cell lines for 1 &#956;M TRP, 10 &#956;M flavopiridol, 100 &#956;M cisplatin, and 100 &#956;M ABT-199.</p><p id="P167">(I) Relationship between LF<sub>50</sub> and RNA Pol IIA t<sub>1/2</sub>. Data in gray denote established transcriptional inhibitors, as shown in <xref rid="F2" ref-type="fig">Figure 2F</xref>. Red and blue data represent PD-like and non-PD-like compounds, respectively.</p><p id="P168">See also <xref rid="SD8" ref-type="supplementary-material">Figure S7</xref> and <xref rid="SD5" ref-type="supplementary-material">Table S7</xref>.</p></caption><graphic position="float" orientation="portrait" xlink:href="nihms-2100174-f0008.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><caption><p id="P169">KEY RESOURCES TABLE</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">REAGENT or RESOURCE</th><th align="left" valign="top" rowspan="1" colspan="1">SOURCE</th><th align="left" valign="top" rowspan="1" colspan="1">IDENTIFIER</th></tr></thead><tbody><tr><td colspan="3" align="left" valign="top" rowspan="1">Antibodies<hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti-Rpb1-NTD rabbit mAb (clone D8L4Y)</td><td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 14958; RRID:AB_2687876</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti-DYKDDDDK Tag (FLAG) rabbit mAb</td><td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 14793S; RRID:AB_2572291</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti-&#946;-actin mouse mAb</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# A2228; RRID:AB_476697</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti-Ptbp1 rabbit mAb</td><td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 57246S; RRID:AB_2799528</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti-Histone-H3 rabbit mAb</td><td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 4499S; RRID:AB_10544537</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti-&#9082;-tubulin mouse mAb</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# T6199; RRID: AB_477583</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti-pH2A.X (Ser139) rabbit mAb</td><td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 9718; RRID:AB_2118009</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti-Mcl-1 rabbit mAb</td><td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 5453; RRID:AB_10694494</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti-Apaf-1 rabbit mAb</td><td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 8723S; RRID:AB_10829610</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti-&#946;-actin rabbit polyclonal Ab</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# A2066; RRID:AB_476693</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IRDye 680RD goat anti-mouse IgG</td><td align="left" valign="top" rowspan="1" colspan="1">LI-COR</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 926&#8211;68070; RRID:AB_10956588</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IRDye 800CW goat anti-rabbit IgG</td><td align="left" valign="top" rowspan="1" colspan="1">LI-COR</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 926&#8211;32211; RRID:AB_621843</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti-Bax rabbit mAb (clone D2E11)</td><td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 5023; RRID:AB_10557411</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti-Bax mouse mAb (clone 6A7)</td><td align="left" valign="top" rowspan="1" colspan="1">BD Biosciences</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 556467; RRID:AB_396430</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mouse IgG1, &#954; isotype control mAb</td><td align="left" valign="top" rowspan="1" colspan="1">BioLegend</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 400101; RRID: AA_2891079</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti-Rpb1 mouse mAb (clone 8WG16)</td><td align="left" valign="top" rowspan="1" colspan="1">BioLegend</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 664906; RRID:AB_2565554</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti-phospho-Rpb1 CTD (Ser2) rabbit mAb</td><td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 13499; RRID:AB_2798238</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti-phospho-Rpb1 CTD (Ser5) rabbit mAb</td><td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 13523; RRID:AB_2798246</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti-phospho-Rpb1 CTD (Ser7) rabbit mAb</td><td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 13780; RRID:AB_2687900</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti-mCherry rabbit polyclonal Ab</td><td align="left" valign="top" rowspan="1" colspan="1">Proteintech</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 26765&#8211;1-AP; RRID: AB_2876881</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti-Tom20 rabbit mAb</td><td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 42406; RRID:AB_2687663</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mouse IgG2a, &#954; isotype control mAb</td><td align="left" valign="top" rowspan="1" colspan="1">BioLegend</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 400201; RRID: AB_2927399</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti-HA Tag mouse mAb</td><td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 26183; RRID:AB_10978021</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alexa Fluor 488 anti-cytochrome c mouse mAb (clone 6H2.B4)</td><td align="left" valign="top" rowspan="1" colspan="1">BioLegend</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 612308; RRID:AB_2565240</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anti-c-Myc rabbit mAb</td><td align="left" valign="top" rowspan="1" colspan="1">Cell Signaling Technology</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 5605; RRID:AB_1903938</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">goat anti-rabbit IgG Alexa Fluor 594</td><td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# A-11012; RRID:AB_2534079</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">goat anti-mouse IgG1 Alexa Fluor 488</td><td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# A-21121; RRID:AB_2535764</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">goat anti-mouse IgG Alexa Fluor 488</td><td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# A-11001; RRID:AB_2534069</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1"><hr/>Bacterial and virus strains<hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NucLight Red Lentivirus</td><td align="left" valign="top" rowspan="1" colspan="1">Sartorius</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 4627</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1"><hr/>Chemicals, peptides, and recombinant proteins<hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">phosSTOP phosphatase inhibitor tablets</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 4906837001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">cOmplete, EDTA-free Protease Inhibitor Cocktail</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 11873580001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Intercept Blocking Buffer</td><td align="left" valign="top" rowspan="1" colspan="1">LI-COR</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 927&#8211;70003</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5-ethynyl uridine</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 909475</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Formaldehyde solution (36.5&#8211;38%)</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# F8775</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">polyadenylated ERCC standards</td><td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 4456740</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SYTOX Green</td><td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# S7020</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Triptolide</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# T3652</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#9082;-amanitin</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# A2263</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ABT-737</td><td align="left" valign="top" rowspan="1" colspan="1">ApexBio</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# A8193</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RSL3</td><td align="left" valign="top" rowspan="1" colspan="1">ApexBio</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# B6095</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Elesclomol</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# SML2651</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MNNG</td><td align="left" valign="top" rowspan="1" colspan="1">Biosynth Carbosynth</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# FM11256</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TNF-&#9082;</td><td align="left" valign="top" rowspan="1" colspan="1">ApexBio</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# P1001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SM-164</td><td align="left" valign="top" rowspan="1" colspan="1">ApexBio</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# A8815</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IAA</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# I5148</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">z-VAD-FMK</td><td align="left" valign="top" rowspan="1" colspan="1">ApexBio</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# A1902</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VX765</td><td align="left" valign="top" rowspan="1" colspan="1">ApexBio</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# A8238</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TTM</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 323446</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rucaparib</td><td align="left" valign="top" rowspan="1" colspan="1">ApexBio</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# A4156</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Necrostatin-1</td><td align="left" valign="top" rowspan="1" colspan="1">SelleckChemicals</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# S8037</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ferrostatin-1</td><td align="left" valign="top" rowspan="1" colspan="1">SelleckChemicals</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# S7243</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Doxycycline Hyclate</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# D5207</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Actinomycin-D</td><td align="left" valign="top" rowspan="1" colspan="1">SelleckChemicals</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# S8964</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ethynylcytidine</td><td align="left" valign="top" rowspan="1" colspan="1">MedChemExpress</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# HY-16200</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cordycepin</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# C3394</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Flavopiridol</td><td align="left" valign="top" rowspan="1" colspan="1">SelleckChemicals</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# S1230</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DRB</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# D1916</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">THZ1</td><td align="left" valign="top" rowspan="1" colspan="1">SelleckChemicals</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# S7549</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">THZ531</td><td align="left" valign="top" rowspan="1" colspan="1">MedChemExpress</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# HY-103618</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">YKL-5&#8211;124</td><td align="left" valign="top" rowspan="1" colspan="1">MedChemExpress</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# HY-101257B</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Abemaciclib</td><td align="left" valign="top" rowspan="1" colspan="1">MedChemExpress</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# HY-16297A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Palbociclib</td><td align="left" valign="top" rowspan="1" colspan="1">ApexBio</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# A8316</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ribociclib</td><td align="left" valign="top" rowspan="1" colspan="1">MedChemExpress</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# HY-15777</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PF3600</td><td align="left" valign="top" rowspan="1" colspan="1">SelleckChemicals</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# S8816</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PF4091</td><td align="left" valign="top" rowspan="1" colspan="1">ChemieTek</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# CT-PF0710</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4-NQO</td><td align="left" valign="top" rowspan="1" colspan="1">SelleckChemicals</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# E0155</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cisplatin</td><td align="left" valign="top" rowspan="1" colspan="1">SelleckChemicals</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# S1166</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Carboplatin</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# C2538</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Camptothecin</td><td align="left" valign="top" rowspan="1" colspan="1">SelleckChemicals</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# S1288</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Topotecan HCl</td><td align="left" valign="top" rowspan="1" colspan="1">SelleckChemicals</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# B2296</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Idarubicin HCl</td><td align="left" valign="top" rowspan="1" colspan="1">SelleckChemicals</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# S1228</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Etoposide</td><td align="left" valign="top" rowspan="1" colspan="1">SelleckChemicals</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# S1225</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Teniposide</td><td align="left" valign="top" rowspan="1" colspan="1">SelleckChemicals</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# S1787</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Niraparib</td><td align="left" valign="top" rowspan="1" colspan="1">SelleckChemicals</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# S2741</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rucaparib phosphate</td><td align="left" valign="top" rowspan="1" colspan="1">SelleckChemicals</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# S1098</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Cycloheximide</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# C1988</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Homoharringtonine</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# SML1091</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Anisomycin</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# A9789</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bortezomib</td><td align="left" valign="top" rowspan="1" colspan="1">ApexBio</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# A2614</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MG-132</td><td align="left" valign="top" rowspan="1" colspan="1">SelleckChemicals</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# S2619</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Brefeldin A</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# B7651</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Thapsigargin</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# T9033</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tunicamycin</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# T7765</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ABT-199</td><td align="left" valign="top" rowspan="1" colspan="1">ApexBio</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# A8194</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ABT-263</td><td align="left" valign="top" rowspan="1" colspan="1">ApexBio</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# A3007</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Panobinostat</td><td align="left" valign="top" rowspan="1" colspan="1">ApexBio</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# A8178</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vorinostat</td><td align="left" valign="top" rowspan="1" colspan="1">ApexBio</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# A4084</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Torin 2</td><td align="left" valign="top" rowspan="1" colspan="1">ApexBio</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# B1640</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rapamycin</td><td align="left" valign="top" rowspan="1" colspan="1">ApexBio</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# A8167</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Mirdametinib</td><td align="left" valign="top" rowspan="1" colspan="1">MedChemExpress</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# HY-10254</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Buparlisib</td><td align="left" valign="top" rowspan="1" colspan="1">MedChemExpress</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# HY-70063</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Capivasertib</td><td align="left" valign="top" rowspan="1" colspan="1">MedChemExpress</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# HY-15431</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SGI-1027</td><td align="left" valign="top" rowspan="1" colspan="1">ApexBio</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# B1622</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">JQ1</td><td align="left" valign="top" rowspan="1" colspan="1">SelleckChemicals</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# S7110</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Staurosporine</td><td align="left" valign="top" rowspan="1" colspan="1">SelleckChemicals</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# S1421</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">H2O2</td><td align="left" valign="top" rowspan="1" colspan="1">Fisher Scientific</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# BP2633500</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LPS</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# L4391</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nigericin</td><td align="left" valign="top" rowspan="1" colspan="1">ApexBio</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# B7644</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">copper(II) chloride</td><td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 405845000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="S63845">S63845</ext-link></td><td align="left" valign="top" rowspan="1" colspan="1">SelleckChemicals</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# S8383</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">G418</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma-Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# G8168</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CoraLite Plus 488-Phalloidin</td><td align="left" valign="top" rowspan="1" colspan="1">Proteintech</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# PF00001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SUPERase-In RNase inhibitor</td><td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# AM2694</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Benzonase Nuclease</td><td align="left" valign="top" rowspan="1" colspan="1">Sigma Aldrich</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# E1014</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Alamethicin</td><td align="left" valign="top" rowspan="1" colspan="1">MedChemExpress</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# HY-N6708</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dimethyl Sulfoxide (DMSO)</td><td align="left" valign="top" rowspan="1" colspan="1">Fisher Scientific</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# MT-25950CQC</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1"><hr/>Critical commercial assays<hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Proteome Profiler Apoptosis Arrays</td><td align="left" valign="top" rowspan="1" colspan="1">R&amp;D Systems</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# ARY009</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gibson Assembly Master Mix</td><td align="left" valign="top" rowspan="1" colspan="1">New England Biolabs</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# E2611</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NEBridge Golden Gate Assembly Kit (BsmBI-v2)</td><td align="left" valign="top" rowspan="1" colspan="1">New England Biolabs</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# E1602</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Gateway LR Clonase II Enzyme mix</td><td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 11791020</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pierce BCA Protein Assay Kit</td><td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 23227</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FuGENE HD Transfection Reagent</td><td align="left" valign="top" rowspan="1" colspan="1">Promega</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# E2311</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">QIAquick PCR Purification Kit</td><td align="left" valign="top" rowspan="1" colspan="1">Qiagen</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 28104</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Rneasy Plus Mini Kit</td><td align="left" valign="top" rowspan="1" colspan="1">Qiagen</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 74134</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Click-iT RNA Alexa Fluor 488 Imaging Kit</td><td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="C10329">C10329</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NEBNext Poly(A) mRNA Magnetic Isolation Module</td><td align="left" valign="top" rowspan="1" colspan="1">New England Biolabs</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# E7490</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NEBNext Ultra II Directional RNA Library Prep Kit</td><td align="left" valign="top" rowspan="1" colspan="1">New England Biolabs</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# E7765</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NEBNext Multiplex Oligos for Illumina</td><td align="left" valign="top" rowspan="1" colspan="1">New England Biolabs</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# E7600</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NextSeq 1000/2000 P<sup>2</sup> XLEAP-SBS Reagent Kit</td><td align="left" valign="top" rowspan="1" colspan="1">Illumina</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 20100987</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NextSeq 2000 P3 Reagent Kit</td><td align="left" valign="top" rowspan="1" colspan="1">Illumina</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 20040561</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CellTiter Glo</td><td align="left" valign="top" rowspan="1" colspan="1">Promega</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# G7571</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">QIAquick Gel Extraction Kit</td><td align="left" valign="top" rowspan="1" colspan="1">Qiagen</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 28704</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Wizard Genomic DNA Purification Kit</td><td align="left" valign="top" rowspan="1" colspan="1">Fisher Scientific</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# PR-A1125</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Q5 Site-Directed Mutagenesis Kit</td><td align="left" valign="top" rowspan="1" colspan="1">New England Biolabs</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# E0554S</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pierce Protein G Magnetic Beads</td><td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 88847</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chromotek RFP-Trap magnetic agarose</td><td align="left" valign="top" rowspan="1" colspan="1">Proteintech</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# rtma</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Quick Western Kit</td><td align="left" valign="top" rowspan="1" colspan="1">LI-COR</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 926&#8211;69100</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Revert 700 Total Protein Stain Kit</td><td align="left" valign="top" rowspan="1" colspan="1">LI-COR</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 926&#8211;11010</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Polybrene</td><td align="left" valign="top" rowspan="1" colspan="1">Millipore</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# TR1003G</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Prolong Diamond antifade mountant</td><td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# <ext-link ext-link-type="pmc:entrez-protein" xlink:href="P36965">P36965</ext-link></td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1"><hr/>Deposited data<hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RNAseq: triptolide exposure time course in U2OS and BAX/BAK DKO cells</td><td align="left" valign="top" rowspan="1" colspan="1">This study</td><td align="left" valign="top" rowspan="1" colspan="1">Gene Expression Omnibus (GEO) accession number: <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE283148">GSE283148</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RNAseq: triptolide exposure in NUP93 or EXOSC5 KO cells</td><td align="left" valign="top" rowspan="1" colspan="1">This study</td><td align="left" valign="top" rowspan="1" colspan="1">Gene Expression Omnibus (GEO) accession number: <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE283149">GSE283149</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RNAseq: nuclear and cytoplasmic fractionation in U2OS or PTBP1 KO cells</td><td align="left" valign="top" rowspan="1" colspan="1">This study</td><td align="left" valign="top" rowspan="1" colspan="1">Gene Expression Omnibus (GEO) accession number: <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE283150">GSE283150</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RNAseq: triptolide exposure following a-amanitin in Pol II switchover system</td><td align="left" valign="top" rowspan="1" colspan="1">This study</td><td align="left" valign="top" rowspan="1" colspan="1">Gene Expression Omnibus (GEO) accession number: <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE283151">GSE283151</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Chemo-genetic profiling data</td><td align="left" valign="top" rowspan="1" colspan="1">This study</td><td align="left" valign="top" rowspan="1" colspan="1">Gene Expression Omnibus (GEO) accession number: <ext-link ext-link-type="pmc:entrez-geo" xlink:href="GSE283147">GSE283147</ext-link></td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1"><hr/>Experimental models: Cell lines<hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">U-2-OS (U2OS)</td><td align="left" valign="top" rowspan="1" colspan="1">ATCC</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# HTB-96</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HT-29</td><td align="left" valign="top" rowspan="1" colspan="1">ATCC</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# HTB-38</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">H1650</td><td align="left" valign="top" rowspan="1" colspan="1">ATCC</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# CRL-5883</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">WI-38</td><td align="left" valign="top" rowspan="1" colspan="1">ATCC</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# CCL-75</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Hs578T</td><td align="left" valign="top" rowspan="1" colspan="1">ATCC</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# HTB-126</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MDA-MB-453</td><td align="left" valign="top" rowspan="1" colspan="1">ATCC</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# HTB-131</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MCF7</td><td align="left" valign="top" rowspan="1" colspan="1">ATCC</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# HTB-22</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MDA-MB-157</td><td align="left" valign="top" rowspan="1" colspan="1">ATCC</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# HTB-24</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HeLa</td><td align="left" valign="top" rowspan="1" colspan="1">ATCC</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# CCL-2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MCF10A</td><td align="left" valign="top" rowspan="1" colspan="1">ATCC</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# CRL-10317</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">A375</td><td align="left" valign="top" rowspan="1" colspan="1">Michael Green lab, UMass Chan Medical School</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HAP1</td><td align="left" valign="top" rowspan="1" colspan="1">Job Dekker lab, UMass Chan Medical School</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HAP1-RPB1-AID</td><td align="left" valign="top" rowspan="1" colspan="1">Valton et al.<sup><xref rid="R19" ref-type="bibr">19</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RPE-1</td><td align="left" valign="top" rowspan="1" colspan="1">Gregory Pazour lab, UMass Chan Medical School</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PC9</td><td align="left" valign="top" rowspan="1" colspan="1">Justin Pritchard lab, Penn State</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lenti-X 293T</td><td align="left" valign="top" rowspan="1" colspan="1">Takara</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 632180</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">U2OS-BAX/BAK-DKO</td><td align="left" valign="top" rowspan="1" colspan="1">Richards et al.<sup><xref rid="R71" ref-type="bibr">71</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">U2OS-mKate2+</td><td align="left" valign="top" rowspan="1" colspan="1">Richards et al.<sup><xref rid="R71" ref-type="bibr">71</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">U2OS-BAX/BAK-DKO-mKate2+</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">U2OS-PTBP1-KO</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">U2OS-BCL2L12-KO</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">U2OS-Rpb1-N792D-&#916;CTD Switchover</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">U2OS-mCherry-PTBP1</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">U2OS-BCL2L12-Flag-HA</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">U2OS-Cas9</td><td align="left" valign="top" rowspan="1" colspan="1">Honeywell et al.<sup><xref rid="R36" ref-type="bibr">36</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">U2OS-TP53-KO</td><td align="left" valign="top" rowspan="1" colspan="1">Honeywell et al.<sup><xref rid="R36" ref-type="bibr">36</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1"><hr/>Oligonucleotides<hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">pLCKO2::TKOv3 library</td><td align="left" valign="top" rowspan="1" colspan="1">Hart et al.,<sup><xref rid="R35" ref-type="bibr">35</xref></sup> Addgene</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 125517</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Primers for PTBP1 knockout validation: Forward primer (same as sequencing primer): 5&#8217;-gatgctgaaggggaa aaaccaggtac-3&#8217;; Reverse primer: 5&#8217;-tcttcaacactgtgccgaacttggag-3&#8217;</td><td align="left" valign="top" rowspan="1" colspan="1">This paper, Integrated DNA Technologies</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Primers for BCL2L12 knockout validation: Forward primer (same as sequencing primer): 5&#8217;-cagctactccagacttctatgctttg-3&#8217;; Reverse primer: 5&#8217;-acggtacagtactaccctaaccatac-3&#8217;</td><td align="left" valign="top" rowspan="1" colspan="1">This paper, Integrated DNA Technologies</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">sgRNA sequences (<xref rid="SD3" ref-type="supplementary-material">Table S1</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">This paper, Integrated DNA Technologies</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">gBlocks for in4mer constructs (<xref rid="SD3" ref-type="supplementary-material">Table S1</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">This paper, Integrated DNA Technologies</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PCR primers for cloning Rpb1 Switchover system: Forward primer: 5&#8217; &#8211;CAATTCCACAACACTTTTGTC TTATACTTGGATCCATGGACTACAAGGACGACGATGACA &#8722;3&#8217;; Reverse primer:</td><td align="left" valign="top" rowspan="1" colspan="1">This paper, Integrated DNA Technologies</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">5&#8217; &#8211;TAGGGGGGGGGGAGGGAGAGGGGC CGGCCGGGGCTCAGCTGGGAGACATGGCACCAC&#8211;3&#8217;</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PCR#1 pLCKO2-TKOv3 library forward: 5&#8217;- GAGGGCCTATTTCCCATGATTC-3&#8217;</td><td align="left" valign="top" rowspan="1" colspan="1">Hart et al.,<sup><xref rid="R35" ref-type="bibr">35</xref></sup> Integrated DNA Technologies</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PCR#1 pLCKO2-TKOv3 library reverse: 5&#8217;- CAAACCCAGGGCTGCCTTGGAA-3&#8217;</td><td align="left" valign="top" rowspan="1" colspan="1">Hart et al.,<sup><xref rid="R35" ref-type="bibr">35</xref></sup> Integrated DNA Technologies</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1"><hr/>Recombinant DNA<hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pX330-PTBP1-Puro</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pX330-BCL2L12-Puro</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pX330-NUP93-Puro</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pX330-EXOSC5-Puro</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pX330-MCL1-Puro</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pX330-MYC-Puro</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pX330-WEE1-Puro</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pX330-TICRR-Puro</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pX330-JUN-Puro</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pX330-FBXO5-Puro</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pX330-DTL-Puro</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pX330-DBR1-Puro</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pX330-BCL2A1-Puro</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pX330-NONT-Puro</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pRDA_550-PTBP1</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pRDA_550-BCL2L12</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pRDA_550-BAX/BAK1</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pRDA_550-Intergenic</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pLVX-Tre3G-FLAG-RPB1-N792D-&#916;CTD</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pLVX-Tet3G</td><td align="left" valign="top" rowspan="1" colspan="1">Clontech</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 631358</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pHAGE-mCherry-PTBP1-IRES-Puro</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pHAGE-BCL2L12-FLAG-HA-IRES-Puro</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Plasmid: pHAGE-BCL2L12-E220A-FLAG-HA-IRES-Puro</td><td align="left" valign="top" rowspan="1" colspan="1">This paper</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1"><hr/>Software and algorithms<hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">TIDE (version 3.3.0)</td><td align="left" valign="top" rowspan="1" colspan="1">Brinkman et al.<sup><xref rid="R72" ref-type="bibr">72</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link xlink:href="https://tide.nki.nl/" ext-link-type="uri">https://tide.nki.nl/</ext-link>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ImageStudio software (version 3.1.4)</td><td align="left" valign="top" rowspan="1" colspan="1">LI-COR</td><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link xlink:href="https://www.licorbio.com/image-studio" ext-link-type="uri">https://www.licorbio.com/image-studio</ext-link>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FlowJo software (version 10.8.1)</td><td align="left" valign="top" rowspan="1" colspan="1">FlowJo</td><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link xlink:href="https://www.flowjo.com/" ext-link-type="uri">https://www.flowjo.com/</ext-link>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FastQC (version 0.12.1)</td><td align="left" valign="top" rowspan="1" colspan="1">Babraham Bioinformatics</td><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link xlink:href="https://www.bioinformatics.babraham.ac.uk/projects/fastqc/" ext-link-type="uri">https://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Kallisto (version 0.46.1)</td><td align="left" valign="top" rowspan="1" colspan="1">Bray et al.<sup><xref rid="R73" ref-type="bibr">73</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link xlink:href="https://pachterlab.github.io/kallisto/" ext-link-type="uri">https://pachterlab.github.io/kallisto/</ext-link>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Tximport (version 1.16.1)</td><td align="left" valign="top" rowspan="1" colspan="1">Soneson et al.<sup><xref rid="R74" ref-type="bibr">74</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link xlink:href="https://bioconductor.org/packages/release/bioc/html/tximport.html" ext-link-type="uri">https://bioconductor.org/packages/release/bioc/html/tximport.html</ext-link>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DESeq2 (version 1.28.1)</td><td align="left" valign="top" rowspan="1" colspan="1">Love et al.<sup><xref rid="R75" ref-type="bibr">75</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link xlink:href="https://bioconductor.org/packages/release/bioc/html/DESeq2.html" ext-link-type="uri">https://bioconductor.org/packages/release/bioc/html/DESeq2.html</ext-link>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AnnotationHub (version 2.20.2)</td><td align="left" valign="top" rowspan="1" colspan="1">Morgan and Shepherd<sup><xref rid="R76" ref-type="bibr">76</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link xlink:href="https://bioconductor.org/packages/release/bioc/html/AnnotationHub.html" ext-link-type="uri">https://bioconductor.org/packages/release/bioc/html/AnnotationHub.html</ext-link>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VAST-TOOLS</td><td align="left" valign="top" rowspan="1" colspan="1">Irimia et al.<sup><xref rid="R77" ref-type="bibr">77</xref></sup> and Tapial et al.<sup><xref rid="R78" ref-type="bibr">78</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link xlink:href="https://github.com/vastgroup/vast-tools" ext-link-type="uri">https://github.com/vastgroup/vast-tools</ext-link>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FASTX-Toolkit (version 0.0.14)</td><td align="left" valign="top" rowspan="1" colspan="1">N/A</td><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link xlink:href="https://github.com/agordon/fastx_toolkit" ext-link-type="uri">https://github.com/agordon/fastx_toolkit</ext-link>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Bowtie (version 1.3.0)</td><td align="left" valign="top" rowspan="1" colspan="1">Langmead et al.<sup><xref rid="R79" ref-type="bibr">79</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link xlink:href="https://bowtie-bio.sourceforge.net/index.shtml" ext-link-type="uri">https://bowtie-bio.sourceforge.net/index.shtml</ext-link>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GSEA software (version 4.2.2)</td><td align="left" valign="top" rowspan="1" colspan="1">Subramanian et al.<sup><xref rid="R80" ref-type="bibr">80</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link xlink:href="https://www.gsea-msigdb.org/gsea/index.jsp" ext-link-type="uri">https://www.gsea-msigdb.org/gsea/index.jsp</ext-link>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Fiji software (version 2.9.0)</td><td align="left" valign="top" rowspan="1" colspan="1">Schindelin et al.<sup><xref rid="R81" ref-type="bibr">81</xref></sup></td><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link xlink:href="https://imagej.net/software/fiji/" ext-link-type="uri">https://imagej.net/software/fiji/</ext-link>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MATLAB software (version R2024b)</td><td align="left" valign="top" rowspan="1" colspan="1">MathWorks</td><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link xlink:href="https://www.mathworks.com/products/matlab.html" ext-link-type="uri">https://www.mathworks.com/products/matlab.html</ext-link>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Prism 10 software</td><td align="left" valign="top" rowspan="1" colspan="1">GraphPad</td><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link xlink:href="https://www.graphpad.com/" ext-link-type="uri">https://www.graphpad.com/</ext-link>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IncuCyte Software (2023a)</td><td align="left" valign="top" rowspan="1" colspan="1">Essen Biosciences</td><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link xlink:href="https://www.sartorius.com/en/products/live-cell-imaging-analysis/live-cell-analysis-software" ext-link-type="uri">https://www.sartorius.com/en/products/live-cell-imaging-analysis/live-cell-analysis-software</ext-link>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">R (version 4.0.1)</td><td align="left" valign="top" rowspan="1" colspan="1">R software</td><td align="left" valign="top" rowspan="1" colspan="1">
<ext-link xlink:href="https://www.r-project.org/" ext-link-type="uri">https://www.r-project.org/</ext-link>
</td></tr><tr><td colspan="3" align="left" valign="top" rowspan="1"><hr/>Other<hr/></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AcroPrep 96 well 3.0 &#956;m glass fiber/0.2 &#956;m Bio-Inert membrane filter plate</td><td align="left" valign="top" rowspan="1" colspan="1">Pall Laboratory</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 5053</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Odyssey CLx scanner</td><td align="left" valign="top" rowspan="1" colspan="1">LI-COR</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 9140</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">VCX 130 Vibra Cell sonicator</td><td align="left" valign="top" rowspan="1" colspan="1">Sonics</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# CV18</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MACSQuant VYB cytometer</td><td align="left" valign="top" rowspan="1" colspan="1">Miltenyi</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 130&#8211;096-116</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">4150 Tapestation System</td><td align="left" valign="top" rowspan="1" colspan="1">Aglient Technologies</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# G2992AA</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NextSeq2000</td><td align="left" valign="top" rowspan="1" colspan="1">Illumina</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 20038897</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">IncuCyte S3</td><td align="left" valign="top" rowspan="1" colspan="1">Essen Biosciences</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 4637</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">EVOS FL Auto 2 automated microscope</td><td align="left" valign="top" rowspan="1" colspan="1">Thermo Fisher Scientific</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# AMAFD2000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Spark microplate reader</td><td align="left" valign="top" rowspan="1" colspan="1">Tecan</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# 30124664</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HiSeq 4000</td><td align="left" valign="top" rowspan="1" colspan="1">Illumina</td><td align="left" valign="top" rowspan="1" colspan="1">Cat# SY-401&#8211;1001</td></tr></tbody></table></table-wrap><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>Highlights</title></caption><list list-type="bullet" id="L1"><list-item><p id="P170">The lethality of RNA Pol II inhibition results from active signaling, not passive mRNA decay</p></list-item><list-item><p id="P171">Death is initiated by loss of hypophosphorylated (not actively elongating) RNA Pol IIA</p></list-item><list-item><p id="P172">Genetic profiling reveals how loss of RNA Pol IIA is sensed and signaled to mitochondria</p></list-item><list-item><p id="P173">Drugs with diverse annotated mechanisms owe their lethality to loss of RNA Pol IIA</p></list-item></list></boxed-text></floats-group></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>